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ABSTRACT 
 
The human mitochondrial pyruvate dehydrogenase complex (PDC) is a vital 
metabolic assembly that controls the key committed step in aerobic carbohydrate 
utilisation and energy production and as such is responsible for overall glucose 
homeostasis in man. PDC, particularly from prokaryotic sources, has been widely 
studied as a model system for investigating the molecular basis of cooperativity 
between physically and functionally linked enzymes in a metabolic pathway and the 
catalytic and regulatory advantages conferred by their organisation into precisely-
engineered ‘molecular-machines’. Defects in human PDC have been implicated in a 
wide variety of genetic, metabolic and autoimmune disorders. Over 200 PDC-linked 
mutations have been reported to date in the human population leading to clinical 
symptoms of various magnitudes and manifestations, mostly in the X-linked gene for 
the α subunit of the E1 component. 
PDC is a vast molecular machine (Mr, 9-10 MDa) composed of multiple copies of 3 
distinct enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase 
(E2), dihydrolipoamide dehydrogenase (E3) and an additional structural protein 
known as E3-binding protein (E3BP). Central to its structural, morphological and 
mechanistic framework is its large oligomeric ‘core’ comprising 60 E2 and 12 E3BP 
polypeptide chains, arranged as pentagonal dodecahedron, to which up to 30 α2β2 E1 
enzymes and 6-12 homodimeric E3 enzymes are tethered tightly, but non-covalently, 
at maximal occupancy. More recently a substitutional model of PDC has been 
proposed where the core is formed by 48 E2 and 12 E3BP with the 12 E3BP 
polypeptides replacing an equivalent number of E2s. The N-termini of the E2 
enzyme(s) each contain two peripherally-extended lipoyl domains that exhibit great 
mobility and in effect, act as ‘swinging arms’ since their attached lipoic acid cofactors 
must visit the active sites of all the three enzymes in strict rotation during the catalytic 
cycle.  Similarly, E3BP is a distinct E2-related polypeptide that is primarily involved 
in E3 integration but also displays overlapping functions with E2 as it contains a 
single, highly-flexible lipoyl domain that can participate in catalysis. 
In this study, a model recombinant human PDC has been reconstituted from its E1, 
E2:E3BP and E3 components that  were all overexpressed in and purified from E. coli 
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in high yield prior to assembling spontaneously into fully-active complex in vitro. The 
wild-type recombinant PDC displayed similar enzymatic activity to the native 
complex purified from human heart. As a prelude to examining 3 novel naturally- 
occurring, E2-linked mutations, the recombinant PDC model was validated initially 
by examining the effects of alterations in its lipoylation status on its activity and 
overall properties and secondly by assessing the characteristics of recombinant PDC 
lacking the E3BP subunit.  A possible enzymatic role for E3BP in promoting 
formation of an S6, S8-diacetylated dihydrolipoamide intermediate on E2 and E3BP 
was also investigated.  
In the first analysis a series of mutant E2:E3BP cores were created containing all 
possible combinations of active and inactive lipoyl domains. These possible 
combinations were ++/+, -+/+, +-/+, --/+, ++/ -, -+/-, +-/- and --/-, where ‘+’ is a 
lipoylated and ‘-’ is a non lipoylated outer, inner or E3BP domain in the E2:E3BP 
cores. Eight recombinant PDC models were successfully reconstituted from these 
cores and analysed for their effects on PDC activity compared to wild-type complex.  
The data indicate that mutation of the outer or inner lipoyl domain of E2 by replacing 
the lipoylatable lysine by glutamine leads to a 25-35% decrease in activity; moreover 
the presence of an active or inactive lipoyl domain on E3BP had no detectable 
influence on PDC function. However, PDC, in which only active E3BP lipoyl 
domains were present, retained 15% of wild-type activity. These data confirm 
previous reports on the functional redundancy of lipoyl domains observed in bacterial, 
yeast and mammalian PDCs and suggest that the E2 lipoyl domains and the lipoyl 
domain of E3BP can act independently as effective substrates for E1, E2 and E3. 
A parallel study on recombinant PDC lacking E3BP, was also consistent with 
previous studies in showing that it retained partial activity in the complete absence of 
this subunit. E3BP-deficient patients retain relatively high levels of PDC activity (15-
20%) as compared to the 3-8% observed using stoichiometric amounts of E3 in our in 
vitro assay. However, our data also suggested that 40-50% PDC activity could be 
achieved in the presence of a 100-200 fold excess of E3 that may account for slightly 
higher activity in the patients. Interestingly, wild-type PDC activity declined by 10-
30% in the presence of a large E3 excess in agreement with the idea that the E1 
binding site on E2 retains a residual affinity for E3 and is able to partially displace the 
rate-limiting E1 enzyme when present in high amounts.   
 vi 
The main objective of the thesis was to apply our recombinant PDC model to conduct 
a detailed investigation of the molecular defects underlying three novel E2 mutations/ 
deletions identified at the genetic level by Dr. Garry Brown, University of Oxford in 
PDC-deficient patients under his care. These were two separate ‘in frame’ 3-bp 
deletions encoding glutamate-35 and valine-455 in the mature E2 protein and a 
phenylalanine-490 to leucine (F490L) substitution located near the active site of the 
enzyme. Full length copies of these mutant enzymes were generated by site-directed 
mutagenesis as well an outer lipoyl domain-GST construct housing the ∆35E deletion. 
In the case of ∆35E mutant, our data from lipoylation assays, circular dichroism, 
tryptophan fluorescence, non-denaturing gel electrophoresis, size exclusion 
chromatography and cross-linking analyses indicate that the mutant lipoyl domain is 
misfolded and displays a pronounced tendency to form dimers or higher order 
aggregates, presumably via inappropriate exposure of hydrophobic surfaces. As a 
result, the bulk of the E2:E3BP core does not assemble properly as evidenced by its 
unusual subunit composition and the presence of several abnormal species including 
non-specific aggregates detected by analytical ultracentrifugation. Mutant E2, 
E2:E3BP core and reconstituted PDC showed low activity (10-20%) as compared to 
wild-type controls, indicating a small proportion of active core can still form under 
these conditions. In this study, replacement of glu-35 by aspartate or glutamine had 
only minor/negligible effects on E2:E3BP core assembly and reconstituted PDC 
activity indicating that the size or charge of amino acid at this position is not critical 
for normal folding and assembly.  
In the valine-455 deletion study, the patient was reported to contain no 
immunologically-detectable E3BP, despite the apparent absence of any mutation in 
the PDX1 gene. Therefore, in this study, it was hypothesised that this E2-based 
mutation might be responsible for preventing integration of E3BP into the E2 core 
assembly, thereby promoting its rapid degradation. Although, this deletion resulted in 
reduced E2 and PDC activity (50%), it was not found to prevent E3BP integration 
when the mutant core was produced at either 30 °C or 37 °C. As this patient has no 
detectable levels of E3BP protein despite the presence of mRNA for this component 
as detected by RT-PCR studies in Oxford, the precise molecular basis for this defect 
remains unclear at present. The patient is currently undergoing a complete medical 
and clinical re-evaluation.  
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Recombinant mutant PDC containing the F490L mutation also loses about 50% 
enzymatic activity as compared to the normal or wild-type PDC confirming the role 
of this mutation in PDC deficiency in this patient. This phenylalanine located near to 
the catalytic site of E2 has been found to be responsible for substrate specificity and 
its substitution could be directly responsible for decreased enzymatic activity in this 
case.  No major structural changes were observed in this mutant core.  
In summary, our recombinant PDC model has proved to be of considerable benefit in 
enabling us to gain a more informed insight into the molecular mechanisms of 
pathogenesis underlying these rare E2-linked mutations, particularly in the case of the 
∆E35-E2 mutant. In the absence of the recombinant model, such detailed 
investigations would have proved impossible owing to the lack of access to human 
tissue from individual patients. 
As a corollary to the main aim of the thesis, a preliminary attempt was made to create 
an equivalent recombinant OGDC model. OGDC is also a mitochondrial assembly 
that is involved in the TCA cycle and is increasingly implicated in the aetiology of 
various neurodegenerative diseases linked to oxidative stress including Alzheimer’s 
and Parkinson’s disease.   
The basic organisation of the OGDC is directed by the self-assembly of 24 copies of 
dihydrolipoyl succinyltransferase (E2o) to form a cubic core, to which multiple copies 
of 2-oxoglutarate dehydrogenase (E1o) and dihydrolipoamide dehydrogenase (E3) 
bind non-covalently. The mammalian E2o is unusual in lacking any obvious E3 or 
E1o binding domain. In this study, E2o and E3 were successfully overexpressed and 
purified.  Initially it was confirmed that E2o and E3 do not interact with each other on 
gel filtration although stable association of all 3 constituent enzymes occurs in the 
native complex.  Full-length E1o was also cloned successfully although it proved 
impossible to achieve detectable expression in our E. coli BL21 host system.  
Previous studies employing subunit-specific proteolysis have identified the extreme 
N-terminal segment of E1o as a key region involved in the maintenance of complex 
stability and integrity and is required for E2 and E3 binding. To investigate this region 
in more detail, three N-terminal E1o fragments of decreasing size were 
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overexpressed, one in His-tag form (193 amino acids) and two as E1o-GST fusion 
proteins (166 and 83 amino acids). In co-expression, purification and gel filtration 
studies, it was found that all these N-terminal truncates of E1o appeared capable of 
interacting with E2o although problems were encountered with rapid degradation and 
unambiguous identification in some cases. However, Western blotting revealed 
conclusively that even the shortest N-terminal E1o fragment (83 amino acids) was 
able to enter into a stable association with E2o. Owing to time constraints and 
difficulties with rapid degradation and/or solubility of the E1o truncates, it remains to 
be determined whether this N-terminal region of E1o can also interact with E2o in a 
post-translational fashion and whether it is directly involved in mediating E3 binding. 
However, this type of approach should continue to provide additional insights in the 
unique subunit organisation of OGDC and is an important step towards creating a 
recombinant model of OGDC. This will be invaluable for future studies on an 
important metabolic assembly that has been increasingly implicated in disorders 
linked to oxidative stress and neurodegeneration.  
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Chapter 1 
 
 
Introduction to pyruvate dehydrogenase 
and 2-oxoglutarate dehydrogenase 
complexes  
 
1.1 Multienzyme complexes  
 
Multienzyme complexes are organised assemblies in which the individual components 
function in a cooperative manner by catalysing consecutive reactions linked by common 
metabolic intermediates. They may provide the means to attain high local substrate 
concentrations, regulate competition amongst competing pathways, coordinate the 
activities of interdependent pathways, and/or sequester toxic and labile intermediates 
within cells. Two or more enzymes associating in this way allow the substrates to travel 
efficiently between the active sites. This process, known as ‘channelling’, can in certain 
cases be kinetically advantageous. Thus multienzyme complexes optimise the catalytic 
activity and ensure the regulated activity of a metabolic pathway. 
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The most prominent examples of multienzyme complexes are the family of stable 2-oxo 
acid dehydrogenase complexes, that include the pyruvate dehydrogenase (PDC), 2-
oxoglutarate dehydrogenase (OGDC) and branched-chain 2-oxoacid dehydrogenase 
(BCOADC) complexes. PDC links glycolysis to the tricarboxylic acid (TCA) cycle and 
fatty acid synthesis by catalysing the oxidative decarboxylation of pyruvate with the 
concomitant production of acetyl-CoA and NADH. OGDC, in contrast, controls a major 
regulatory step in the TCA cycle and decarboxylates its substrate, 2-oxoglutarate to form 
succinyl-CoA (Sheu and Blass, 1999). Finally, the BCOADC oxidatively decarboxylates 
the branched chain 2-oxoacids derived by transamination of valine, leucine and isoleucine 
in addition to methionine and threonine (Jones and Yeaman, 1986) (Fig. 1.1). 
The molecular understanding of the 2-oxoacid dehydrogenases began in 1950s with the 
isolation of lipoic acid. The years from 1960-80 involved mainly the application of 
standard protein-chemical and enzymatic techniques for isolation, characterisation and 
determination of the catalytic and regulatory functions of these complexes. This has been 
supplemented in recent years by the increasing application of recombinant DNA, 
biophysical techniques and refined structural and functional approaches. The pioneering 
studies on these complexes were undertaken on the microbial multienzyme complexes that 
have paved the way for advances and new insights into the organisation of these complexes 
in other species. Interestingly, there are considerable differences in the structure, function 
and regulation of these multienzyme complexes across plant, bacterial and animal species 
as elucidated by various recent studies. Human pyruvate dehydrogenase complex (PDC), 
the most prominent member of the mammalian 2-oxoacid dehydrogenase complex family 
is an excellent example of a multienzyme assembly and a major focus of research. PDC 
plays an important role in many metabolic disorders, one of which is congenital childhood 
lactic acidaemia, that is a poorly understood group of genetic diseases (Robinson and 
Sherwood, 1984). The most common cause of this inherited defect is a deficiency of the 
pyruvate dehydrogenase complex. It has also been described in patients with 
subacute/chronic neurodegenerative disease without significant metabolic acidosis (Dahl et 
al., 1992). Two clinical forms of lactic acidaemia related to PDC deficiency are 
recognized, neonatal and juvenile. The neonatal form is a relatively common cause of 
lactic acidosis in the first weeks of life and may also feature an erythematous rash. The 
juvenile form presents with lactic acidosis, alopecia, intermittent ataxia, seizures and 
erythematous rash. 
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Figure 1.1: Schematic representation of involvement of 2-oxoacid dehydrogenases in 
cellular metabolism 
 
Multienzyme complexes are shown in blue and their products in green. 
Chapter 1  
 
4 
4 
 
1.2 Subunit organisation of the pyruvate dehydrogenase 
complex 
 
PDC in mammalian systems is composed of multiple copies of three main enzymes - 
pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and 
dihydrolipoamide dehydrogenase (E3). In addition to these enzymes, there are two 
regulatory components, namely a tightly bound, tissue specific E1-kinase and a phospho-
E1-phosphatase. Specific PDC phosphatases involved in the activation of the complex and 
are loosely bound to it (Teague et al., 1982). Mammalian PDC also contains an accessory 
protein, formerly known as protein X, now referred to as E3-binding protein (E3BP) 
(Behal et al., 1993).  
In mammals the basic framework of the complex is provided by a central core composed 
primarily of E2 subunits. Sixty copies of E2 and/or E3BP are arranged in a pentagonal 
dodecahedron displaying 532 symmetry (Yeaman et al., 1978) (Fig. 1.2 A). However, the 
E2 core in the PDC of Gram negative bacteria and in all the known OGDCs and 
BCOADCs, exists as a 24-meric cubic structure with octahedral (432) symmetry (Fig.1.2 
B). The E1 enzyme of PDC in mammals exists as an α2β2 heterotetramer with up to thirty 
E1s arranged around the E2 core (Reed, 1974). E3 is a ubiquitous flavin-containing 
dehydrogenase and is present as a homodimer with 6-12 copies occupying the 12 
pentagonal faces of the E2 core (Yeaman et al., 1978). Twelve copies of E3BP are tightly 
associated with E2 where, it mediates E3 binding to the complex (Gopalakrishnan et al., 
1989; Lawson et al., 1991). Other studies have also suggested that one E3BP molecule 
binds to each of the 12 faces of the E2 core while 6-12 E3 homodimers are attached to the 
complex via E3BP (Sanderson et al., 1996b). Recently another model of PDC core 
organisation has been suggested based on sedimentation equilibrium and small angle x-ray 
scattering data. According to this substitution model, the core comprises 48:12 E2:E3BP 
instead of 60:12 to which 12 E3 are bound in 1:1 stoichiometric relationship with E3BP 
(Hiromasa et al., 2004).  
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It has been shown that E2 and E3BP must be co-expressed to promote their co-integration 
into a native oligomeric core. E3BP is thought to have its C-terminal region embedded in 
the core structure while the rest of the molecule extends outwards. Until recently, it was 
generally accepted that the PDC comprises at maximum occupancy 60 E2 monomers, 30 
E1 heterotetramers, 12 E3BP monomers and 6-12 E3 dimers. Recent isothermal titration 
calorimetry studies, however, have suggested that one E3 dimer binds two E3BPs implying 
that each E3 is capable of forming cross bridges with the 12 E3BPs across adjacent 
pentagonal faces of the E2 core assembly assuming 60:12 meric E2:E3BP core 
organisation (Fig.1.3 A). In a similar way, it has been suggested that the E1 tetramers may 
also form crossbridges between pairs of E2 monomers along the 30 edges of the E2 core 
assembly (Fig.1.3 B). However, this study is in conflict with recent X-ray structures for the 
human E3 in association with E3BP where 1:1 binding of the E3BP didomain (lipoyl and 
E3-binding domains) and E3 has been shown (Ciszak et al., 2006).  
 
1.3 Catalytic mechanism  
 
PDC is responsible for controlling a key committed step in carbohydrate utilisation by 
catalysing the oxidative decarboxylation of pyruvate to yield acetyl CoA, CO2 and NADH 
(Patel and Roche, 1990). This is a multi-step reaction involving a high degree of 
cooperation among the constituent enzymes of this multienzyme complex (Fig. 1.4). As no 
net production of carbohydrate is possible from its acetyl CoA product, PDC is the main 
regulator of glucose homeostasis in mammals (Sugden and Holness, 2003). E1 catalyses a 
two-step reaction, that is the first and the rate-limiting step in the overall catalytic 
mechanism. Active E1 has an absolute requirement for the cofactor thiamine diphosphate 
(ThDP) and Mg2+ ions. Pyruvate forms an adduct with the thiazole ring of ThDP and this 
undergoes decarboxylation to produce a 2 (1-hydroxyethylidene) ThDP intermediate that 
undergoes oxidation while the dithiolane ring of the lipoyl moiety on E2 becomes 
reductively acetylated. This reductive acetylation step supplies the acetyl group and 
electrons that are transferred, via E2 and E3 respectively, to CoA and NAD+. Both of these 
initial partial reactions are catalysed by E1. E2 then mediates the transfer of the acetyl 
group from its S8-acetyldihyrolipoamide intermediate to free CoA, thus forming acetyl 
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CoA. E3 reoxidises the reduced lipoyl moiety of E2 regenerating the disulphide bridge in 
the lipoyl group with NAD+ acting as the final electron acceptor. 
 
1.4 Pyruvate dehydrogenase (E1) 
 
Mature E1 in mammalian systems exists as a heterotetramer composed of two copies each 
of E1α and E1β subunits (Barrera et al., 1972). The E1 component is a thiamine 
diphosphate dependent (ThDP) enzyme that catalyses the decarboxylation of pyruvate to 
CO2 to form the intermediate compound 2(1-hydroxyethylidene) ThDP and the reductive 
acetylation of the lipoyl groups of the E2 as shown in Fig. 1.4. The enzymatic reaction also 
requires Mg2+, that interacts with the pyrophosphate linkage of ThDP to facilitate binding 
(Walsh et al., 1976). The crystal structure of human E1 PDC has been resolved at a 
resolution of 1.95 Å (Ciszak et al., 2003) providing detailed insights into the catalytic 
mechanism and interaction between the two active sites. ThDP is found at the end of a 20 
Å long hydrophobic channel that is capable of accommodating the lipoyl-lysine swinging 
arms. Although both active sites are chemically equivalent, their dynamic non-equivalence 
has been established indicating that one active-site catalyses the decarboxylation step while 
the other concurrently reductively acetylates E2-bound lipoamide. Similarly, access to 
ThDP is granted to either pyruvate or the lipoyl–lysine moiety at any given moment, 
resulting in flip-flop mechanism (Ciszak et al., 2003). There is a 20 Å tunnel that acts as a 
proton wire and is lined with acidic residues connecting the two active sites. Mutagenesis 
of these acidic residues greatly reduced the rate of E1-mediated decarboxylation (Frank et 
al., 2004). Chemical modification had previously identified cysteine-62 of the α subunit 
and tryptophan-135 of the β subunit (Ali et al., 1995) as being involved in the active site of  
mammalian E1. The amino acid sequences surrounding this tryptophan residue are 
conserved in E1β from several species, suggesting that this region may constitute a 
structurally and/or functionally essential part of the enzyme. Site-directed mutagenesis of 
these two residues has indicated that they are involved in coenzyme binding and could also 
be important for the stability of the E1 heterotetramer. 
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Figure 1.2: Structures of the octahedral and icosahedral E2 inner cores 
(acetyltransferase domains) of PDC 
 
(A) Octahedral E2 core of the A. vinelandii PDC; left to right, twofold, threefold, and 
fourfold views. (B) Icosahedral core of the B. stearothermophilus PDC; left to right, 
twofold, threefold, and fivefold views. In both instances, the three different subunits of a 
single trimer are in different colours, most readily seen on the threefold views (Fussey et 
al., 1991). 
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Figure1.3: Schematic representation of possible subunit organisation of E1 and E3 on 
the surface of the E2:E3BP core assembly 
 
Putative crossbridges between E3 dimer and two E3BPs of PDC (A). Cross bridges 
between E1 tetramers and pairs of E2 monomers of PDC (B). SBD (subunit binding 
domain), LI & L2 (outer and inner lipoyl domains). 
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Figure 1.4: Reaction mechanism for pyruvate dehydrogenase complex 
 
The reactions catalysed by E1 are shown in red, the reaction catalysed by E2 is in green, 
and that catalysed by E3 is indicated in yellow. R represents CH3. Adapted from Perham 
(2000). 
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1.5 Dihydrolipoamide acetyltransferase (E2) 
 
E2 is the central, structural and functional component of all the known PDCs as it forms a 
core about which the other components are tethered tightly but non-covalently. It catalyses 
the transfer of acetyl groups from S8-acetyl dihydrolipoamide to CoA (Butterworth et al., 
1975). The E2 subunit associates as trimers initially before assembling into a larger 
multimeric structure (Hendle et al., 1995). Mammalian E2-PDC has two highly conserved 
lipoyl domains at its N-terminus called outer and inner lipoyl domains, respectively. These 
are followed by a small subunit-binding domain consisting of 30-40 amino acids. At the C-
terminus a large catalytic inner domain is present known as the catalytic domain that is 
also responsible for E2 self-assembly and integration of E3BP (Fig. 1.5). Individual 
domains are connected to each other by well-defined linker regions rich in alanine, proline 
and acidic amino acids. 
1.5.1 Linker regions of E2 
Linker regions of E2 comprise segments of polypeptide chains approximately 20-30 amino 
acids in length. These linker regions are rich in alanine and proline and charged amino 
acids. NMR studies have shown that these linker regions are very flexible but also have a 
degree of rigidity, providing the mobility needed to allow the lipoyl domains and the 
lipoamide prosthetic group to migrate between the catalytically active sites of the three 
constituent enzymes (Fussey et al., 1991). When deletions were made in the linker region 
that separates the lipoyl domain from the dihydrolipoamide dehydrogenase-binding 
domain in a genetically-modified E. coli E2 containing a single lipoyl domain, overall 
PDC activity was impaired without any effect on the reactions of the individual enzymes. 
Moreover, it was necessary to shorten the linker region sequence that separates the lipoyl 
domain from the peripheral-binding domain in the modified E2-PDC to approximately half 
of its original length before there was a pronounced effect on complex activity. Thus it was 
concluded that linker should be at least 13 amino acids long for maintenance of full 
activity (Miles et al., 1988).  
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Figure 1.5: Schematic representation of the domain and linker regions of E2 and 
E3BP of PDC across various species  
 
The domains are separated by long, flexible but extended linker regions of polypeptide 
chain (indicated in light blue). Lipoylated domains are indicated by a star. Adapted from 
Perham (2000). 
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1.5.2 The lipoyl domains of E2 
 
The lipoyl domains play a crucial role in coupling the activities of the three enzyme 
components of PDC by providing ‘swinging arms’ that are mobile and responsible for 
efficient substrate product transfer among the three successive active sites (Fussey et al., 
1991; Yeaman et al., 1978). A specific lysine side chain of each lipoyl domain is modified 
with a lipoamide prosthetic group that is essential for transportation of acetyl groups from 
El to E2, and reducing equivalents from E2 to E3. Lipoic acid is 6, 8-thioctic acid or 1, 2 
dithiolane-3-pentanoic acid and is a sulphur containing cofactor (see section 1.5.3 for 
details). A correctly-folded lipoyl domain is required for the efficient attachment of its 
lipoyl group and recognition by its cognate lipoyl-ligase and El component. The covalent 
attachment of the lipoic acid cofactor to apoprotein requires two enzymes in mammals. 
Firstly a lipoate activating enzyme promotes the formation of lipoyl AMP (Tsunoda and 
Yasunobu, 1967). Then a second enzyme, lipoyl AMP:Nε -lysine-lipoyltransferase, which 
depends on a structural cue rather than a specific amino acid motif, initiates lipoylation of 
the lysine residue (Fujiwara et al., 1994; Fujiwara et al., 1999). In contrast, in E. coli, 
lipoate-protein ligase A is responsible for cofactor attachment and catalyzes both lipoate-
activating and transferring reactions (Morris et al., 1994; Zhao et al., 2003).   
 
1.5.3 Structure of the E2 lipoyl domain  
 
The structure of the lipoyl domain from a number of prokaryotic sources has been solved 
by NMR spectroscopy. However, only one structure has been solved from a mammalian 
source (Howard et al., 1998). The overall backbone structure of the lipoyl domain is quite 
similar in all species examined so far. It comprises a β-barrel-sandwich hybrid that is now 
known to be typical for lipoyl domains (Fig.1.6). The domain is formed by two similar and 
almost parallel four-stranded antiparallel β-sheets connected by loops and turns. The β-
sheets each consist of three major and one minor strand, and are formed around a well-
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defined core of hydrophobic residues. The lipoylatable lysine residue is located on an 
exposed type-1 β turn in one of the β-sheets, within a conserved DKA motif. Highly 
conserved aspartic acid (D) and alanine (A) residues do not appear to be important for the 
recognition of the lipoylatable residue lysine, as determined by site-directed mutagenesis 
whereas the position of the lysine residue itself appears to be critical for lipoylation. When 
the lysine residue was mutated to alanine or moved one residue in either direction, 
lipoylation was not observed as determined by mass spectrometry. This shows that 
lipoylating enzymes require a precise structural cue in order to initiate lipoylation. In the B. 
stearothermophilus lipoyl domain of E2, the combined results of site-directed mutagenesis 
and NMR spectroscopy pointed to the surface loop, close in space to the beta-turn 
containing the lipoyl-lysine residue, as a major determinant of the interaction of lipoyl 
domain with E1 (Wallis and Perham, 1994). In this study the mutant domain retained its 
overall three dimensional structure and ability to become lipoylated but could not be 
reductively acetylated by E1. Jones and co-workers (Jones et al., 2001) found that the 
lipoyl domain of E2 undergoes conformational changes when interacting with their 
homologous E1s but not heterologous E1s. Gong & co-workers (Gong et al., 2000) 
determined the contribution of particular amino acids of the outer lipoyl domain of human 
PDC in E1 recognition and found that the specificity loop involves L140, S141, and T143. 
Other residues that markedly reduce activity of this enzyme on mutagenesis are E162, 
D172, A174, and E179 located close to the lipoylatable lysine residue (K173). They also 
found that influential residues are spread over more than 24 Å on one side of the outer 
lipoyl domain, suggesting surface residues in this region contribute towards substrate 
recognition 
At the far end of one of the sheets, the lipoyl-lysine residue is presented to the solvent in a 
beta-turn connecting two successive strands. The N-terminal and C-terminal ends of the 
folded domain meet on the exact opposite side of the domain in two adjacent beta-strands 
of the other sheet. Lipoyl domains display a remarkable internal symmetry that projects 
one β-sheet onto the other β-sheet after rotation of approximately 180° about a 2-fold 
rotational symmetry axis. 
In E. coli PDC it has been shown that there are three lipoyl domains per E2 chain although 
only the outermost domain needs to be lipoylated for optimal activity and growth (Fussey 
et al., 1988). It was concluded that the reason for retaining three lipoyl domains is to 
extend the reach of the outermost lipoyl cofactor rather than to provide extra cofactors for 
catalysis.  
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Lipoic acid is 6, 8-thioctic acid or 1, 2 dithiolane-3-pentanoic acid and functions in 
transacylation, redox and transport reactions. It plays a central role in oxidative 
decarboxylation where it is covalently attached to a specific lysine side chain on each 
lipoyl domain to form a lipoamide prosthetic group. It is formed from octanoic acid via an 
enzymatic S insertion (Brody et al., 1997). Lipoic acid has a therapeutic role in many PDC 
deficiency symptoms. Clinical improvement has been achieved by oral administration of 
lipoic acid in a young patient (Matalon et al., 1984). In addition, lipoic acid has been 
reported to prevent symptoms of vitamin E deficiency (Podda et al., 1994) and to protect 
against cerebral ischaemia perfusion in rodents (Cao and Phillis, 1995). Ziegler and co-
workers (Ziegler et al., 1997) evaluated the efficacy and safety of the oral treatment with 
the antioxidant lipoic acid in non-insulin dependent diabetes mellitus patients with 
autonomic neuropathy. Treatment with lipoic acid was well tolerated and slightly improved 
the patients with cardiovascular autonomic neuropathy symptoms. 
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Figure 1.6: Structure of the lipoyl domain of the E2-PDC from B. stearothermophilus  
 
The two sets of β-sheets are shown in light blue (strands 1, 3, 6, and 8) and dark blue 
(strands 2, 4, 5, and 7). The lysine residue that becomes lipoylated is in the loop between 
strands 4 and 5 (indicated in green), and the prominent surface loop between strands 1 and 
2 is indicated in red. The orientation of the side chain of the target lysine residue is 
undetermined (Dardel et al., 1993). 
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1.5.4 Peripheral subunit binding domain of E2 
  
The primary function of this domain in human E2 is to bind E1 primarily through the E1β 
subunit (Lessard and Perham, 1995), but it may also retain a residual binding affinity for 
E3 (McCartney et al., 1997). The three dimensional structure of this domain from B. 
stearothermophilus PDC (Kalia et al., 1993) has been resolved and shown to comprise two 
α helices connected by a loop. It is about 43 amino acids in length with 33 of these 
residues forming a structured core composed of two α helices connected by a loop that 
contains a short 310 helix. Two highly conserved hydrophilic residues, Asp34 and Thr24 
are found buried in the structure and these residues are thought to be crucial for the 
stability of the domain (Spector et al., 1998). Sequence comparison of this domain from a 
variety of organisms has shown that they share a very similar structure (Russell and Guest, 
1991) and indeed is one of the most highly conserved regions of the E2 protein.  
 
1.5.5 The C-terminal acetyltransferase domain of E2 
 
The C-terminal domain of E2 forms the central core of PDC by associating into trimers 
that are located on each vertex. Eight such trimers are found in the cubic core in A. 
vinelandii (Mattevi et al., 1993b; Mattevi et al., 1992), while 20 each are found in the 
icosahedral core of B. stearothermophilus (Milne et al., 2002), yeast (Stoops et al., 1992; 
Stoops et al., 1997) and bovine PDC (Behal et al., 1994). The trimers are fairly loosely 
associated via bridges, 20 Å in length, along the two fold axes creating highly dynamic 
structures.  
The C-terminal domain of E2 is responsible for the acetyltransferase activity of this 
enzyme and provides the binding sites involved in E2 self-assembly into the structural 
core. The active site is located in a 30 Å long channel at the C-terminal domain subunit 
interface and runs across trimers. A conserved sequence motif, DHRXXDG, is thought to 
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accommodate the histidine and aspartate necessary for catalysis (Radford et al., 1987). 
Two substrates for transacetylation, CoASH and the acetylated lipoyl domain have to 
approach the E2 active site from opposite directions (Izard et al., 1999). CoASH binds to 
the inside of the E2 core, while the acetylated lipoyl domain interacts with the outside 
(Mattevi et al., 1993b; Mattevi et al., 1993c; Mattevi et al., 1992). Structural homology has 
been observed between the C-terminal domain of E. coli E2 and several chloramphenicol 
acetyltransferases (CATs) (Fussey et al., 1988). The comparison of this domain with CAT 
also shows two highly conserved residues, a histidine and an aspartic acid, thought to be 
involved in the catalytic mechanism of E2. This prediction was later confirmed when the  
crystal structure of the cubic E2 core from A. vinelandii was solved to 2.6Å resolution 
(Mattevi et al., 1993c; Mattevi et al., 1992). CAT is also organised as a tightly-associated 
trimer of identical chains with a catalytic centre, containing a 30 Å long channel, found at 
the interface between subunits and is structurally similar to E2  from A. vinelandii (Leslie, 
1990). 
 
1.6 E3 binding protein (E3BP)  
 
This subunit, also originally known as protein X, has been found only in the PDC of 
mammals (De Marcucci and Lindsay, 1985), Ascaris suum (Klingbeil et al., 1996) and 
yeast (Behal et al., 1989). The presence of this subunit in PDC was not recognised for 
many years until 1985, because it was thought to be a degradation product of E2 as it 
contained a covalently-attached lipoyl group that can be reductively acetylated in a similar 
manner to the lipoyl domain of E2. It was found to be an individual component of PDC 
when anti-sera raised against other components of PDC failed to elicit a reaction against 
E3BP and vice-versa (De Marcucci and Lindsay, 1985; Jilka et al., 1986). Peptide mapping 
and radiolabelling studies further confirmed E3BP as a fourth separate component of PDC 
(De Marcucci et al., 1986; Hodgson et al., 1986; Jilka et al., 1986; Neagle et al., 1989). The 
main function of this protein is to bind E3 to the core structure; hence it was renamed E3 
binding protein (Lawson et al., 1991). Initially the precise role of the E3BP subunit was not 
known exactly because of its high affinity for the 60-meric E2 assembly from which it 
could only be dissociated under denaturing conditions. However, it was found that this 
subunit could be cleaved by selective proteolytic degradation employing arg C, releasing a  
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15 kDa N-terminal fragment, whereas the 35 kDa C-terminal fragment was still bound to 
the high molecular weight core of the complex. Arg C cleavage of E3BP was prevented by 
the presence of E3; moreover the proteolytically-modified E2:E3BP was no longer able to 
bind E3 with high affinity (Sanderson et al., 1996a).   
 The human PDX1 gene encoding E3BP was cloned in 1997 (Harris et al., 1997) and 
showed high similarity to that of E2-PDC. It consisted of a lipoyl domain, a subunit 
binding domain, a C-terminal domain and flexible linker regions (Fig. 1.5). The lipoyl 
domain of E3BP can be acetylated but no acetyltransferase activity or other catalytic role 
has been identified for E3BP. In the absence of E3BP, PDC sustains a low level of activity 
since the peripheral subunit-binding domain of the E2 displays residual affinity for E3 
(McCartney et al., 1997). Removal of E2 lipoyl domains by collagenase treatment of the 
complex results in retention of 15-20% of overall PDC activity as compared to wild-type 
complex, suggesting that the E3BP lipoyl domain can compensate for the missing E2 
lipoyl domains to some extent (Sanderson et al., 1996a).  
Recent studies with low resolution structure analyses indicate that there is 2:1 binding of 
E3BP and E3 forming a stable complex. One lipoyl domain of this complex may be 
peripherally extended away from the E3 dimer, whereas the second lipoyl domain is 
docked into one of the E3 active sites that are located at the monomer-monomer interface  
in a dynamic state (Smolle et al., 2006) suggesting, as is the case for E1, that the two 
actively interact with their cognate substrate in a flip-flop mechanism.  
Complexes deficient in E3BP have been shown to retain partial PDC activity both in vivo 
and in vitro. Reconstitution studies have shown that bovine PDC lacking E3BP is able to 
retain residual activity in the presence of a molar excess of E3. However, in the presence of 
stoichiometric amounts of E3, little or no activity was apparent (McCartney et al., 1997). 
This is thought to be due to retention of a limited ability of mammalian E2 to bind to the 
E3 component, allowing E3 to bind specifically but with low affinity. 
This retention of residual binding activity is supported by studies on a group of patients 
who have no immunologically-detectable E3BP but, can still sustain PDC activity at 
approximately 10-20% of wild-type levels (Geoffroy et al., 1996; Marsac et al., 1997). 
Such patients displayed symptoms that were indistinguishable from those associated with 
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classical PDC deficiency. Initially it was unclear if such patients produced low amounts of 
E3BP that might be compatible with the maintenance of life. However subsequent analysis 
of E3BP deficient patients indicated that they carried large deletions within the open 
reading frame of E3BP cDNA (Marsac et al., 1997). These large deletions occurred as a 
result of point mutations at intron-exon boundaries in genomic DNA leading to aberrant 
splicing and loss of an entire exon (Dey et al., 2002). 
 
1.7 Dihydrolipoamide dehydrogenase (E3) 
 
E3 is a member of the enzyme family known as the pyridine disulphide oxidoreductases 
involved in the transfer of electrons between pyridine nucleotides and disulphide 
compounds. The other main members of this family include glutathione reductase, 
thioredoxin reductase and NADH peroxidase.  
In PDC, E3 brings about reoxidation of the reduced lipoyl moiety on E2 and E3BP. 
Initially the dihydrolipoamide on E2 transfers its electrons to a reactive cysteine pair on 
E3, and then the electrons are passed via a tightly bound FAD cofactor before being finally 
transferred to NAD+. The end result is the formation of NADH and an oxidised lipoamide 
moiety on E2 that is now ready for the next catalytic cycle.  
In the PDC, E3 exists as a dimer of two identical subunits. Each subunit contains a redox 
active disulphide, a non-covalently bound FAD molecule and NAD+ binding site. Only the 
dimeric form of the enzyme is active and can interact correctly with E2 (Schulze et al., 
1991). The three dimensional structures of E3 from several different sources have been 
solved by x-ray crystallography the most recently from human (Brautigam et al., 2005). 
E3 also contains two active sites, each of which is formed by the flavin ring of FAD, two 
cysteine residues from one monomer and a histidine residue from the second monomer 
(Toyoda et al., 1998). Site-directed mutagenesis of this histidine residue (His-425) in 
human E3 resulted in almost complete abolition of E3 activity and it was concluded that 
His-452, was the probable proton acceptor/donor critical to   E3 catalysis. In addition, the 
local environment around His-452 and Glu-457 is important in the binding of 
Chapter 1  
 
20 
20 
dihydrolipoamide to the enzyme (Kim and Patel, 1992). E3 is thought to be the identical 
gene product serving all three 2-oxoacid dehydrogenase multienzyme complexes in 
mammals.  
 
1.8 Regulation of PDC  
 
PDC is located at a significant branch-point in metabolism channelling intermediates into 
the tricarboxylic acid cycle (Fig. 1.1.). Two major types of regulatory mechanism are 
present in PDC from higher organisms. One is the end product inhibition by NADH and 
acetyl CoA and the other involves covalent modification of the complex by a 
phosphorylation / dephosphorylation mechanism mediated by several protein kinases that 
are tightly bound to the complex and a specific phosphoprotein phosphatase that is more 
loosely associated (Behal et al., 1993) (Fig. 1.7).  
Stimulation of the pyruvate dehydrogenase kinase activity by acetyl-CoA and NADH is 
thought to occur due to changes in acetylation and reduction states, respectively of the 
transacetylase lipoyl moieties (Yeaman et al., 1978). Four isoenzymes of PDC kinase 
namely PDK1, PDK2, PDK3 and PDK4 have been identified and characterised, PDK4 
being the most recent (Rowles et al., 1996). 
Initially PDC kinase (PDK) was thought to be organised as a heterodimer having an α 
subunit of molecular weight 48,000 and the β subunit of molecular weight 45,000 (Stepp et 
al., 1983). However, more recently it became apparent that there was a possibility of the 
individual isozymes of PDK forming homo- and heterodimers, which might differ with 
respect to their kinetic parameters and regulation in mammals. Indeed Boulatnikov and 
coworkers (Boulatnikov and Popov, 2003) have recently demonstrated heterodimerisation 
between PDK1 and PDK2.  
The kinase is present in very small quantities and is tightly bound to the complex. PDK 
catalyse the phosphorylation of three serine residues present on E1 α subunit. These are 
Ser-264, Ser-271 and Ser-203 in human PDC. Phosphorylation at site 1 occurs 
independently. However, phosphorylation at site 2 (Ser-271) and site 3 (Ser–203) requires 
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the presence of E2 (Yeaman et al., 1978). Each of these isoenzymes exhibits tissue specific 
expression and acts at different preferential sites. PDK1 and 4 are mainly expressed in liver 
and muscle tissues, while PDK3 is present in the kidney, brain and testes. PDK2 is present 
in most tissues (Gudi et al., 1995). Site 1 seems to be preferentially phosphorylated by 
PDK2, site 2 by PDK3 while site 3 can only be phosphorylated by PDK1 (Korotchkina and 
Patel, 2001). PDK1-3 associate with the E2 inner lipoyl domain while PDK4 preferentially 
interacts with the  E3BP lipoyl domain (Yeaman et al., 1978). 
PDC kinase is a target protein in several drug development programmes since inhibitors of 
this enzyme should activate PDC, thereby increasing carbohydrate utilisation and is of 
particular interest in the treatment of diabetes.  
Pyruvate dehydrogenase is phosphorylated and inactivated by its specific, intrinsic, cAMP-
independent protein kinase, using Mg ATP as substrate (Cooper et al., 1974). Reactivation 
of the enzyme complex is accomplished by a Mg2+ and Ca2+ dependent phosphoprotein 
phosphatase, that removes the phosphoryl groups from phospho-E1. Huang and co-workers 
(Huang et al., 1998) showed that there are at least two isoenzymes of pyruvate 
dehydrogenase phosphatase (PDP), designated as PDP1 & PDP2 in mammals, that are 
different with respect to tissue distribution and kinetic parameters and, therefore, are likely 
to be different functionally. These isoenzymes have tissue specific expression with PDP1 
located primarily in muscle whereas PDP2 is found in liver and adipose tissue (Huang et 
al., 1998). In contrast to PDK, PDP is loosely associated with PDC, although its catalytic 
activity is increased 7-16 fold by interaction with the E2 lipoyl domain (Chen et al., 1996).   
Like PDP1, PDP2 is a Mg2+ dependent enzyme, but its sensitivity to Mg2+ ions is almost 
ten-fold lower than that of PDP1. In contrast to PDP1, PDP2 is not regulated by Ca2+ ions. 
Instead, it is sensitive to the polyamine spermine, which in turn has no effect on the 
enzymatic activity of PDP1 (Huang et al., 1998).  
Another long term regulatory mechanism involves several hormones and nutritional factors 
that control the levels and activity of the PDC in several tissues. These factors have been 
studied, but to a lesser extent and probably affect the long term regulation of PDC through 
changes in the levels of its catalytic and regulatory components by controlling gene 
expression at the  transcriptional and translational level (Patel and Harris, 1995).  
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Figure 1.7: Regulatory mechanism for PDC by feedback inhibition and covalent 
modification via protein kinase(s) and phosphoprotein phosphatase(s) 
 
Adapted from Behal et al. (1993). 
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1.9 Pyruvate dehydrogenase complex defects 
 
As human PDC is composed of several different gene products, a genetic defect involving 
any one of them can lead to impairment in its function. Deficiencies of the pyruvate 
dehydrogenase complex are now well documented and mutations have been described in 
the genes PDHA1, PDHB, DLAT, DLD, PDX1 and PDP1 encoding the E1α, E1β, E2, E3, 
E3BP and PDP1 proteins, respectively (Brown, 1992; Brown et al., 2004; Lissens et al., 
2000; Seyda et al., 2000).  
Pyruvate dehydrogenase complex deficiency is one of the most common disorders leading 
to neurodegeneration associated with abnormal mitochondrial metabolism as the citric acid 
cycle is a major biochemical process central to energy production and maintenance of 
intracellular ATP levels. Malfunction of the cycle leads to abnormal lactate build-up 
resulting in non-specific symptoms (e.g., severe lethargy, poor feeding, tachypnea), 
especially during times of illness, stress, or high carbohydrate intake. Progressive 
neurological symptoms usually start in infancy but may be evident at birth or in later 
childhood. These symptoms may include developmental delay, intermittent ataxia, poor 
muscle tone, abnormal eye movements or seizures. 
The vast majority of these lesions reported to date are caused by mutations in the coding 
region of the gene responsible for E1α. About 80 point, insertion and deletion mutations 
have been reported in the E1α subunit causing a range of symptoms of varying degrees of 
severity in individual patients (Chun et al., 1993). The gene for E1α is localised on the X 
chromosome (Szabo et al., 1990) exposing it to a greater chance of mutation. In addition, 
location of the E1α gene on the X chromosome is responsible for variations in the clinical 
symptoms of E1α mutation between males and females, specifically the potential for the 
occurrence of mosaicism in heterozygous females. Complete PDC E1α deficiency has not 
been observed in males and is presumed to be lethal at an early stage of development. By 
contrast, mutations that abolish E1α protein synthesis are commonly found in heterozygous 
female patients whose tissues are composed of two populations of cells as a consequence 
of X chromosome inactivation. In these females, some cells have completely normal PDC 
function whereas others are highly deficient (Dahl et al., 1992).  
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The random pattern of X inactivation in different individuals, and in different tissues in the 
same individual, contributes significantly to the widely divergent clinical presentations in 
female patients. Although the majority of these heterozygous females present with obvious 
PDC deficiency, a small number of females carrying an E1α subunit mutation have mild 
symptoms or no symptoms at all, presumably because of an X-inactivation pattern 
favouring expression of the normal X chromosome (Fujii et al., 1994; Matthews et al., 
1994).  There is a male preponderance amongst severely affected patients whereas females 
tend to have milder metabolic and neurological dysfunction (Brown et al., 2004). 
Mutations affecting the PDHB gene encoding E1β have been identified in two patients 
only so far. In both cases a single amino acid substitution destabilises the E1 
heterotetramer (Brown et al., 2004).  
Although not reported as frequently as E1 defects, abnormalities in E2, E3 and E3 binding 
protein have also been found producing a broad range of symptoms of varying severity 
(Chun et al., 1991; Dahl et al., 1992; Endo et al., 1991). Mutations in the PDX1 gene 
encoding E3BP have been reported in a dozen patients (Aral et al., 1997; Geoffroy et al., 
1996; Ling et al., 1998; Marsac et al., 1993; Ramadan et al., 2004). 
More than 20 cases of E3 deficiency have been reported due to different mutations in the 
DLD gene encoding the E3 enzyme, common to PDC, OGDC and BCOADC (Hong et al., 
1996; Robinson et al., 1989).  
Defects in the E2 component have also been detected in patients with severe lactic 
acidaemia (Robinson et al., 1990). However the numbers of patients encountered with 
defects in the E2 are relatively few.  
PDC deficiency must be differentiated from other disorders causing lactic acidosis, 
particularly defects of the electron transport chain. Although electron transport chain 
defects may have similar neurological manifestations to PDC defects, they also have 
systemic manifestations (skeletal and cardiac myopathies) not found in inborn errors of 
PDC. Biochemically these two entities can be differentiated because electron transport 
chain defects have an abnormally elevated lactate /pyruvate ratio and impaired fatty acid 
oxidation (Robinson et al., 1989). Further detailed information on this topic is provided in 
section 4.1, Chapter 4. 
Chapter 1  
 
25 
25 
Another type of disease involving PDC subunits is primary biliary cirrhosis. This is an 
autoimmune disease characterised by the production of anti-mitochondrial auto-antibodies 
(AMA) against components of PDC although the major auto-antigen is the E2 component 
(Fussey et al., 1988; Gershwin et al., 1987). The primary epitope appears to be the inner 
lipoyl domain of E2 and involves the lipoamide prosthetic group. Since this domain is 
conserved in E3BP, it is also another major target of the autoimmune response (Surh et al., 
1989). Autoantibodies have also been reported against E2-OGDC (Fussey et al., 1988), 
BCOADC (Fussey et al., 1991) and the E1α protein (Fregeau et al., 1990). 
Defects in ThDP-containing enzymes such as pyruvate dehydrogenase have been reported 
in brain and peripheral tissues from patients suffering from Alzheimer’s disease (Gibson et 
al., 1988). A 50% decline in the activity of PDC, OGDC and cytochrome oxidase has also 
been shown in patients’ brains suffering from Alzheimer’s disease (Gibson et al., 1998). 
The exact molecular mechanism involved in linking PDC and OGDC to this disease is not 
known, however, possibilities are that free oxygen radicals and accompanying oxidative 
stress may cause damage to these enzymes (Shi et al., 2005). Defects in PDC may also 
reduce acetyl-CoA levels leading to impaired production of acetylcholine that is an 
important  neurotransmitter in both the peripheral and central nervous systems (Szutowicz 
et al., 2006). Many patients suffering from systemic sclerosis, a multi-system connective 
tissue disorder, also produce antibodies to E1α (Fujimoto et al., 1995). Detailed enzymatic 
and genetic analysis of patients with such defects is very important in understanding the 
exact role of each component of PDC and also beneficial for clinical prenatal diagnosis, 
improved treatment regimens and potentially gene therapy in the future.  
The diagnosis of PDC deficiency has been enhanced by the availability of specific assays 
for PDC and its catalytic components. Immunological and molecular biological methods 
have facilitated characterisation of the genetic basis of specific PDC defects. Immunoblots 
and RNA blot analyses using specific antibodies and cDNA probes corresponding to all the 
catalytic components of PDC indicate considerable heterogeneity in PDC deficiencies 
(Brown et al., 2004; Patel et al., 1992).  
As PDC is ultimately responsible for tailoring the appropriate usage of glucose in the body 
to match the varying energy requirements of individual tissues on a minute-by-minute 
basis; therefore, PDK and its inhibitors are of great importance as therapeutics for diabetes, 
where glucose metabolism is impaired. Early interventions to treat PDC deficiency include 
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dietary manipulation and vitamin supplementation (Falk et al., 1976; Matalon et al., 1984). 
Ketogenic diets appear to lower blood lactate levels, but do not significantly improve 
neurological function in most cases. Another form of therapy includes the provision of 
thiamine and/or lipoic acids in an attempt to maximise residual PDC activity. Reduced 
lactic acidosis was observed in PDC deficient patients on treatment with dichloroacetate, 
which is an E1-kinase inhibitor (Berendzen et al., 2006; Stacpoole, 1989; Stacpoole et al., 
2006). 
Recently, a vector using recombinant adeno-associated virus (rAAV) that contained a full-
length E1α green fluorescent protein (GFP) construct was used to deliver wild type E1α 
into mitochondria after injection of the construct in vivo into the central nervous system of 
rats and in vitro into human cells. Transfection of cultured fibroblasts from a male patient 
with E1α deficiency led to partial restoration of PDC activity, as determined by 
decarboxylation of 14C-pyruvate. These data indicate that at least partial correction of PDC 
defects may be feasible by gene transfer (Stacpoole et al., 2003). 
 
1.10 Biophysical tools in the study of PDC 
 
PDC is a highly important multienzyme complex central to the energy metabolism of an 
organism. Various researchers using a combination of molecular biological, biochemical 
and biophysical approaches have determined the structure, function and modes of 
interaction of various components of PDC. For structural determination, the choice of 
biophysical techniques depends largely upon the physical and biochemical properties of 
the protein to be studied and also on the advantages and limitations of the techniques 
employed. For example, crystallography gives a very high resolution (up to 0.1 nm) 
revealing fine details of atomic structure but requires the production of high quality 
crystals, which is always not feasible. The crystal structure of human E1-PDC has been 
resolved at a resolution of 1.95 Å (Ciszak et al., 2003) and the crystal structure of human 
E3 (Brautigam et al., 2005) and E3BP-subunit binding domain in association with E3 has 
been recently resolved at 2.6 Å (Ciszak et al., 2006). 
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NMR is another versatile tool for structural determination of macromolecules in solution 
giving high resolution (0.2-0.3 nm), information about the flexibility and dynamics of 
specific regions of polypeptides and providing a means for mapping sites of protein-protein 
interaction. However, this approach requires concentrated solutions of protein and is 
limited to the analysis of relatively small proteins (Mr, 30 kDa or less). The structure of the 
inner lipoyl domain of human PDC has been resolved through NMR (Howard et al., 1998). 
Similarly, the three-dimensional structure of the lipoyl domain (Dardel et al., 1993) and the 
peripheral subunit-binding domain of dihydrolipoamide acetyltransferase from the PDC of 
B. stearothermophilus has also been solved by this approach (Kalia et al., 1993). 
Small angle X-ray scattering (SAXS) is another biophysical tool that is often employed in 
combination with other structural and biochemical methods and is an important 
complementary approach to generate consistent models of biological macromolecules 
(Koch et al., 2003). SAXS not only provides low-resolution models of protein complexes 
in solution, but also in many cases delivers answers to significant functional questions. For 
example the structure of human E3 bound to subunit binding domain of E3BP has been 
resolved by SAXS and shows great asymmetry (Smolle et al., 2006). Most importantly, the 
method permits the study of native oligomeric protein complexes in near physiological 
state and the analysis of structural changes in response to variations in external conditions, 
thus yielding valuable information on the relationship between these structural changes and 
the operation of the proteins under investigation. In many cases solution structures differ 
significantly and are more open and extended than the equivalent crystal structures.  
Determination of the three-dimensional (3D) organization of PDC is key to understanding 
its highly regulated, multi-functional roles and underlying molecular mechanisms. While 
much progress has been made in the determination of 3D structures of the constituent 
enzymes of microbial and yeast PDCs through X-ray crystallography, NMR spectroscopy 
and electron cryomicroscopy (cryo EM), 3D structural studies of the human PDC 
complexes have been hampered both by sample unavailability and by the increased 
complexity of additional regulatory components. Construction of a recombinant human 
PDC in vitro by expressing and purifying its individual enzymes in E. coli has been 
achieved in this laboratory followed by their spontaneous reconstitution into active 
complex. This should facilitate detailed investigation of how the multiple components of 
human PDC and their cofactors interact with each other in normal as well as pathological 
states. Various biochemical, molecular as well as common biophysical techniques such as 
circular dichroism, size exclusion chromatography and analytical ultracentrifugation have 
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been used in this study. Analytical ultracentrifugation is an extremely versatile and 
powerful technique for characterizing the solution-state behaviour of macromolecules. 
When coupled with contemporary data analysis methods, experiments performed in the 
analytical ultracentrifuge are capable of rigorously determining sample purity, 
characterizing assembly and disassembly mechanisms of biomolecular complexes, 
determining subunit stoichiometries and detecting and characterizing macromolecular and 
conformational changes.  
Circular dichroism (CD) is an excellent tool for rapid determination of the secondary 
structure and folding properties of proteins that have been obtained using recombinant 
techniques or purified from tissues. The most widely used applications of protein circular 
dichroism are to determine whether an expressed, purified protein is folded correctly or if 
mutations affect its conformation or stability. CD is defined as the differential absorbance 
of left circularly polarized light (LCPL) and right circularly polarized light (RCPL): CD = 
Abs (LCPL) – Abs (RCPL). Ellipticity is the unit of circular dichroism and is defined as 
the tangent of the ratio of the minor to major elliptical axis. To be “CD active”, a molecule 
must be structurally asymmetric and exhibit absorbance in the uv region. Asymmetry can 
result from chiral molecules such as the peptide backbone of proteins, a non-chiral 
molecule covalently attached to a chiral molecule (aromatic amino acid side chains), or a 
non-chiral molecule in an asymmetric environment (e.g. a chromophore bound to a 
protein). Increased relative absorption of left polarized light results in a positive CD signal, 
while a negative signal is the result of right polarized light being more highly absorbed. 
Proteins are CD active (all amino acids except glycine contain a chiral carbon), and the 
resulting CD signals are sensitive to protein secondary and tertiary structure.  
Three common secondary structure motifs (alpha helix, beta sheet, and random coil) 
exhibit distinctive CD spectra in the far-ultraviolet region (170-260 nm). Alpha-helical 
proteins have negative peaks at 222 nm and 208 nm and a positive peak at 193 nm. 
Proteins with well-defined, antiparallel β-pleated sheets (β-helices) have a trough at 218 
nm and a peak at 195 nm, whereas disordered proteins have very low ellipticity above 210 
nm and negative bands near 195 nm (Greenfield and Fasman, 1969; Holzwarth and Doty, 
1965; Venyaminov et al., 1993). Secondary structure determination by CD is reported to 
achieve accuracies of 0.97 for helices, 0.75 for beta sheet, 0.50 for turns and 0.89 for other 
structure types (Manavalan and Johnson, 1987).  
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Using CD spectra, the secondary structure of proteins can be estimated using a variety of 
computer algorithms. The near ultraviolet region (320-260 nm) provides a fingerprint of 
the tertiary structure of proteins. Asymmetric environments of aromatic amino acids, that 
are sensitive to protein conformation in the local environment, provide the basis of the 
near-uv CD signal (Greenfield, 1975).  
Tryptophan fluorescence is another approach widely used in protein studies to determine 
structural changes in proteins. The major goal in the application of this tool is to interpret 
the fluorescence properties in terms of structural parameters and to predict the structural 
changes in the protein. Since the wavelength and intensity of tryptophan fluorescence 
emission spectra is sensitive to the surrounding environment therefore, it is regularly 
employed to monitor perturbation of the local tertiary structure.  
 
1.11 The 2-oxoglutarate dehydrogenase complex (OGDC) 
 
This mitochondrial enzyme assembly catalyses the oxidative decarboxylation of 2- 
oxoglutarate to succinyl CoA. E1o also utilizes thiamine diphosphate (ThDP) as a cofactor. 
The ThDP is tightly but non-covalently bound to E1, which catalyses the oxidative 
decarboxylation of 2-oxoglutarate and subsequent binding of the resultant succinyl moiety 
to a sulphur residue of E2 bound lipoic acid with concomitant regeneration of the ThDP. 
The core enzyme E2 catalyses succinyl group transfer to coenzyme A producing succinyl-
CoA. A multiple random coupling mechanism has been proposed for the E2 lipoyl domain 
in OGDC from E. coli (Hackert et al., 1983). E3 catalyses the two electron transfer of 
reducing equivalents from E2 to produce NADH and H+
. 
The basic organisation of this complex is also believed to be similar to PDC with 24 copies 
of dihydrolipoyl succinyltransferase (E2o) forming a cubic core structure displaying 
octahedral symmetry to which 12 copies of 2-oxoglutarate dehydrogenase (E1o) bind non-
covalently (Yeaman et al., 1978). An estimated 6 copies of dihydrolipoamide 
dehydrogenase (E3) are attached non-covalently to the six faces of this complex. In 
mammalian OGDC, some early studies suggested that E1o
 
appears to bind more tightly to 
the E2o
 
core than E3 (Yeaman et al., 1978).
 
More recent reports indicate that single copies 
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of E1o and E3 form a high-affinity subcomplex, with the homodimers binding to the E2o 
core through the N-terminal region of  E1o (McCartney et al., 1998). 
OGDC plays an important role in the regulation of 2-oxoglutarate concentration which is a 
key citric acid cycle intermediate and a common substrate for several enzymes. Regulation 
of OGDC is subject to feedback inhibition with its end products, NADH and succinyl CoA 
inhibiting the E1o component directly (Lawlis and Roche, 1981). Changes in both Ca2+ 
and Mg2+ concentrations can also control OGDC activity and along with ThDP are 
required for maximal enzyme activity (Panov and Scarpa, 1996). Agonists that increase 
cytosolic free Ca2+ levels have been shown to stimulate metabolic flux through the 2-
oxoglutarate dehydrogenase complex. Another study indicated that physiological 
concentrations of inorganic Pi may exert significant activation of OGDC that could further 
be potentiated by Mg2+ (Chinopoulos et al., 1999). A number of inhibitors reduce the 
activity of this complex including several reactive oxygen species and lipid peroxidation 
products such as 4-hydroxy-2-nonenal (Andersson et al., 1998; Chinopoulos et al., 1999; 
Humphries and Szweda, 1998; Park et al., 1999). Hydrogen peroxide interacts with nitric 
oxide (NO) to form peroxynitrite a reactive nitrogen species that is also reported to be an 
effective inhibitor of OGDC (Park et al., 1999). Hydroxynonenal and perhaps hydrogen 
peroxide may reduce the activity of OGDC relatively selectively compared to other 
mitochondrial components of energy metabolism (Lucas and Szweda, 1999). Methotrexate 
and some other environmental toxins can also inhibit OGDC function (Caetano et al., 
1997).   
 
1.12 Dihydrolipoamide succinyltransferase (E2o) 
 
The core protein, E2o
 
is encoded by the DLST gene that in humans is located on 
chromosome 14q24.3. The human DLST gene and a pseudogene were first characterised in 
1994 (Nakano et al., 1994). The sequence of the human gene showed minor variations 
from those of previously published cDNAs (Ali et al., 1994; Nakano et al., 1993). 
Determination of the entire sequence of the dihydrolipoamide succinyltransferase gene of 
human OGDC revealed a complete absence of any obvious nucleotide sequence 
corresponding to the E3-binding and/or E1-binding domain. It has been suggested that the 
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exon coding for the E3-binding and/or E1-binding domain may have been lost from the 
gene during evolution (Nakano et al., 1994). Thus human dihydrolipoamide 
succinyltransferase possesses a unique structure consisting of only two domains in contrast 
to the dihydrolipoamide acyltransferases of the other 2-oxoacid dehydrogenase complexes. 
 
1.13 2-oxoglutarate dehydrogenase (E1o) 
 
E1o
 
in humans is coded by the OGDH gene located on chromosome at position 7p13-p14 
and the gene was initially characterised in 1998 by Koike (Koike, 1998). Although, 
thiamine diphosphate is a cofactor for this enzyme, its deficiency did not lower the levels 
of the mRNA for this component in several tissue culture systems (Pekovich et al., 1998). 
In the octahedral complex of OGDC, E1o exists as an α2 homodimer whereas E1 of PDC is 
a heterotetramer. Studies on mammalian OGDC employing specific proteolysis and N-
terminal sequence analysis, have identified a proteolytically sensitive region at the extreme 
N- terminus of the E1o component with significant sequence similarity to the E3BP and E2 
components of mammalian PDC (Rice et al., 1992). These similarities suggested that E1o  
may perform some functions normally devolved to E2 in PDC and BCOADC. Gel 
permeation of the E1o/E3 fraction of OGDC, under associative conditions, has 
demonstrated that these two enzymes interact with high affinity to form a stable 
subcomplex with an apparent Mr consistent with a 1:1 stoichiometry. These studies provide 
the first direct biochemical evidence that uniquely, in mammalian OGDC, its constituent 
E1O enzyme is responsible for binding the E3 component to the multi-enzyme complex 
(McCartney et al., 1998), a function similar to protein E3BP in PDC. Moreover, 
subsequent immunological analysis indicated that antiserum to E1o
 
recognised antigenic 
epitopes in E3BP of PDC, whereas anti-E3BP-specific serum was also able to weakly 
recognise E1o (McCartney et al., 1998).  
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1.14 Dihydrolipoamide dehydrogenase (E3) 
 
Human dihydrolipoamide dehydrogenase (E3) is an enzymatic component common to the 
mitochondrial 2-oxoacid dehydrogenase and glycine decarboxylase complexes and has 
been described earlier in section 1.7 in this chapter. It is encoded by the DLD gene which 
was first characterised in 1993 (Feigenbaum and Robinson, 1993).  
Site-directed mutagenesis of human E3 has shown that lysine-54 is necessary for the 
protein-FAD interaction and for the catalytic activity of this enzyme whereas, glutamate–
192 is involved in maintaining the appropriate orientation of lysine-54 during catalysis 
(Liu et al., 1999). The amount of E3 found in mitochondria typically exceeds the amount 
required for the maximal activation of OGDC, PDC and BCOADC. This finding has led to 
speculation that E3 may also have roles in the transfer of electrons between substrates 
within mitochondria including ascorbic acid (Xu and Wells, 1996).  
  
1.15 Role of OGDC in disease 
 
OGDC deficiencies have been associated with several neurodegenerative disorders 
including Alzheimer’s disease and Parkinson’s disease. It is also linked to primary biliary 
cirrhosis, characterised by the presence of anti-mitochondrial antibodies against the 
subunits of the 2-oxoacid dehydrogenase complexes including E2o
 
(Kaplan and 
Lundsgaarde, 1996). However, deficiency of OGDC is more characteristically associated 
with neurological syndromes. This association is not surprising because of the acute 
dependence of the integrity of the nervous system on oxidative metabolism. The 
neurological syndromes linked to OGDC deficiency vary from fatal disease of the neonates 
to chronic disease of the elderly. Infantile lactic acidosis with severe mental retardation is 
the characteristic symptom of OGDC deficiency (Hong et al., 1996; Munnich et al., 1982; 
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Robinson et al., 1989; Shaag et al., 1999). Many symptoms of OGDC deficiency are a 
result of deficiency of E3, with accompanying deficiencies in PDC as well as BCOADC 
(Hong et al., 1996; Munnich et al., 1982; Robinson et al., 1989). The affected patients can 
be homozygous for mutations in DLD or can be compounded heterozygotes, inheriting 
different defective DLD genes from each of their parents (Robinson et al., 1989). 
Psychomotor retardation in early childhood has been associated with somewhat milder 
deficiency of OGDC (Bonnefont et al., 1992; Guffon et al., 1993). Intermittent 
psychomotor symptoms occur in Ashkenazi Jews who generally have mild E3 deficiency 
(Shaag et al., 1999). For example, a group of these children have intermittent attention 
deficit disorder with mild ataxia, incoordination and hypotonic weakness linked to a single 
G229C mutation in the DLD gene. 
Friedreich’s ataxia (Wong et al., 1999) is another condition associated with OGDC 
deficiency (Sheu and Blass, 1999). This condition was named after the German physician 
Nicholas Friedreich, who first described the condition in the 1860s. These patients develop 
ataxia and signs of damage to the long tracts of the spinal cord, with significant clinical 
manifestations typically beginning in adolescence or early adult life (Sheu and Blass, 
1999). The primary genetic defect is in the FRDA gene (Wong et al., 1999). FRDA 
encodes the protein frataxin that is involved in free radical metabolism within 
mitochondria. The Friedrich mutations can lead to inactivation of a number of key 
mitochondrial enzymes including aconitase (Rotig et al., 1997). E3 deficiency has been 
confirmed in the brain of Friedreich’s ataxia patients (Mastrogiacomo et al., 1996).  
Loss of mitochondrial enzyme activities including PDC and OGDC has been found in 
spinocerebellar ataxia also (Sheu and Blass, 1999; Sorbi et al., 1989). These ataxias 
involve varying combinations of signs and symptoms associated with dysfunction of the 
spinal cord and cerebellum and sometimes other parts of the brain. The precise gene 
product involved differs among the various types of spinocerebellar ataxias characterised 
so far (Pandolfo and Montermini, 1998).  
Another important association of OGDC is with Parkinson’s disease, a common disease of 
later life that impairs secondary motor function and often impairs intelligence as well. The 
best known defect in energy metabolism is in complex 1 of the electron transport chain, 
that may be caused in some Parkinson’s disease patients by a defect in mitochondrial DNA 
(Schapira et al., 1998). Deficiency of OGDC has been found in Japanese patients with 
Parkinson’s disease, based on immunocytochemical studies (Mizuno et al., 1994). A 
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genetic abnormality in the DLST gene, encoding E2o
  
has also been reported in Japanese 
patients suffering from Parkinson’s disease (Kobayashi et al., 1998). The Parkinson’s 
syndrome can be induced by poisoning with the compound MPTP (1-methyl 4-phenyl 1, 2, 
3, 6-tetrahydropyridine), a chemical that is related to the opioid analgesic drugs. This 
chemical is converted in mitochondria to MPP+. MPP+ inhibits complex 1 of the electron 
transport chain but also inhibits OGDC. The reported activity of OGDC in human brain is 
about 10% of that of complex 1, suggesting that MPTP inhibition of OGDC might be 
functionally more important than inhibition of the electron transport chain per se (Sheu and 
Blass, 1999).  
Alzheimer’s disease (AD) accounts for over 80% of dementias in older people (Nolan et 
al., 1998). The classical pathological lesions visible under the light microscope are amyloid 
plaques and neurofibrillary tangles (Geddes et al., 1997). Among the characteristic 
biochemical lesions are oxidative stress and deficiency of OGDC (Butterworth and 
Besnard, 1990; Gibson et al., 1988; Mastrogiacomo et al., 1996; Terwel et al., 1998). At 
least two mechanisms may contribute to the reduction of OGDC activity in AD. A genetic 
component is implied by the finding that OGDC deficiency persists in cultured skin 
fibroblasts from many but not all patients with AD (Sheu and Blass, 1999). However, a 
plausible pathogenic mutation has not been defined as yet. Secondary damage to OGDC 
also appears to occur in AD due to other mutations and particularly as a result of oxidative 
stress. OGDC is particularly susceptible to oxidative stress (Sheu and Blass, 1999) which 
appears to be an important part of AD process and may be the main contributor to the 
reduction of OGDC activity in this disease. Thus genetic and non genetic mechanisms are 
not mutually exclusive and indeed polymorphisms (or mutations) in a gene encoding an 
OGDC component may sensitise OGDC to damage by free radicals.  
Human apolipoprotein E (APOE), a major component of lipoproteins,  plays a central role 
in the metabolism and redistribution of  lipids such as cholesterol and dysfunctional forms 
of APOE are associated with increased risk for AD (Corder et al., 1993; Farrer et al., 1997; 
Saunders et al., 1993; Strittmatter et al., 1993). Indeed, evidence indicates that DLST and a 
dysfunctional isoform of APOE, APOE4 may interact in the causation of AD (Sheu and 
Blass, 1999). In molecular genetics studies, the association of DLST with AD was found to 
be significant only in patients who were also positive for APOE4. The presence of this 
isoform has been proposed to be deleterious as a result of increased production of free 
radical evident from significantly enhanced lipid oxidation in brain cortex (Ramassamy et 
al., 1999) and such mechanisms can also affect OGDC.  
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Amyloid aggregates of the amyloid-beta (Abeta) peptide are implicated in the pathology of 
AD. Anti-Abeta monoclonal antibodies (mAbs) have been shown to reduce amyloid 
plaques in vitro and in animal studies. Consequently, passive immunization is being 
considered for treating AD and anti-Abeta mAbs are now in phase II trials (Gardberg et al., 
2007). 
OGDC defects have also been found associated with diabetes. Maturity-onset diabetes of 
the young (MODY) is a rare form of juvenile diabetes mellitus that presents with 
hyperglycaemia in the absence of ketosis. Mutations in the gene encoding hepatocyte 
nuclear factor-1α (HNF1α) are the cause of MODY3. Induction of HNF1-P291fsinsC the 
most common HNF1α mutation, is generated by a mutational hotspot in exon 4 occurring 
in unrelated families. This frameshift mutation, resulting from insertion of a C in a poly(C) 
tract centred around codon 290, encodes a truncated protein of 315 amino acids. This 
mutation has been reported to significantly inhibit expression of mitochondrial E1o mRNA 
and protein with a corresponding decrease in OGDC catalytic activity (Wang et al., 2000). 
 
1.16 Aims of this thesis 
 
The main aim of this thesis is to develop a recombinant model of human PDC for studying 
genetic mutations found in the human population. To achieve this, a recombinant model of 
PDC is created by overexpressing and purifying its various constituent enzymes before 
assembling into a fully-active complex. Initially reconstituted PDC is evaluated for its 
functional abilities by using various biochemical and molecular biology approaches to 
study the effects of known mutations in PDC on lipoylation status and role of E3BP. Once 
the usefulness and validity of this novel model system is established as described in 
Chapter 3, this model is used to study the role of three recently-discovered mutations in the 
E2 enzyme of PDC encountered in indvidual patients. Two of these mutations are unusual 
‘in frame’ three base pair deletions and the third one is a substitution of an amino acid 
located in the proximity of the active site. Structure function relationships are studied by 
mimicking the natural mutations in a PDC recombinant model. These mutations and 
subsequent analysis of their effects on PDC assembly and enzymatic functions are 
described in Chapter 4.  
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This study is designed not only to generate new information on the precise consequences 
of the mutations at a molecular level and of their underlying consequences leading to the 
appearance of clinical symptoms, but also to establish the utility of this recombinant PDC 
model as a vehicle for conducting more comprehensive studies of this kind in future. 
Analysis of such mutant PDCs carrying the appropriate single amino acid substitutions/ 
deletions within the E2 and E3BP core polypeptides should provide important new insights 
into the PDC structure, assembly, mode of action and regulation and will be of potential 
clinical value for the future.  
A minor ancillary aim of this thesis also involves preliminary study of subunit 
interaction/organisation of components OGDC as described in Chapter 5, with a view to 
mapping the domain organization of E1o more precisely, in particular those regions 
involved in maintaining critical subunit contacts. This will provide more information on the 
structural organisation of OGDC and will be a step towards creating a recombinant model 
of OGDC that is increasingly implicated in various metabolic, genetic and autoimmune 
disorders.  
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Chapter 2  
 
 
Materials and Methods  
 
 
 
2.1 Biological materials 
2.1.1 Bacterial strains  
E. coli strains BL21 (DE3), BL21 (DE3) Star, BL21 (DE3) plysS as well as Top 10 and 
DH5α were purchased from Invitrogen. 
 
2.1.2 Bacterial media 
Luria Broth (LB) was prepared by dissolving 10 g Bacto–tryptone, 5 g Bacto-yeast-extract 
and 10 g NaCl per litre of distilled H2O, pH 7.5. LB plates were made by adding 7.5 g of 
micro agar to 500 ml LB. All media were autoclaved before use. Wherever it was 
necessary, broth and LB plates were supplemented with ampicillin at 50 µg/ml, kanamycin 
at 30 µg/ml and chloramphenicol at 34 µg/ml. 
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2.1.3 Mutagenic primers 
The following mutagenic primers were ordered from Sigma Genosys. The mutations 
created are shown in colour. 
Primers for lysine-46 to glutamine mutation in E2-PDC 
K46Q forward  
5’-GAG ATA GAA ACT GAC CAG GCC ACT ATA GGT TTT TG-3’ 
K46Q reverse  
5’-CAA AAA CCT ATA GTG GCC TGG TCA GTT TCT ATC TC-3’ 
Primers for lysine-175 to glutamine mutation in E2-PDC 
K175Q forward 
5’-GAG GTT GAA ACT GAT CAG GCC ACT GTT GGA TTT GAG-3’ 
K175Q reverse  
5’-CTC AAA TCC AAC AGT GGC CTG ATC AGT TTC AAC CTC-3’ 
Primers for lysine-44 to glutamine mutation in E3BP-PDC 
K44Q forward 
5’-GAA ATT GAG ACT GAC CAG GCT GTG GTT ACC-3’ 
K44Q reverse 
3’-GGT AAC CAC AGC CTG GTC AGT CTC AAT TTC-5’  
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Primers for glutamate-35 deletion in E2-PDC  
∆E35 E2 forward 
5’-GAG GGG GAC AAA ATC AAT GGT GAC CTA ATT GCA GAG-3’ 
∆E35 E2 reverse 
5’-CTC TGC AAT TAG GTC ACC ATT GAT TTT GTC CCC CTC-3’ 
Primers for glutamate-35 to glutamine mutation in E2-PDC 
E35Q E2 forward 
5’-GAG GGG GAC AAA ATC AAT CAG GGT GAC CTA ATT GCA GAG-3’ 
E35Q E2 reverse 
5’-CTC TGC AAT TAG GTC ACC CTG ATT GAT TTT GTC CCC CTC-3’ 
Primers for glutamate -35 to aspartate mutation in E2-PDC 
E35D E2 forward 
5’-GGG GGA CAA AAT CAA TGG TGA CCT AAT TGC AGA G-3’ 
E35D E2 reverse 
5’-CTC TGC AAT TAG GTC ACC ATC ATT GAT TTT GTC CCC-3’ 
Primers for phenylalanine- 490 to leucine mutation in E2-PDC 
P490L E2 forward  
5’-GGA ATT AAG AAT TTA TCT GCT ATT ATT AAC CCA CC-3’ 
P490L E2 reverse  
5’-GGT GGG TTA ATA ATA GCA GAT AAA TTC TTA ATT CC-3’ 
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Primers for valine-455 deletion in E2-PDC 
∆V455 E2 forward 
5’-GAA ACC ATT GCT AAT GAT GTT TCT TTA GCA ACC AAA GCA AG-3’  
∆V455 E2 reverse 
5’-CTT GCT TTG GTT GCT AAA GAA ACA TCA TTA GCA ATG GTT TCC-3’ 
 
2.1.4 Oligonucleotide primers  
 
The following oligonucleotide primers were ordered from MWG-Biotech AG. The 
restriction sites created are shown in colour.  
Primers for E1-OGDC construct  
OGDE1(Nde1) forward  
5’-GCT CAT ATG AGA CCA TTG ACG GCT TCC CAG-3’ 
OGDE1(Xho1) reverse  
5’-AGG CTC GAG CTA CGA GAA GTT CTT GAA GAC G-3’ 
Primers for N-terminal E1 (166amino acid) GST fusion construct  
E1BamH1 forward  
5’-CAT TTT CAG GAT CCA GAC CAG CAG CAG CTA GG- 3’ 
E1500EcoR1 reverse 
5’-GCA CTG GAA TTC TCA GAA AGT GGT GGT GGG CAA G-3’ 
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Primers for N-terminal E1 (83 amino acids) GST fusion construct  
E1BamH1 forward 
5’-CAT TTT CAG GAT CCA GAC CAG CAG CAG CTA GG- 3’ 
E1250EcoR1 reverse  
5’-GAC CAG GAA TTC TCA ATG GGC CAC AGC AGC AGC CAG-3’ 
 
All PCR primers were designed to obtain a balanced G:C composition, compatible melting 
temperatures and contain a GC clamp at the 3’ termini. They were screened for internal 
secondary structures e.g. hairpin loops or possible dimerisation using software available at 
the Sigma Genosys website (http://orders.sigma-genosys.eu.com/). 
 
2.1.5 Chemicals and standard materials  
 
Ampicillin, kanamycin, chloramphenicol, rubidium chloride, L-glutathione reduced, N-
ethylmaleimide (NEM), lipoic acid, lipoamide, L-cysteine, NADPH, NADH, NAD+, CoA, 
thiamine diphosphate, trypsin, phosphotransacetylase, acetyl phosphate, pepstatin, 
leupeptin, aprotinin, Ponceau S dye, ethidium bromide and glutaraldehyde were purchased 
from Sigma. 
QIAquick Gel Extraction kit, Penta His-HRP kit and Ni-NTA Agarose were purchased 
from Qiagen. Quick Ligation Kit was purchased from New England Biolabs. Wizard SV 
DNA Minipreps Kit, restriction enzymes, Taq polymerase, dNTP and 10 kb DNA ladders 
were from Promega. Quick Change Site-directed Mutagenesis Kits were from Stratagene.  
HiPrep 16/60 Sephacryl S-300 High Resolution and Glutathione Sepharose 4B columns, 
nitrocellulose membrane (ECL Hybond), ECL Western blotting detection reagents, low 
molecular weight SDS Marker Kits, thrombin, zinc chloride and PD10 columns were 
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purchased from Amersham. 20 MC metal chelate resin was purchased from Applied 
Biosystems, USA. Dialysis cassettes of various cut off sizes were obtained from Pierce 
(USA).  
Precast 4-12% Bis-Tris gels and MES SDS Buffer were purchased from Invitrogen. 
Protease inhibitor EDTA-free and Complete Protease Inhibitor Mini tablets were 
purchased from Roche. Imidazole was from VWR. Centricon filters with cut off sizes 5, 
30, 60 and 100 kDa and N, N, N-1 N-1- tetramethylethylene diamine (TEMED) were from 
Fisher. Acrylamide 30% (w/v) was from Thistle Scientific. Bradford reagent was from 
BioRad. Bacto-tryptone, Bacto yeast extract, DTT, and IPTG were from Melford 
Laboratories Ltd. Coomassie Blue dye was obtained from Fluka and sodium borohydride 
from Aldrich. Monoclonal antibody PD2 (patient derived hybridoma IgG) was a kind gift 
from Professor Freda Stevenson, University of Southampton.  
 
2.2 Molecular biology methods  
2.2.1 Polymerase chain reaction 
  
Polymerase chain reactions were carried out in a PTC 100 TM thermocycler (Genetic 
Research Instrumentation). A typical single 100 µl reaction mixture using the Promega 
PCR kit consisted of the following ingredients-  
    10x PCR buffer                                         10.0 µl  
    dNTP mixture                                           16.0 µl  
    5' primer                                                      5.0 µl  
    3' primer                                                      5.0 µl  
    Platinum®Taq DNA polymerase                 0.5 µl (2.5 units) 
    DNA template                                             50 ng 
     Sterile water                                              to a final volume of 100 µl 
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Platinum® Taq DNA Polymerase High Fidelity is an enzyme mixture composed of 
recombinant Taq DNA polymerase, Pyrococcus species derived thermostable polymerase, 
and Platinum® Taq Antibody. Pyrococcus species polymerase possesses a proofreading 
ability by virtue of its 3' to 5' exonuclease activity. Mixture of the proofreading enzyme 
with Taq DNA polymerase increases fidelity approximately six times over that of Taq 
DNA polymerase alone. Additionally, because a proofreading enzyme is present in the 
mixture, amplification of simple and complex DNA templates over a large range of target 
sizes is possible. Targets 12-20 kb can be amplified with some optimization. 
One of the most critical factors for successful amplification of DNA is the magnesium ion 
concentration. Too much MgCl2 will cause high levels of non-specific amplification, 
whereas too little will inhibit the reaction. Therefore, in this protocol 1.5 mM MgCl2 was 
used as the final concentration for the Taq DNA polymerase. Template was denatured for 5 
min at 94 °C prior to the initial cycle. A typical cycling temperature profile 
was: denaturing at 94 °C for 45 s, annealing at 60 °C for 45 s and extension at 72 °C for 1 
min for 25-30 cycles. A 10 min extension at 72 °C was given at the end of each cycle. 
Annealing temperatures were critical and required experimental optimisation. Low 
temperature annealing increases non-specific amplification; high temperatures inhibit 
annealing but may increase specificity. Typical annealing reactions were performed in the 
range of 55 °C to 65 °C. PCR products were viewed by agarose gel electrophoresis using 
1% (w/v) agarose. 
 
2.2.2 Agarose gel electrophoresis 
 
The appropriate amount of agarose was dissolved in 1X TAE (40 mM Tris, 1mM EDTA, 
40 mM glacial acetic acid, pH 7.5) for pouring agarose gel slabs. DNA samples for 
analysis were diluted fivefold by the addition of loading buffer (0.25% (w/v) bromophenol 
blue, 0.25% (v/v) xylene cyanol FF, 15% (w/v) Ficoll), before being loaded on the agarose 
gel. These were run at 100 V/250 mA for 40 min to 1 h until the dye front was about 1 cm 
from the bottom of the gel. Gels were then stained with a small volume of ethidium 
bromide before being viewed under a UV transilluminator. 
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2.2.3 Extraction of DNA from agarose gel  
 
DNA was purified from agarose gels using the QIAquick Gel Extraction kit. The DNA was 
run on the gel and excised using a sterile scalpel blade. The excised agarose containing the 
DNA was solubilised at 50 οC in the appropriate buffer and 100% (v/v) isopropanol. This 
solubilised mixture was applied to a spin column and centrifuged for 1 min to allow the 
DNA to bind to the column. The column was washed with 750 µl of Wash Buffer 
containing 80% (v/v) ethanol. Residual ethanol was removed by centrifuging the column 
for 2 min before eluting the DNA in 50 µl of Buffer EB (10 mM Tris-HCl, pH 8.5). The 
quantity and quality of DNA was analysed by agarose gel electrophoresis. 
 
2.2.4 Restriction digestion  
 
Restriction digestions were performed either as a step prior to cloning for preparing vector 
and insert or for diagnostic purposes. Restriction enzymes and buffers from Promega were 
used as per manufacturer’s instructions. Digestions were usually performed at 37 οC for 60 
min and analysed by agarose gel electrophoresis. 
 
2.2.5 Ligation 
 
Vector was cut with appropriate restriction enzymes, treated with calf intestinal 
phosphatase and gel purified. The insert was ligated into the vectors at a 3:1 insert : vector 
ratio using the Quick Ligation Kit. The Quick Ligation Kit enables ligation of cohesive end 
or blunt end DNA fragments in 5 min at room temperature (25 °C). Products were 
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transformed into chemically competent E. coli DH5α cells and grown overnight on LB-
ampicillin plates at 37 °C. 
 
2.2.6 Ethanol precipitation of DNA 
 
Before sending DNA for sequencing, ethanol precipitation was carried out. A solution of 3 
M sodium acetate (50 µl) was added to about 50 µl DNA suspension and left on ice for 30 
min in an Eppendorf tube. Thereafter, it was centrifuged at 13,000 rpm for 15 min. The 
supernatant was discarded and 250 µl of ice cold 70% (v/v) ethanol was added before 
centrifuging it again for 15 min. After again discarding the supernatant, tubes were left to 
air dry for 20-30 min.  
 
2.2.7 DNA sequencing 
 
Ethanol precipitated DNA samples were sent for sequencing, which was carried out by 
MWG Biotech. The sequencing results were read and analysed by Gene-Jockey software. 
 
2.2.8 Production of competent cells 
 
Competent cells were made using the rubidium chloride method. The appropriate E. coli 
strains were streaked on a LB-agar plate and grown overnight at 37 οC. A single colony 
was picked and cultured overnight in 5 ml LB. This 5 ml culture was subcultured into 100 
ml LB and grown at 37 οC with continuous shaking until an optical density at 550 nm of 
0.50 was obtained. The culture was chilled on ice for 5 min and then spun at 2000 -3000 
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rpm in an AllegraTm 6R centrifuge at 4 οC in 50 ml sterile Falcon tubes. The supernatant 
was poured off and each pellet was resuspended gently by pipetting in 20 ml buffer 1 (30 
mM potassium acetate pH 5.8, 100 mM rubidium chloride, 10 mM calcium chloride, 50 
mM manganese chloride and 15% (v/v) glycerol). The solution was re-spun in the same 
manner as before and the supernatant discarded. The pellet was resuspended in 2 ml buffer 
2 (10 mM MOPS, pH 6.5, 75 mM calcium chloride, 10 mM rubidium chloride and 15% 
(v/v) glycerol) by gentle pipetting and chilled on ice for 15 min before storing in 200 µl 
aliquots. Competent cells were stored at -80 οC until required. 
 
2.2.9 Transformation of competent bacteria 
 
Competent cells were thawed on ice. To 50 µl of competent bacteria, 1 µl DNA (about 0.1-
50 ng) was added. The bacterial cells were chilled on ice for 15 min. Cells were then heat 
shocked for 90 s at 45 οC and then returned to ice for 2 min. To these cells, 450 µl LB 
media was added and this bacterial cell suspension was incubated at 37 οC for 45 min with 
continuous shaking. About 200 µl of suspension was plated on a LB plate containing the 
appropriate antibiotic and incubated overnight at 37 οC. 
 
2.2.10 Purification of DNA from bacterial cultures (Miniprep) 
 
DNA was purified using the Wizard SV DNA Miniprep kit. The kit was used as per 
manufacturer’s instructions. A single colony grown on a LB plate was picked and cultured 
in 5 ml LB medium containing the same antibiotic. The culture was incubated at 37 οC 
overnight with continuous shaking and cells pelleted by centrifuging at 10,000 rpm for 5 
min in an AllegraTm 6R centrifuge. The pellet was re-suspended in 250 µl Cell Re-
suspension solution (50 mM Tris-HCl, pH 7.8, 10 mM EDTA, 100 µg /ml RNAse A). 
Cells were lysed by the addition of 250 µl of Cell Lysis Solution (0.2 M NaOH, 1% (w/v) 
SDS) and incubated for 5 min in the presence of 250 µg alkaline protease to inactivate any 
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endonucleases released during cell lysis. Cell Neutralising Buffer 350 µl (4.09 M GdmCl, 
0.759 M potassium acetate, 2.12 M acetic acid) was added and the mixture was centrifuged 
at 10,000 rpm for 10 min in a Sanyo Microcentaur benchtop centrifuge to pellet the cell 
debris. The supernatant was poured into a spin column and centrifuged briefly to allow the 
DNA to bind to the membrane of the spin column. The column was washed twice with 
Column Wash Solution (60 mM potassium acetate, 10 mM Tris-HCl, pH 7.8, 60% (v/v) 
ethanol) prior to elution of the DNA with 100 µl nuclease free water. The quality of the 
DNA was analysed by agarose gel electrophoresis.  
 
2.2.11 Site-directed mutagenesis 
 
The QuikChange Site-directed mutagenesis kit was employed to make point mutations 
using PfuTurboDNA polymerase. The DNA template in which mutations were to be 
created, was prepared by the standard Miniprep protocol. For the PCR reaction, the 
mixture consisted of 5 µl  10x reaction buffer, 50 ng double stranded DNA template, 125 
ng each of forward and reverse primers, 1 µl of dNTP mix and double distilled water to 
make a  final volume of 50 µl. Cycling parameters were as follows: initial denaturing at 95 
°C for 1 min, followed by 12-18 cycles involving 95 °C for 1 min, annealing at 50-60 °C 
for 1 min and extension at 65 °C for 1-2 minutes/kb of plasmid length. PCR was carried 
out in a PTC 100 TM Programmable Thermal Controller. Following temperature cycling, 
the product was treated with 10 U/µl Dpn I. The Dpn I endonuclease is specific for 
methylated and hemimethylated DNA and is used to digest the parental DNA template and 
to select for mutation-containing, newly-synthesized DNA. DNA isolated from almost all 
E. coli strains is dam methylated and therefore susceptible to Dpn I digestion. Dam 
methylation is the addition of a methyl group to adenine in the sequence 5'-GATC-3' in 
newly-synthesized DNA. The nicked vector DNA containing the desired mutations was 
then transformed into XL1-Blue supercompetent cells. Cells were heat pulsed for 45 s at 
42 °C followed by returning to ice for 2 min. LB media (0.5 ml) was added to the 
transformation reaction and incubated at 37 °C for 1 h with shaking at 225-250 rpm. About 
100-200 µl incubated reaction mixture was plated on LB plates containing ampicillin. 
Plates were incubated at 37 °C for 16 h. Colonies were picked and grown in LB media 
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containing ampicillin overnight at 37 °C. Next day, plasmids were purified from these 
cultures and sent for sequence analysis to enable detection of the desired mutation.   
 
2.3 Protein methods  
2.3.1 Large-scale protein induction 
 
A single colony was picked and added to 15 ml of LB medium containing the appropriate 
antibiotic. Cells were grown at 37 °C overnight with continuous shaking. At this stage, 500 
ml LB supplemented with antibiotic was inoculated with 10-15 ml overnight culture and 
grown at 37 °C with constant shaking until an A600 of 0.5 was reached. For small-scale 
induction 100 ml LB was inoculated with 1-5 ml overnight culture. The cultures were 
induced by the addition of 1 mM IPTG. For overexpression of E2-PDC, E3BP or OGDC 
proteins, 0.1 mM lipoic acid was also added to the medium. Individual cultures were 
shaken at 200-220 rpm at various temperatures ranging from 16-37 °C for different lengths 
of times as required. Samples (1 ml) were taken at regular time intervals to check for 
overexpression. These were pelleted by centrifugation and the pellets resuspended in 
Laemmli sample buffer (10 µl per 0.1 A600 unit) and viewed by SDS-PAGE as described in 
section 2.3.4. Cells were harvested by centrifugation at 10,000 rpm for 10-15 min at 4°C in 
a JA14 rotor in a Beckman J2-21 centrifuge and pellets stored at –20 °C. 
 
2.3.2 French press treatment   
 
E. coli pellets from 500 ml cultures were mixed with 20 ml of appropriate binding buffer 
(50 mM KH2PO4, 1M NaCl, 0.5 mM Imidazole, pH 8) or PBS (170 mM NaCl, 3 mM KCl, 
10 mM Na2HPO4, 1 mM KH2PO4, pH 7.2). Protease inhibitor cocktail tablets were added 
at this point. Cells were disrupted by 3-4 passes through a French pressure cell at 950 psi. 
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The disrupted cells were spun at 10,000 rpm at 4 °C for 10 min and the supernatant 
containing soluble protein was kept for protein purification.    
 
2.3.3 Checking the solubility of recombinant proteins 
 
Overexpression cultures (50 ml) were centrifuged at 3,000 rpm for 15 min at 4 οC. The 
supernatant was discarded and pellets re-suspended in 3 ml binding buffer prior to French 
press treatment. An aliquot (100 µl) was kept aside for SDS-PAGE for analysing whole 
cell extracts. An aliquot (100 µl) of the disrupted cell extract was centrifuged at 4 οC at 
13,000 rpm in a Sanyo Microcentaur benchtop centrifuge and the supernatant was saved 
while the pellet was re-suspended and washed with PBS buffer 3 times; each time the 
supernatant was discarded and replaced with fresh PBS buffer. Finally the pellet was 
suspended in binding buffer (100 µl) and the suspension saved for a pellet sample. An 
equal volume of Laemmli sample buffer was mixed with the whole cell extract, 
supernatant fraction and pellet suspension and the solubility of the recombinant protein 
reviewed by SDS-PAGE. 
 
2.3.4 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
Sodium dodecyl sulphate (SDS) is an anionic detergent that denatures proteins and confers 
a net negative charge. In denaturing SDS-PAGE, separation of proteins is based not on the 
intrinsic electrical charge of the polypeptide but on molecular weight. The following 
buffers were prepared for making SDS gels: - 
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SDS-PAGE buffers  
Resolving gel :   8-15% (w/v) acrylamide,  
                           0.5 M Tris-HCl buffer, pH 8.8 
                           0.1% (w/v) SDS 
                           0.1% (w/v) ammonium persulphate  
                           0.1% (v/v) N,N,N-1 N-1- tetramethylethylene diamine (TEMED) 
 
Stacking gel :     5.4% (w/v) acrylamide 
                           0.06 M Tris-HCl buffer, pH 6.8 
                           0.1% (w/v) SDS 
                           0.1% (w/v) ammonium persulphate 
                           0.1 % (v/v) TEMED  
 
SDS buffer          0.025 mM Tris-HCl buffer, pH 8.3 
                            0.2 M glycine 
                            1% (w/v) SDS  
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Laemmli sample buffer   2% (w/v) SDS  
                                       10% (w/v) sucrose 
                                       62.5 mM Tris-HCl, pH 6.8 
                                        Pyronin Y dye (trace). 
Samples for SDS-PAGE were suspended in 10 µl Laemmli sample buffer and DTT (150 
mM final concentration) was added prior to boiling for 5 min to ensure that all proteins 
were denatured. The denatured protein samples were loaded either onto precast 4-12% Bis-
Tris gels using ready-made MES SDS buffer (1M MES, 1M Tris base, 69.3 mM SDS, 20.5 
mM EDTA, free acid, pH 7.5) and run at a constant current of 125 mA per gel. 
Alternatively, the gels were made with a 4% stacking gel and 10-15% resolving gel, the 
composition of which is described above. SDS buffer (as above) was employed as running 
buffer at a constant current of 125 mA per gel. Proteins were stained with 0.1% (w/v) 
Coomassie Brilliant blue dye dissolved in 50% (v/v) methanol, 10% (v/v) acetic acid for 
30 min with shaking. Protein bands were visualised by destaining the gels in 10% (v/v) 
methanol and 10% (v/v) acetic acid overnight.  
 
2.3.5 Non denaturing gel electrophoresis  
 
Non denaturing or native gels were prepared to separate proteins based on their size and 
charge. A native gel comprised both a stacking gel and a resolving gel. For preparing these 
gels, separating buffer (1.5 M Tris-HCl, pH 8.8) and stacking buffer (0.05 M Tris, pH 6.8) 
were prepared initially.  
For a 6% resolving gel, 2 ml 30% (w/v) acrylamide, 2.5 ml separating buffer, 2 ml distilled 
water, 50 µl 10% (w/v) ammonium sulphate and 8 µl TEMED were mixed together. The 
mixture was poured into a glass plate sandwich and allowed to polymerise. A space 
(approx 0.5 cm) on the top of the sandwich was left for the stacking gel but was first filled 
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with dH2O. For preparing the 5% stacking gel, 2.3 ml water, 0.67 ml 30% (w/v) 
acrylamide, 1 ml stacking buffer, 30 µl of 10% (w/v) ammonium persulphate and 7 µl 
TEMED were mixed. When the resolving gel was fully polymerised, the water on its top 
was discarded and stacking gel mixture was poured onto it. A comb was inserted into this 
mixture to make wells for protein samples. Stacking gel was allowed to polymerise and the 
comb was removed when polymerisation was complete. After securing the gel in the 
electrophoresis tank, electrophoresis buffer (25 mM Tris, 192 mM glycine; pH 8.8) was 
poured into the chamber. Protein samples (10-20 µl) were first suspended in sample buffer 
(312.5 mM Tris-HCl, pH 6.8, 50% (v/v) glycerol, 0.05% (w/v) bromophenol blue and 1.4 
ml water) before loading into wells. Unused wells were also filled with sample buffer. 
Electrophoresis was carried out at 100-200 volts at constant current until the dye front 
migrated to the bottom of the gel. The gels were removed and viewed after staining with 
Coomassie Brilliant blue dye.   
 
2.3.6 Purification of His-tagged proteins 
 
Buffers for purification of His-tagged proteins by affinity chromatography- 
Stripping buffer          50 mM EDTA, 1M NaCl 
Zinc Loading buffer    0.1 M ZnCl2, pH 4.5 
Salt Wash buffer          0.5 M NaCl  
Buffer A                      50 mM KH2PO4, 1 M NaCl, 0.5 mM imidazole; pH 8 
Buffer B                     50 mM KH2KPO4, 1M NaCl, 500 mM imidazole; pH 6 
All buffers were filtered through Whatman filters of pore size 2 µm using a vacuum pump 
and stored at 4 οC. Distilled water was also filtered. His-tagged proteins were purified 
using metal chelate affinity chromatography on a BioCAD Sprint workstation (Applied 
Biosystems, USA). A 20 MC column (Applied Biosystems) was washed initially with 5 
column volume (CV) of stripping buffer to remove any remaining metal ions from 
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previous use. This was followed by a wash with 5 CV of dH2O. Zinc ions were loaded on 
to the column matrix by passing 30 CV of Zinc Loading buffer prior to a wash with 5 CV 
of dH2O. Unbound zinc ions were removed with a 5 CV wash of Salt Wash buffer and the 
column was equilibrated with 5 CV of buffer B followed by 10 CV of buffer A. Samples 
were injected in 5 ml aliquots and washed through with 3 CV of buffer A. After the final 
injection, the column was washed with 9 CV of buffer A. Finally, the His-tagged protein 
was eluted from the column employing a 0-100% gradient of buffer B and the eluate 
collected in 2 ml fractions.  
 
2.3.7 Ni-NTA affinity purification 
 
The E1 enzyme of PDC was purified using nickel nitrilo-triacetic acid (Ni-NTA) resin. The 
following buffers were prepared for Ni-NTA affinity purification. 
E1 Lysis buffer  
50 mM KH2PO4, pH 7. 
 0.2 mM MgCl2                                                 
0.2 mM thiamine diphosphate  
5 mM β-mercaptoethanol 
 
E1 Buffer A 
50 mM KH2PO4, pH 7.5 
100 mM KCl 
0.2 mM MgCl2 
0.2 mM thiamine diphosphate  
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E1 Imidazole Wash buffer 
50 mM KH2PO4, pH 7.5 
100 mM KCl 
0.2 mM MgCl2 
0.2 mM thiamine diphosphate 
50 mM imidazole 
E1 Buffer B 
50 mM KH2PO4, pH 7.5 
100 mM KCl 
0.2 mM MgCl2 
0.2 mM thiamine diphosphate 
500 mM imidazole 
Four pellets, each from a 500 ml culture, were suspended in 25 ml E1 Lysis buffer 
containing four tablets of Complete protease inhibitor cocktail (EDTA-free) and disrupted 
by French press treatment (section 2.3.2). The lysate was spun for 20 min at 10,000 rpm in 
a Beckman J2-21 centrifuge using a JA-17 rotor and the supernatant collected in a fresh 
tube. Ni-NTA resin (1 ml) contained in ethanol was added to a second Falcon tube and left 
to settle. The resin supernatant was sucked out with a pipette and the resin washed with E1 
Buffer A. Washed resin was then mixed with the lysate supernatant with gentle rotation for 
1 h at room temperature. The supernatant and resin mix was poured into an empty PD-10 
column. The resin was washed with 200 ml E1 Buffer A and then with 50 ml of E1 
Imidazole Wash buffer. The protein was eluted with 1 ml E1 buffer B in three separate 1 
ml elutions. Aliquots of eluted fractions were checked for purity by analysing on SDS-
PAGE.  
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2.3.8 Dialysis of proteins  
 
In order to exchange buffers, proteins were dialysed in 4-5 l of the buffer of choice 
overnight at 4 οC. Dialysis was usually conducted according to manufacturer’s instructions 
in dialysis cassettes.  
 
2.3.9 Concentration of proteins  
 
Proteins were concentrated by centrifuging the samples in a Centricon concentrator with a 
specific molecular weight ‘cut off’ depending on the protein under investigation. Samples 
were centrifuged at a speed of 3000 rpm in an Allegra Tm 6R centrifuge for various times 
until the desired volume was achieved. 
 
2.3.10 Determination of protein concentration  
 
Dividing the measured absorbance of a protein solution by the calculated or known molar 
extinction coefficient (ε) yields the molar concentration of the protein.  The absorbance of 
various proteins was measured using an Ultospec 4300 Pro uv/visible spectrophotometer, 
whereas, the molar extinction coefficient was determined by analysing the known sequence 
of the protein in PROTPRAM (http://expasy.org/tools/protparam.html). The extinction 
coefficient for the 60: 12 meric E2:E3BP was calculated as 217,590 M-1 cm -1 at 280 nm. 
The extinction coefficient for the outer lipoyl domain protein was determined as 50,450 M-
1
 cm-1 at 280 nm, while the extinction coefficient for the E3 dimer was calculated as 22600 
M-1 cm-1, exploiting FAD absorbance at 450 nm. Similarly, for E1 an extinction coefficient 
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at 280 nm was determined as 140,000 M-1 cm -1. The concentration (in mg/ml) was 
calculated by multiplying the molar concentration by the respective molecular weight of 
the protein.  
 
2.3.11 Measuring protein concentration using the Bradford assay 
 
Bio-Rad assays were also performed to determine protein concentration on occasions and 
to ensure equal loading of wild-type and mutant versions of the same protein. The dye 
Coomassie Brilliant Blue G-250 is converted from red to blue upon protein binding 
followed by an increase in absorption at 595 nm. A standard curve was plotted using 
known concentrations of IgG versus A595 values of IgG bound to this dye. The 
concentrations of unknown protein bound to dye were thereafter calculated using this 
standard curve. A Shimadzu UV-2101 PC UV-VIS scanning spectrophotometer was used 
for these determinations.  
 
2.3.12 Size exclusion chromatography 
 
Size exclusion chromatography was performed using a HiPrep 16/60 Sephacryl S-300 
High Resolution column (bed volume 120 ml) attached to a BioCAD 700E workstation. 
The column was equilibrated with 2 CV of gel filtration buffer (50 mM potassium 
phosphate, 150 mM NaCl; pH 7.5) at a flow rate of 0.5 ml/minute. A concentrated protein 
sample (1 ml) was loaded onto the column and absorbance was monitored at 280 nm. Peak 
fractions were collected and analysed by SDS-PAGE. An estimate of the molecular mass 
of protein was carried out from a standard curve generated by plotting the ratio of elution 
volume to void volume (Ve/Vo) versus log10 molecular mass of a range of standard 
proteins of known sizes (Fig. 4.16 A; Chapter 4). 
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2.3.13 Purification of glutathione S-transferase (GST) tagged 
proteins  
 
The following buffers were prepared for the purification of GST tagged proteins:- 
PBS buffer - 170 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.2 
Glutathione elution buffer - 50 mM Tris-HCl buffer, pH 8.0, 10 mM reduced  
glutathione.  
GST-fusion proteins were produced in 500 ml LB cultures for 3-5 h and the E. coli pelleted 
by centrifugation. The bacterial pellet from 250 ml culture medium was resuspended in 10 
ml PBS buffer. One tablet of Protease inhibitor (EDTA free) was added to 10 ml 
suspension followed by disruption using French press treatment. The crude extract was 
centrifuged at 10,000 rpm at 4 οC in a Beckman J2-21 centrifuge using a JA17 rotor. The 
soluble supernatant fraction was used for further purification. A glutathione Sepharose 4B 
column with bed volume 5 ml, attached to BioCAD Sprint workstation was washed with 5 
CV of PBS. The supernatant was passed through the column followed by 5 CV washes of 
PBS. The bound protein was eluted in glutathione buffer and collected in 2 ml fractions. 
The fractions were concentrated and visualised by SDS–PAGE after staining with 
Coomassie Brilliant blue.  
 
2.3.14 Removal of GST tag  
 
Purified GST-tagged proteins were dialysed against either PBS or 50 mM Tris buffer, pH 
7.5. Thrombin was added at 100 U/ mg protein and incubated with gentle shaking either at 
room temperature or at 37 °C for 4-16 h. Cleavage of the GST-tag was viewed by taking 
samples at 2 h time intervals and visualising by SDS-PAGE. 
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2.3.15 Western Blotting  
 
Proteins were separated by SDS-PAGE and electrophoretically transferred onto 
nitrocellulose membrane (ECL Hybond, Amersham) at 425 mA for 45 min in the presence 
of transfer buffer (25 mM Tris-HCl buffer, pH 7.2, 192 mM glycine, 0.02% (w/v) SDS, 
20% (v/v) methanol). The nitrocellulose membrane was briefly checked for the presence of 
transferred proteins by staining with Ponceau S solution. This was followed by shaking for 
1 min and washing with dH2O. Excess binding sites were blocked by immersing the 
nitrocellulose membrane in blocking solution (20 mM Tris-HCl buffer, pH 7.2, 15 mM 
NaCl, 5% (w/v) milk powder, 0.25% (v/v) Tween-20) for 1 h at room temperature with 
constant shaking. The membrane was washed twice with wash solution (20 mM Tris-HCl 
buffer, pH 7.2, 15 mM NaCl, 1% (w/v) milk powder, 1% (v/v) Tween-20), each for 10 
min. After these washes, the membrane was incubated in primary antibody solution (20 
mM Tris-HCl buffer, pH 7.2, 15 mM NaCl, 5% (w/v) milk powder, 0.25% (v/v) Tween-20 
and a 1:2500 dilution of primary antibody) at room temperature for 1 h. Excess primary 
antibody was removed by 4 changes of wash solution and membrane was again incubated 
at room temperature in secondary antibody solution (20 mM Tris-HCl buffer, pH 7.2, 15 
mM NaCl, 5% (w/v) milk powder, 0.25 (v/v) Tween-20 and a 1:1000 dilution of secondary 
antibody conjugated with horseradish peroxidase). In the case of anti-His tag antibody, the 
primary antibody was already conjugated with horseradish peroxidase; therefore no 
secondary antibody was required. 
The membrane was then washed for 15 min with wash solution followed by a 30 min wash 
in high salt solution (20 mM Tris-HCl buffer, pH 7.2; 150 mM NaCl). Detection of 
immune complex was carried out according to the manufacturer’s instructions employing 
the ECL Western blotting reagents.  
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2.3.16 Dihydrolipoamide acetyltransferase (E2) assay   
 
E2 activity was measured by monitoring the formation of acetyldihydrolipoamide at 232 
nm (Yang et al., 1997).  
The following stock buffers and chemicals were prepared for dihydrolipoamide 
acetyltransferase assay:            
1 M Tris-HCl, pH 7.4 
100 mM acetyl phosphate  
1 mM CoA 
1 mM Dihydrolipoamide 
Preparation of dihydrolipoamide (DHL): For preparing dihydrolipoamide, lipoamide 
(DL-6,8-thioctic acid amide) (1 g) was dissolved in 25 ml 80% (v/v) methanol and cooled 
on ice. Sodium borohydride (1 g) was dissolved in 5 ml distilled H2O and also cooled on 
ice before adding to the lipoamide solution while stirring on ice. At this stage the mixture 
was removed from ice, stirred for a further 20 min at room temperature and the pH 
adjusted to 2.0 with 0.25 M HCl. DHL was extracted from the solution by mixing 
thoroughly with 50 ml chloroform. The mixture was allowed to settle into two phases; the 
bottom organic phase was decanted into another flask and the chloroform extraction 
process was repeated 4 times. Chloroform was removed by evaporation using a rotary 
evaporator. The resulting precipitate was dissolved in a 2.5: 1.0 ratio of toluene and 
heptane and heated to ensure complete re-suspension. The mixture was dried until a small 
volume was left using a rotary evaporator. This was further dried until a white precipitate 
of DHL formed. The precipitate was stored at -20  οC. The quality of the DHL was checked 
by assaying E3 activity with increasing amounts of DHL, dissolved in 100% ethanol at a 
concentration of 20 mg/ml (100 mM) until no further increase in the activity was recorded.  
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The assay was performed at 30 οC  in a total reaction volume of 1 ml in a quartz cuvette 
containing 30 mM Tris-HCl, pH 7.4, 1 mM DHL, 1 mM acetyl phosphate, 20 µM CoA and 
2U  phosphotransacetylase. A baseline was established before E2 samples were added. The 
change in absorbance was measured over 45 s using a Shimadzu UV-2101 UV-VIS 
scanning spectrophotometer and recorded as ∆A232 min-1. E2 activity is expressed as 
change in absorbance/min since the extinction coefficient of the immediate product, 8-
acetyldihydrolipoamide has not been determined accurately. 
 
2.3.17 PDC assay 
 
Enzymatic activity of PDC was determined by  monitoring production of NADH at 340 nm 
(Brown and Perham, 1976). For enzymatic assays of recombinant and native PDC, the 
following solutions were prepared:- 
Solution A  
3 mM NAD+, 
2 mM MgCl2. 6H2O, 
0.2 mM ThDP  
All the above ingredients were dissolved in approx. 5 ml of 1 M KPi buffer, pH 7.6. After 
dissolving, 70 ml of water was added. The pH of the solution was adjusted to 7.6 with 
KOH and the volume was finally adjusted to 100 ml with dH2O.  
Solution B  
0.13 M Cysteine   HCl 
6.8 mM CoASH (tri-lithium salt) 
The above ingredients were dissolved in 20 ml dH2O.  
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Solution C 
Pyruvate (100 mM) was dissolved in dH2O.  
For enzymatic assay of PDC, 670 µl of solution A and 14 µl of solution B were added to 
plastic cuvette at 30 °C. To this 14 µl of solution C was added immediately prior to adding 
10-50 µl purified PDC. The solution was mixed rapidly and the change in absorbance at 
340 nm (∆A340 nm) was monitored over the first 90 s. 
 
2.3.18 Structure prediction by Swiss modelling 
 
A preliminary structure of the E2 outer lipoyl domain and its mutant version was 
determined based on sequence homology to other resolved protein structures in the Protein 
DATA Bank using SWISS MODEL (Schwede et al., 2003). Then a model of the domain 
was generated using RASMOL 2.6. 
 
2.3.19 Analytical Centrifugation  
2.3.19.1 Calculation of buffer densities and viscosities 
Buffer densities and viscosities were calculated from the buffer composition using the 
computer program SEDNTERP (Laue et al., 1992). 
2.3.19.2 Sedimentation velocity  
Sample optical density was in the range of 0.1 to 1. Protein samples (380 µl) each present 
in gel filtration buffer (50 mM potassium phosphate, 150 mM NaCl, pH 7.5) were loaded 
into 12 mm path length, charcoal-filled, epon double sector centrepieces. A high speed of 
20k rpm was used to cause rapid sedimentation of solute towards the bottom of the cell. 
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This high speed produces a depletion of solute near the meniscus and formation of a sharp 
boundary between the depleted region and the uniform concentration of sedimenting solute 
(the plateau) (Fig. 2.1). The rate of movement of this boundary was measured leading to 
the determination of sedimentation coefficients that depend directly on the mass of the 
particles and inversely on the frictional coefficients, which is in turn a measure of effective 
size. A series of scans was collected using interference optics. The data were analysed 
using the computer program SEDFIT (Schuck, 2000; Schuck et al., 2002) and 
sedimentation coefficients determined. 
 
2.3.20 Circular dichroism (CD) 
 
Circular dichroism spectroscopy measures differences in the absorption of left-handed 
polarized light versus right-handed polarized light which arise due to structural asymmetry. 
For CD studies, proteins were dialysed against 50 mM K2HPO4 buffer, pH 7.5. Circular 
dichroism experiments were performed at room temperature on a Jasco J-810 
spectropolarimeter scanning the spectra in the far and near uv regions. All circular 
dichroism experiments were performed in collaboration with Dr. S. Kelly IBLS, University 
of Glasgow.  
 
2.2.21 Tryptophan fluorescence 
 
Tryptophan fluorescence is widely used as a tool to monitor changes in protein structure 
and to make inferences regarding local structure and dynamics. Protein samples in 50 mM 
K2HPO4 buffer, pH 7.5 were excited at 295 nm and fluorescence emission spectra were 
recorded at 320-350 nm in a Perkin Elmer LS 50B spectrophotometer. All tryptophan 
fluorescence experiments were carried out in collaboration with Dr. S. Kelly IBLS, 
University of Glasgow.  
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Figure 2.1: Schematic representation of sedimentation of solute in a sedimentation 
velocity experiment  
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Chapter 3 
 
Production and assessment of a 
recombinant human PDC model system  
 
3.1 Introduction 
 
The pyruvate dehydrogenase complex (PDC) is a nuclear-encoded, mitochondrial 
multienzyme assembly that provides the primary link between glycolysis and the TCA 
cycle by catalysing the irreversible conversion of pyruvate to acetyl-CoA. Human PDC is 
composed of multiple copies of three distinct enzymes E1, E2 and E3 and another 
structural protein termed E3BP. Inborn errors of PDC were initially described about 35 
years ago and are the most common cause of congenital lactic acidosis.  
Over 200 naturally-occurring mutations in this complex have been identified in the human 
population at the genetic level. More than 90% of the cases of PDC deficiency involve 
defects in the E1 enzyme. There have been a small number of deficiencies involving E2 
and E3. In addition, there have been reports of both E3BP and E1 phosphatase defects 
(Patel et al., 1992). Clinical presentation of these mutations is highly variable ranging from 
mild lactic acidosis and muscular weakness to severe developmental and 
neurodegenerative conditions. In most of the cases, mutational analysis is not sufficient to 
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explain the clinical heterogeneity of the PDC deficiency. The clinical investigation of 
specific enzymatic and regulatory defects in PDC is limited largely because the main 
clinical symptom namely, lactic acidosis, is common to many other mitochondrial 
disorders. Analysing mutations using human tissues also poses many challenges; lack of 
access to tissues from individual patients being the main problem owing to the practical 
and ethical issues involved.   
Analysis of these pathological mutations becomes even more important as no systematic 
therapeutic approaches are available for treating PDC deficiency. Alternative strategies 
have been utilized to treat the major symptoms but unfortunately, none of the approaches 
have been tested in a systematic fashion and there is no clear evidence of any universally 
effective therapy. Early interventions included vitamin supplementation and dietary 
manipulation such as ketogenic diets to provide an alternative source of acetyl–CoA. These 
therapies do lower the blood lactate, but do not dramatically improve neurological 
function. With the characterisation of PDC deficiency at a molecular level, its 
pathophysiology should become clearer and it should also be possible to evaluate different 
therapeutic approaches more effectively.  
The aim of this study was to produce a recombinant model PDC by overexpressing its 
constituent enzymes in E. coli followed by purification and reconstitution in vitro. This 
could then be used subsequently to conduct detailed analysis of naturally occurring 
mutations of particular interest in human PDC. For assembly of recombinant PDC, all the 
human clones of PDC subunits were already available in the laboratory. Each of the 
individual enzymes i.e. E1, E2:E3BP and E3 were also His-tagged permitting rapid metal-
based affinity chromatography, leading to high yields and routine rapid purification of 
fully-active enzymes. As the His-tag is a small peptide it normally does not affect the 
folding and function of proteins. Protease cleavage is, therefore, usually not necessary 
before reconstitution, although it is an option with most modern vectors that normally have 
a specific protease cleavage site engineered into the plasmid. Moreover, this system allows 
anchorage of the protein to resins that have a high binding capacity and also permits the 
study of interactions between proteins in which one of the potential partners is not tagged.  
Another major aim of this study was to test the validity and effectiveness of the 
recombinant PDC model to conduct in depth analyses of genetic defects in PDC 
encountered in the human population. Once this ability could be verified successfully, it 
was anticipated that it would be possible to carry out comprehensive evaluation of the 
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underlying molecular basis of PDC malfunction in specific cases of interest. This would be 
invaluable in relating patient symptoms to the effects of specific mutations and in 
developing improved therapies and treatment protocols in future for recently detected 
mutations. Thus, reconstituted recombinant PDC should provide us with an ideal biological 
tool to mimic many natural mutations and correlate their effects on function/assembly with 
patient symptoms.  
Before the advent of recombinant DNA technology, it was necessary to rely entirely on 
extraction of proteins and enzymes from natural sources, which was often laborious and 
time consuming. It was usually impossible to procure mutant protein samples in the case of 
genetic diseases owing to lack of access to patient tissue. Use of the recombinant model to 
study these defects overcomes many of these challenges and is a non invasive and efficient 
method for obtaining mutant enzymes for further analysis. Human growth hormone, 
human insulin, follicle stimulating hormone are some of the human recombinants that have 
replaced the original enzymes harvested from animal and human tissues. In addition, there 
are others like erythropoietin granulocyte colony stimulating hormone, alpha-glactosidase 
and alpha-L-iduronidase that are readily available only in recombinant form. Development 
of a functional recombinant PDC, a massive molecular machine, that is implicated in 
various genetic, metabolic and autoimmune diseases like PDC deficiency, diabetes, 
Alzheimer’s disease and primary biliary cirrhosis represents the largest recombinant 
multienzyme system produced to date in E. coli. 
Although genetic defects in PDC are considered to be rare, their frequency of occurrence is 
difficult to estimate owing to the diverse and non-specific pattern of clinical presentation. 
In particular the most common manifestation, the presence of metabolic lactic acidosis to 
varying degrees can be attributed to a wide range of metabolic disorders and is a sign of 
mitochondrial dysfunction in general. It is now clear that its frequency has been 
underestimated in the past and more patients are being diagnosed with PDC deficiencies 
than ever before. In this study, the effects of 3 rare, recently-discovered mutations in the 
E2 enzyme on overall complex function and assembly are investigated with a view to 
obtain a more detailed understanding of its catalytic mechanism, regulation and mode of 
assembly (see Chapter 4).  
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Before carrying out such an investigation and to gain experience in developing and 
handling this reconstituted PDC model system, it was important to test the ability of the 
recombinant model in terms of mimicking such mutations. Therefore, it was decided 
initially to test the overall properties of reconstituted wild-type and mutant PDCs carrying 
all possible combinations of active and inactive lipoyl domains and also PDC totally 
lacking the E3BP subunit. This chapter describes reconstitution of recombinant PDC from 
overexpressed and purified E2:E3BP, E1 and E3 and various experiments performed to test 
the validity of this recombinant PDC model. Initially wild-type recombinant PDC and PDC 
lacking E3BP were reconstituted and the effects of adding increased amounts of E3 on the 
overall complex activity were investigated. Mutant PDCs lacking the full complement of 
active lipoyl domains were also generated and a comprehensive evaluation carried out on 
the effect of reduced lipoylation on overall complex activity. In the last section, 
recombinant wild-type PDC and PDC lacking E3BP have been used to determine a 
possible role for E3BP subunit in the so-called diacetylation reaction that is a unique 
characteristic of mammalian and yeast PDCs. These experiments not only validated the 
usefulness of the recombinant PDC model for subsequent analysis of natural mutations but 
also generated interesting additional data on structure-function relationships at the 
molecular level.   
 
3.2 Post-translational mixing of E2 and E3BP   
 
Initial experiments revealed that successful production of functional E2:E3BP core 
required co-expression of E2 and E3BP. Thus these two components that are tightly 
integrated into the ‘core’ assembly do not co-associate if mixed post-translationally. In this 
study, E2 in pET-11b (without His-tag) and E3BP in pET-28b (with His-tag) were 
expressed separately in E. coli BL21 (DE3) Star cells at 30 ºC for 5 h. After individual 
expression, bacterial pellets were disrupted by French press treatment (see section 2.3.2) 
and mixed together. The mixed supernatant of both cultures was subjected to zinc chelate 
chromatography (see section 2.3.6). It was observed that only His-tagged E3BP could be 
purified and E2 failed to associate with it post-translationally (Fig. 3.1) and came out in the 
‘flow through’ (data not shown). This was in contrast to a similar purification (see section 
3.3) in which co-transformed E2 and E3BP in the same bacterial host cells were found to 
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co-integrate successfully into a purified oligomeric E2:E3BP assembly. In addition, it was 
found that protein E3BP that has a marked tendency to precipitate when purified alone did 
not precipitate in the latter case, presumably as a direct result of its integration into the 
oligomeric E2 core. 
 
3. 3 Overexpression of E2 and E3BP 
 
E. coli BL21 (DE3) Star cells were transformed with two separate plasmids, pET-11b and 
pET-28b housing E2 and E3BP respectively to obtain a functional 60-meric:12-meric 
E2:E3BP core, using double antibiotic selection with ampicillin and kanamycin. Successful 
overexpression was achieved (Fig. 3.2) after induction with 1 mM isopropyl β-
thiogalactopyranoside (IPTG). Overexpressions were originally carried out in E. coli BL21 
(DE3), BL21 (DE3) plysS, and BL21 (DE3) Star strains as described in Methods section 
2.3.1 and the latter found to be the most effective. In this expression system, only E3BP 
contained a His-tag and its expression was limiting to ‘core’ assembly so that only 
assembled E2:E3BP ‘core’ was purified with E2 being present by virtue of its stable 
association with His-tagged E3BP. E3BP has been shown to be tightly associated with the 
E2 core assembly and in contrast to E1 and E3, cannot be dissociated even by treatment 
with high salt or high pH. Chaotrophic agents such as p-hydroxymercuriphenylsulfonate or 
5 M urea are required to dissociate E3BP from the E2 core (De Marcucci and Lindsay, 
1985); however, such treatment also promotes general dissociation of the core assembly 
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Figure 3.1: E2 and E3BP do not integrate into a core on post-translational mixing 
 
E2 and E3BP were separately overexpressed at 30 ºC for 5 h (lanes 3 and 5, respectively). 
SDS-PAGE analysis on a 4-12% Bis-Tris gel shows that only His-tagged E3BP was 
purified on zinc chelate chromatography (lane 6), indicating that on post-translational 
mixing the two subunits do not associate to form a native core assembly. Molecular weight 
markers (Mw) are in lane 1. 
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Figure 3.2: Overexpression of E2:E3BP core 
 
SDS-PAGE analysis on a 4-12% Bis-Tris gel showing overexpression of wild-type 
E2:E3BP core at 15 ºC in E. coli BL21 (DE3) Star cells at zero time (T0) and 15 h post 
induction (T15). Molecular weight markers (Mw) are in lane 1.  
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3.4 Purification of E2:E3BP 
 
E2:E3BP core assembly was purified by zinc chelate chromatography as described in 
Methods section 2.3.6. In this system only E3BP was His-tagged and E2 was co-purified 
owing to its stable interaction with E3BP. After initial isolation, the core was further 
purified by gel filtration in GFC buffer (50 mM KH2PO4, 150 mM NaCl, pH 7.5) using a 
Sephacryl HiPrep S-300 High Resolution column attached to a BioCAD 700E workstation. 
The high Mr core was stored at -20 °C in 50% (v/v) glycerol until further use. Interestingly, 
it was observed that excess E3BP produced from this plasmid that was not integrated into 
core could be separated by gel filtration (Fig. 3.3 A). The integrated core eluted at the void 
volume as expected, but excess E3BP eluted later with an elution volume corresponding to 
a Mr value of 100,000 consistent with its presence as a dimeric species (Fig. 3.3 A & B). 
 
3.5 Lipoylation of E2:E3BP core 
 
Interestingly, the essential covalent modification of human E2 and E3BP lipoyl domains, 
namely insertion of the lipoic acid co-factor, can be achieved in E. coli. This is 
accomplished through the action of its endogenous bacterial lipoyl ligase. The two 
peripherally located lipoyl domains of E2 (present in tandem repeat at its N-terminus) and 
the single lipoyl domain of E3BP (also with a similar N-terminal location), both require the 
covalent attachment of the lipoic acid moiety to a specific lysine residue within these 
domains that is situated at the exposed tip of a type 1 β-turn. Complete lipoylation was 
ensured by addition of exogenous lipoic acid (0.1 mM) to the medium during induction of 
heterologous protein synthesis and checked by employing PD2 (patient derived hybridoma 
IgG) monoclonal antibody that recognises only the lipoylated forms of E2 and E3BP 
exclusively (Thomson et al., 1998). Successful lipoylation of E2:E3BP core was found to 
be occurring on Western blotting with PD2 antibody (Fig. 3.4) confirming that the 
heterologous human lipoyl domain is recognised by the bacterial lipoylation machinery. 
Initially it was thought that E. coli lipoyl ligase was capable of recognising a specific DKA 
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motif present on the lipoyl domains of E2 and E3BP. Later, however, it was demonstrated 
that it was primarily a precise structural cue that was recognised by the lipoylating 
machinery of the cell as opposed to a conserved sequence motif (Wallis and Perham, 
1994).  
 
3.6 Solubility of E2:E3BP core 
 
Checking the solubility of recombinantly produced oligomeric cores prior to purification is 
an important step in their characterisation as the presence of soluble protein generally  
suggests that they are capable of folding into their native or near native state in the 
bacterial host and in addition that the N-terminal His-tag has not adversely affected folding 
or expression. Bacterial cells containing overexpressed E2:E3BP core were disrupted by 
French press treatment to permit the release of soluble protein into the supernatant fraction 
and insoluble cellular debris was removed by centrifugation. To achieve optimal solubility 
and production of the E2:E3BP core, it was initially overexpressed at different 
temperatures after induction with IPTG. In one set, expression was induced at 30 °C for 4-
5 h with 1 mM IPTG and in a second set at 37 °C for 3 h. In the third set, overexpression 
was induced with 1 mM IPTG at 22 °C for 5-6 h while a similar induction was also carried 
at 15 ºC overnight for 18 h with 0.5 mM IPTG. All the overexpressions were studied using 
E. coli BL21 (DE3) Star cells. Although, E2:E3BP could be expressed successfully at all 
temperatures, on solubility checking, it was found to be most soluble when expressed at 15 
°C (Fig. 3.5). Therefore, E2:E3BP core was overexpressed at this temperature in 
subsequent experiments in E. coli BL21 (DE3) Star cells. 
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Figure 3.3: His-tag purification and gel filtration of E2:E3BP core  
 
(A) His-tagged E2:E3BP core, purified by zinc chelate chromatography was gel filtered 
through a Sephacryl HiPrep S-300 High Resolution column attached to a BioCAD 700E 
workstation. (B) On SDS-PAGE analysis, the peak eluting at the void volume 
corresponded to E2:E3BP core (lane 2) and the second peak to excess E3BP (lane 4) not 
bound to the core. Molecular weight markers (Mw) are in lanes 1 and 3. 
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Figure 3.4: Western blot analysis of the wild-type E2:E3BP core with PD2 antibody  
 
Panel A shows SDS-PAGE analysis of E2:E3BP core prior to Western blot analysis (panel 
B) with PD2 antibody. The blot shows that the core was lipoylated as PD2 antibody 
recognises only lipoylated subunits of PDC (Thomson et al., 1998). 
 
  
                                                       
 
E2 
E3BP 
Lipoylated 
E2:E3BP   
kDa 
 
97.0 
 
66.0 
45.0 
 
33.0 
 
20.1 
 
14.4 
Mw 
66.0 kDa 
 
A 
B 
Chapter 3  
 
75 
75 
 
 
                                                                   
 
Figure 3.5: Solubility checking of wild-type E2:E3BP core overexpressed at various 
temperatures 
 
E2:E3BP core was overexpressed at 15 °C, 22 °C, 30 °C and 37 °C in E. coli BL21 (DE3) 
Star cells. SDS-PAGE analysis on a 4-12% Bis-Tris gel shows that at 30 °C, 37 °C and 22 
°C, E2:E3BP was largely insoluble and present mainly in the pellet samples (PS) (lanes 4, 
7 and 10 respectively) and not in supernatant samples (SS) (lanes 3, 6 and 9 respectively). 
When expressed at 15 ºC overnight, the core assembly was soluble and present in the 
supernatant sample (SS) (lane 12) and not in the pellet sample (PS) (lane 13). Whole cell 
extracts (WE) in lanes 2, 5, 8 and 11, respectively. Molecular weight markers (Mw) are in 
lane 1. 
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3.7 Overexpression of E3 
 
E. coli BL21 (DE3) plysS cells were transformed with E3 cDNA housed in the pET-14b 
vector. Overexpression was induced by the addition of 0.1mM IPTG at 22 °C and viewed 
by SDS-PAGE analysis (Fig. 3.6). E3 was overexpressed at this temperature in all 
experiments unless stated otherwise.  
 
3.8 Overexpression of E1 
 
Co-expression of the α and ß subunits of E1 was first successfully achieved in the 
laboratory by co-transformation of E. coli with two separate plasmids, pET- 28b for E1α  
and pET-141b for E1ß using double antibiotic selection with ampicillin and kanamycin. 
However, difficulties were experienced in reconstituting active, soluble hetero-tetrameric 
human E1, although high levels of expression of both subunits were readily attained. This 
problem was finally overcome by Dr. Alison Prior, who subcloned the genes for both E1α  
and E1 ß from pET-28b and pET-11b respectively into a modified pQE-9 vector system to 
permit their co-expression from a single plasmid in E. coli M15 cells. These cells contain a 
kanamycin-resistant plasmid, pREP4 which encodes the lac repressor encoded by the lacI 
gene. The levels of expression in this vector system were relatively low, but were sufficient 
to produce 2-3 mg of E1 protein on a routine basis (Fig. 3.7) from 2-3 l of culture. 
Overexpression was induced by 1 mM IPTG at 18 ºC overnight.  
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 Figure 3.6: Overexpression of E3 
 
Overexpression of the E3 enzyme was carried out in E. coli BL21 (DE3) plysS cells at 22 
°C. SDS-PAGE analysis on a 4-12% Bis-Tris gel shows expression levels at zero time (T0) 
and after 5 h of induction (T5). Molecular weight markers (Mw) are in lane 1. 
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Figure 3.7 Overexpression of co-transformed E1α and E1β subunits  
 
E1α and E1 β were co-expressed in E. coli M15 cells at 18 °C overnight. SDS-PAGE 
analysis on a 12% Bis-Tris gel shows samples at zero time (T0) and 15 h after induction 
(T15). Molecular weight markers (Mw) are in lane 1.  
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3.9 E3 purification  
 
E3 was purified by zinc chelate chromatography (see section 2.3.6). Purified fractions were 
gel filtered using GFC buffer (50 mM KH2PO4, pH 7.5, 150 mM NaCl) prior to SDS-
PAGE analysis for checking the purity of pooled fractions (Fig. 3.8). The enzyme was 
stored at 4 ºC until required. 
 
3.10 E1 purification  
 
E1 was purified by the protocol described in the Methods section 2.3.7. Attempts to dialyse 
purified E1 resulted in precipitation of the enzyme. Therefore, purified fractions were 
concentrated in a Centricon concentrator with a ‘cut off’ size of 100 kDa with addition of 
excess Buffer A (50 mM KH2PO4 , 1 M NaCl, 0.5 mM imidazole, pH 8), to lower the 
concentration of imidazole. SDS-PAGE analysis was performed to check its purity (Fig. 
3.8). Purified enzyme was stored at -20 ºC in 50 % (v/v) glycerol. 
 
3.11 Reconstitution of recombinant PDC 
 
For reconstituting recombinant PDC from its constituent enzymes, the concentration of 
each purified enzyme was measured using its extinction co-efficient (see Methods section 
2.3.10). Then enzymes were mixed together in stoichiometric amounts i.e. for each µmole 
of E2:E3BP core, 12 µmole E3 and 30 µmole E1 were added at room temperature. After 
mixing the individual components, reconstituted PDC was immediately assayed. 
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Recombinant PDC was found to assemble spontaneously from its constituent enzymes 
within a 2 min preincubation period when they were mixed in the equivalent ratios to those 
found in the native complex. PDC activity was measured using standard 
spectrophotometric assay techniques (see Methods section 2.3.17) in which NADH 
production was monitored spectrophotometrically at 340 nm in the presence of pyruvate as 
substrate. Reconstituted recombinant PDC appeared to be fully active and displayed a 
similar specific activity (3.5-4 µmol NADH min –1 mg protein–1 ) to reported values for the 
native, wild-type complex isolated from human heart (Palmer et al., 1993). 
 
Chapter 3  
 
81 
81 
 
 
 
                                            
                                            
Figure 3.8: Reconstitution of PDC from individual components  
 
SDS-PAGE analysis on a 4-12% Bis-Tris gel shows PDC (lane 1) reconstituted from 
stoichiometric amounts of purified E1 (lane 2), E3 (lane 3) and E2:E3BP (lane 4). 
Molecular weight markers (Mw) are in lane 5.  
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3.12 Effect of increasing amounts of E3 on wild-type PDC 
activity 
 
Recombinant human PDC assembled spontaneously from its constituent enzymes within a 
2 min preincubation period when they were mixed in the equivalent ratio as the native 
complex i.e. in stoichiometric amounts. This reconstituted recombinant human PDC 
appeared to be fully active and displayed a similar specific activity to PDC purified from 
human tissue. These initial studies confirmed that the individual components of PDC retain 
their capability to interact with each other in the recombinant model and mimic the 
functional abilities of the native complex. Recombinant PDC was reconstituted as 
described in section 3.11 of this Chapter. Enzymatic assay of wild-type recombinant PDC 
in the presence of excess amounts of purified E3 (up to 200-fold) was performed using the 
spectrophotometric method described in Methods section 2.3.17. With the addition of 
increasing amounts of E3, there was a slight but significant decline (20-25%) in overall 
PDC activity as shown in Fig. 3.9. The decline in activity is probably caused by 
displacement of the rate-limiting E1 enzyme from its binding site on E2 by excess E3 
confirming earlier observations (McCartney et al., 1997) that E3 displays a residual affinity 
for E2.  
 
3.13 Effect of increasing amounts of E3 on the activity of 
PDC lacking E3BP 
 
Recombinant PDC was reconstituted by adding stoichiometric amounts of E1 and E3 to 
recombinant E2 core produced in the absence E3BP. Activity assays were performed in the 
same way as for native PDC. Recombinant PDC lacking E3BP displayed little activity (3-
8%) with stoichiometric amounts of E1 and E3. However, overall activity rose gradually 
with increasing E3 with activity levels reaching approx. 50% of wild-type values with a 
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200-fold excess of this component (Fig. 3.9). These results were in agreement with 
previous studies on the native bovine complex (McCartney et al., 1997) and again 
suggested that the partial activity of PDC detected in the total absence of E3BP stems from 
the ability of E3 to interact with the E1 binding site on E2 with low affinity.  
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Figure 3.9: Effect of increasing amounts of E3 on the activity of recombinant wild-
type PDC and recombinant PDC devoid of E3BP  
 
A decline in the activity of native PDC is observed with increasing amounts of added E3 
(blue) whereas there is a marked increase in the activity of recombinant PDC (without 
E3BP) with increasing amounts of E3 (red). Added E3 ranges from stoichiometric amounts 
to a 200-fold excess. 
                                 Fold excess of E3 
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3.14 Effect of differing combinations of active and 
inactive lipoyl domains in E2:E3BP core on overall PDC 
activity 
 
The lipoyl group is attached in amide linkage to the N6-amino group of a lysine residue 
located on an exposed type-1 β turn within lipoyl domains. It is a highly specific post-
translational modification carried out by an ATP-dependent lipoate protein ligase (Morris 
et al., 1994). A major advantage of producing recombinant human E2 components of PDC, 
in E. coli is that the bacterial ligase is capable of inserting exogenous lipoic acid onto the 
key lysine of a variety of heterologous lipoyl domains. The apodomains can be lipoylated 
in vitro also with partially purified E. coli lipoate protein ligase (Quinn et al., 1993). This 
ligase is also responsible for the octanoylation of lipoyl domains in the absence of lipoic 
acid or when there is excessive production of apodomains (Ali et al., 1990; Dardel et al., 
1990; Quinn et al., 1993). While overexpressing wild-type and mutant E2 and E2:E3BP 
cores, exogenous lipoic acid was added to ensure complete lipoylation. The effects of loss 
of lipoylation of recombinant E2 and E3BP lipoyl domains and its effect on overall activity 
was assessed in this study.  
A series of mutant E2:E3BP cores was created lacking the full complement of active lipoyl 
domains. In these mutant cores, lipoylation was prevented by selectively altering the 
lipoylatable lysine to glutamine in individual domains, thereby preventing co-factor 
insertion. As discussed earlier also, the lipoyl domains play a crucial role in coupling the 
activities of the three enzyme components of PDC by providing ‘swinging arms’ that are 
mobile and responsible for substrate transfer among the three successive active sites 
(Fussey et al., 1991; Yeaman et al., 1978). Thus, eight distinct ‘cores’ containing all 
possible combinations and numbers of active/ inactive E2/E3BP lipoyl domains namely 
++/+, ++/-, +-/+, +-/-, -+/+, -+/-, --/+ and --/- were constructed using site-directed 
mutagenesis. A schematic representation of these cores is depicted in Fig. 3.10. 
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Figure 3.10: Schematic representation of eight wild-type and mutant constructs of 
E2:E3BP cores 
 
Representation shows either lipoylated (green) or non-lipoylated domain (black); E2 outer 
lipoyl domain (OD), E2 inner lipoyl domain (ID) and E3BP lipoyl domain (XD) in eight 
E2:E3BP cores generated to determine the effect of lipoylation status on overall complex 
activity.  
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The ‘+’ represents wild-type lipoylated domain in E2:E3BP core, whereas, ‘-’is a mutant 
lipoyl domain created in the core by lysine to glutamine replacement employing site-
directed mutagenesis (Methods section 2.2.11). The appropriate mutants were created by 
A. S. Stephanou, University of Glasgow, by designing and using mutagenic primers 
described in Materials and Methods, section 2.1.3. In all the constructs, wild-type, K46Q, 
K175Q and K46Q:K175Q E2 were contained in the pET-11b vector exhibiting ampicillin 
resistance whereas wild-type and K44Q E3BP were housed in pET-28b displaying 
kanamycin resistance. After checking for the correct mutations by DNA sequencing, wild-
type and mutant E2 and E3BP constructs were co-transformed into E. coli BL21 (DE3) 
Star cells in eight different combinations as shown in Fig. 3.10. Co-transformed cells were 
induced to overexpress at 30 ºC in LB medium with 1 mM IPTG and with the addition of 
0.1 mM lipoic acid. Wild-type and mutant cores were isolated by zinc chelate 
chromatography as described in Methods section 2.3.6 and subsequently gel filtered as 
described in Methods section 2.3.12. SDS-PAGE analysis was conducted to check their 
purity (Fig. 3.11). 
Western blot analysis of these eight wild-type and mutant ‘cores’ with PD2 antibody 
revealed varying degrees of lipoylation in which the wild-type core displayed a strong E2 
signal whereas cores with either a single  active inner or outer lipoyl domain displayed less 
cross-reactivity. Mutant E2 core with both inner and outer lipoyl domains inactive 
exhibited no signal with E2. Active E3BP lipoyl domain in mutant and wild-type cores 
also gave a signal, although weak as compared to lipoylated E2 domains. Complete loss of 
signal indicating no lipoylation was observed when all the lipoyl domains were rendered 
inactive in E2 as well as E3BP (Fig. 3.11).  
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Figure 3.11: SDS-PAGE and Western blot analysis of wild-type and mutant E2:E3BP 
cores by PD2 antibody 
 
 SDS-PAGE (1A) and Western blot analysis with PD2 antibody (1B) of ++/+, -+/+ and +-
/+ E2:E3BP cores in lanes 1, 2 and 3 respectively. SDS-PAGE (2A) and Western blot 
analysis with PD2 antibody (2B) of --/+, ++/-, -+/-, +-/- and --/- E2:E3BP cores in lanes 4, 
5, 6, 7 and 8 respectively. The ‘+’ represents wild-type lipoylated domain in E2:E3BP 
core, whereas, ‘-’ is a mutant non-lipoylated domain. 
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To investigate the effect of the differing combinations of active and inactive lipoyl 
domains on overall PDC activity, eight sets of recombinant PDCs were reconstituted from 
the various wild-type and mutant cores by adding stoichiometric amounts of E1 and E3 
employing the protocol described in section 3.11. Equal amounts of wild-type and mutant 
PDCs were assayed in duplicate as described in Methods 2.3.17 and the activity compared 
to the wild-type PDC as control (100% activity). Mutant PDCs were found to sustain high 
levels of activity (65-75%) with approx. half of their full complement of lipoyl domains 
(only inner or outer lipoyl domain active on E2). Moreover, the presence or absence of a 
functional lipoyl domain on E3BP had no additional significant effect on activity with E2s 
possessing either one or two active lipoyl domains (Fig. 3.12). Interestingly, however, 
PDC with only E3BP-linked active lipoyl domain retained approx. 15% of wild-type 
activity while total loss of activity required non-lipoylation of all 3 domains. 
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Figure 3.12: Effect of differing combinations of active and inactive lipoyl domains on 
recombinant PDC activity 
  
Histogram corresponds to enzymatic activity of recombinant PDCs with the following 
types of E2:E3BP cores: 1 ++/+, 2 ++/-, 3 +-/+, 4 +-/-, 5 -+/+, 6 -+/-, 7 --/+ and 8 --/-. The 
‘+’ represents wild-type lipoylated domain in E2:E3BP core whereas, ‘-’ is a mutant non-
lipoylated domain. Samples were assayed in duplicate and error bars indicate extent of 
variation between duplicates. 
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3.15 Discussion  
 
Recombinant PDC could be successfully reconstituted from purified E2:E3BP, E1 and E3. 
Its enzymatic function was fully restored indicating that all the enzymes were correctly 
folded. It displayed a specific activity (3.5-4 µmol NADH min –1 mg protein–1 ) similar to 
PDC purified from human heart (Palmer et al., 1993). Interaction between the three 
components was further tested in an assay where increasing amounts of E3 were added to 
the recombinant PDC. With the addition of increasing E3, overall complex activity was 
found to decrease gradually, presumably due to partial displacement of the E1 enzyme by 
excess E3. This result was consistent with surface plasmon resonance measurements 
performed by Dr. Susan Richards in our laboratory (unpublished data). In this study the 
affinity of E3BP for E3 was found to be approx. 100-fold higher (Kd value of 5.31 x 10-9 
M) than for the equivalent E2-E3 interaction (Kd value 3.39 x 10-7 M) confirming that the 
E1 binding site on E2 retains a residual affinity for E3. This residual affinity for E3 has 
also been reported previously (McCartney et al., 1997). Interestingly, it is reminiscent of 
the situation in B. stearothermophilus PDC, where E1 and E3 must compete for a single 
binding site on E2 and are capable of displacing each other (Lessard et al., 1996).     
When increased amounts of E3 were added to recombinant PDC lacking the E3BP subunit 
and overall complex activity monitored, it was found that the activity gradually rose to 
approx. 50% of wild-type activity levels in the presence of a 100-200 fold E3 excess. 
These data are also compatible with the presence of a low affinity binding site for E3 on 
the E2 core assembly that is able to partially substitute for the E3BP-located subunit 
binding domain in the absence of the latter subunit.  
All these findings are also in agreement with the previous surprising identification (in 
collaboration with French colleagues) of PDC deficient patients with metabolic lactic 
acidosis who totally lack E3BP. These patients possess a partially active PDC (10-20% of 
wild-type) as compared to the control group (Geoffroy et al., 1996; Marsac et al., 1997) 
again indicating that even in vivo the E2 subunit provides a weak secondary E3 binding 
site. However in this genetic defect, E3 is not stably integrated into the mutant complex 
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which functions much less efficiently under these conditions. In summary, these studies 
highlighted the partial functional redundancy of the E3BP subunits, while also 
demonstrating that E2 and E3BP display both overlapping and distinct functions. Analysis 
of E3BP deficient PDC, both in vitro and in vivo, has contributed to a better understanding 
of the role of E3BP subunit and has provided a rational basis for conducting prenatal 
diagnosis for possible E3BP deficiency in affected families (Marsac et al., 1993).  
The effect of differing combinations of active and inactive lipoyl domains of E2:E3BP 
core on lipoylation status was also studied using a series of 8 mutant PDCs. On Western 
blotting with PD2 antibody, it was seen that mAb cross-reactivity was at a maximum when 
all the lipoyl domains were fully functional and gradually declined with the loss of 
lipoylatable domains on E2 and E3BP. Overall complex activity also declined gradually 
with the loss of functional lipoyl domains. However, inactivation of inner or outer lipoyl 
domains on E2 caused minor reduction in overall complex activity indicating considerable 
redundancy at this level. Thus reducing the complement of lipoyl domains by approx. 50% 
led to a 25-35% loss of activity. Moreover, introduction of E3BP with a non-functional 
lipoyl domain had no further significant effect on activity in comparison to wild-type PDC 
or in the case of mutants carrying an inactive outer or inner lipoyl domain on E2. Finally, 
PDC in which only the 12 lipoyl domains of E3BP were lipoylated also retained partial 
activity (15%) and only complete loss of lipoylation led to complete inhibition. 
This study represents the first systematic investigation of the effects of alterations in the 
lipoylation status of the E2:E3BP core on mammalian PDC complex activity. The 
enzymatic activity results were found to be consistent with the lipoylation status as 
determined by Western blotting. The observation that recombinant PDC displayed 15% 
activity with only E3BP containing active lipoyl domains (12 out of a possible 132/108) is 
in agreement with the results of Rahmtullah and co-workers (Rahmatullah et al., 1990) and 
Sanderson and co-workers (Sanderson et al., 1996a) where 10-15 % activity is retained 
with the proteolytical removal of lipoyl domains of E2 on collagenase treatment. This 
suggested that E3BP-linked domains can substitute to some extent for the lipoyl domains 
of E2 in overall complex catalysis. These data also demonstrated considerable functional 
redundancy at this level that is genetically advantageous as null mutations producing 
totally inactive PDC would be expected to be embryonically lethal. Interestingly, this study 
is the first in mammalian PDC in which the correctly folded E2 and E3BP domains have 
been retained in a non-functional state. Previous studies have employed genetically 
engineered or proteolytically modified E2:E3BP core assemblies, where the entire domain 
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is absent, potentially allowing greater flexibility and improved access to catalytic sites for 
the remaining active domains. Our data, however, tend to confirm and extend these earlier 
studies and indicate that inner and outer lipoyl domains of E2 or the single E3BP lipoyl 
domain are all effective substrates for E1, E2 and E3 and that there is no obvious 
preferential recognition of individual domains by these enzymes. In addition, the presence 
of a full complement of domains in which a high proportion is inactive does not produce 
any apparent steric hindrance effects.  
 
3.16 Study on involvement of E3BP in diacetylation  
 
In PDC, acetyl group transfer occurs after the initial decarboxylation step, which is 
catalysed by E1 with the production of CO2 and an enzyme-bound hydroxyethylidene 
thiamine diphosphate derivative. There is then E1-mediated reductive acetylation of the 
lipoamide cofactor attached to E2 and /or E3BP leading to formation of a S8-acetyl 
intermediate. Subsequently acetyl groups migrate between the S6 and S8 positions (Koike 
and Koike, 1976). In the final step, E3 re-oxidises E2 and E3BP linked lipoamide cofactors 
followed by reduction of NAD+
.
 
It is a unique property of mammalian PDC to be able to generate a S6, S8 diacetyl–
dihydrolipoamide intermediate on addition of either pyruvate in the absence of CoASH or 
NADH and acetyl CoA. Treatment of PDC with pyruvate or NADH and acetyl CoA leads 
to rapid initial generation of a S8–acetyldihydrolipoamide intermediate and exchange of 
acetyl groups between S6 and S8 sulphur atoms on the dithiolane ring. The formation of the 
S6, S8 diacetyl–dihydrolipoamide intermediate by mammalian PDC was initially detected 
by 13C-NMR spectroscopy (O'Connor et al., 1982). 
This property does not require the presence of E2 lipoyl domains as the capacity of E3BP 
lipoamide thiols to undergo the diacetylation reaction is shown to be unaffected by the 
removal of E2 lipoyl domains in collagenase-modified PDC complex (which causes 
selective removal of lipoyl domains of E2). This was shown by studies on 14C–acetylation 
in bovine heart PDC, where the single lipoyl domain of E3BP was shown to be capable of 
diacetylation (Sanderson et al., 1996b). Moreover, collagenase-treated PDC possessed 
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residual activity (about 15%), indicating that protein-E3BP-linked lipoamide groups could 
substitute for the lipoyl domains of E2 in overall complex catalysis. 
Interestingly, the ability to catalyse diacetylation is absent in the bacterial PDC complex 
and so is the E3BP subunit. However, it has been demonstrated in bovine and S. cerevisiae 
PDC complexes, where the E3BP polypeptide  has been well characterised (Hodgson et al., 
1986). The equivalent phenomenon is also absent in the OGDC complex where transfer of 
a succinyl group occurs and a single S6 or S8 succinyl-dihydrolipoamide intermediate is 
formed. Therefore, it was suspected that formation of the diacetyl dihydrolipoamide 
intermediate could be uniquely mediated through E3BP. This reaction might be of 
physiological relevance to permit PDC to act as a reservoir for acetyl groups and electrons 
under conditions of excess acetyl CoA and NADH production, e.g. on high fat diets or in 
abnormal states such as starvation and diabetes. In these conditions, each molecule of PDC 
could bind a maximum of 264 acetyl groups (assuming a 60E2:12E3BP core) and an 
equivalent number of electrons, thereby providing a safe buffer against production of 
ketone bodies and regulate the formation of NADH. If indeed E3BP is involved uniquely 
in diacetylation, then it could be of great physiological importance. The cell lines of 
patients deficient in E3BP were of considerable interest in this regard (Marsac et al., 1993). 
In this study, reconstituted recombinant PDC provided an important tool to study this 
potential enzymatic and physiological role of E3BP as no specific catalytic function for 
E3BP has been revealed to date.   
It has been shown that the E2 component of E. coli PDC can be inactivated selectively by 
maleimides in the presence of pyruvate or NADH (Brown and Perham, 1976; Danson and 
Perham, 1976). The E2-bound lipoyl moieties become reductively acetylated or reduced 
and the corresponding intermediates react with NEM when there are free thiol groups 
present leading to inactivation of the complex. Hodgson et al. (1986) also showed that the 
presence of NADH or pyruvate promoted incorporation of NEM into E2 as well as E3BP 
components.  
On the addition of NADH and acetyl CoA to PDC, however, it has been shown that the 
complex is rapidly protected once again from inhibition by NEM. Hodgson et al. (1986) 
also demonstrated that the group incorporating NEM in E3BP was in all respects similar to 
the lipoyl groups on the E2 subunit. 
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The extent of protection against NEM inhibition, was found to be greater as the time of 
preincubation was increased (Cate et al., 1980) and formation of a S6, S8 diacetyl–
dihydrolipoamide intermediate under these conditions was identified.  
To elucidate whether addition of a second acetyl group to the S-acetyldihydrolipoamide 
intermediate is a unique catalytic function of E3BP, a recombinant PDC was reconstituted 
from purified E1, E2, a molar excess of E3 and devoid of E3BP. As discussed earlier, 
reconstituted PDC complex in the absence of E3BP shows limited activity (3-8%) as E3 is 
not stably integrated into the complex in these conditions. Native bovine PDC extracted as 
per the protocol described by De Marcucci and co-workers (De Marcucci et al., 1988) was 
used as a control in this experiment.  
Four conditions were tested using recombinant PDC (without E3BP) and native PDC (Fig. 
3.13). In the first reaction, native as well as recombinant PDC (devoid of E3BP) were 
incubated with 0.2 mM NADH and 1 mM NEM. In the second reaction instead of NADH, 
0.2 mM NAD+ was added followed by addition of 1 mM NEM. In the third reaction, native 
as well as recombinant PDC (devoid of E3BP) were incubated with 0.2 mM NADH and 
0.4 mM AcCoA followed by incubation with 1 mM NEM. In the fourth reaction, both the 
complexes were treated with NAD, AcCoA and NEM as before. In all the reaction 
mixtures, 50 mM DTT was added to quench excess NEM. After 10 min NEM treatment, 
activity assays of all the individual complexes (100 µl) were performed as described in 
Methods section 2.3.17.  
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Figure 3.13: Recombinant PDC devoid of E3BP is protected from inhibition by NEM 
due to formation of diacetylated dihydrolipoamide groups  
Native bovine PDC and recombinant PDC reconstituted from stoichiometric amounts of 
E2, E1 and a 200-fold excess of E3, were individually incubated with following chemicals 
for the stated times and conditions before the enzymatic assays were carried out . 
1 PDC + 0.2 mM NADH (10 min) + 1 mM NEM (10 min) + 50 mM DTT (10 min).                        
2 PDC + 0.2 mM NAD+ (10 min) + 1 mM NEM (10 min) + 50 mM DTT (10 min). 
3 PDC + 0.2 mM NADH (10 min) + 0.4 mM AcCoA (10 min) + 1 mM NEM (10 min) + 
50 mM DTT (10 min). 
4 PDC + 0.2 mM NAD+ (10 min) + 0.4 mM AcCoA (10 min) +1 mM NEM (10 min) + 50 
mM DTT (10 min). 
Bars represent percentage activity of native (purple) and recombinant (blue) PDC 
complexes in above four conditions. Samples were assayed in duplicate and error bars 
indicate extent of variation between duplicates. Native PDC (100 µg) and recombinant 
PDC (200 µg) were employed for each analysis to account for the large molar excess of E3 
in the recombinant PDC. Activity of native bovine PDC was taken as 100% control. 
 
           
          Recombinant PDC devoid of E3BP 
 
               Native bovine PDC  
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3.17 Results and discussion on diacetylation of E3BP 
 
In the first reaction, native and recombinant PDC were monitored and incubated with NEM 
in the presence NADH; the activities were found to be inhibited in both the complexes 
(Fig. 3.13). This was in agreement with the previous studies (Brown and Perham, 1976; 
Danson and Perham, 1976) where NADH was shown to cause reduction of lipoamide 
groups on E2 and E3BP, facilitating incorporation of NEM and thus inhibiting overall PDC 
function.  
When the same reaction was carried out in the presence of NAD+, instead of NADH, 
reduction of lipoamide groups did not take place as anticipated and no loss of activity was 
observed in both PDC complexes (Fig. 3.13). Similar results have been reported in earlier 
studies with bovine PDC (Hodgson et al., 1986).  
In the third reaction, on the addition of acetyl CoA in combination with NADH to both 
these PDC cores, incubation with NEM did not cause inhibition of the activities of either 
complex. One explanation for this restored activity of PDC has been given by Hodgson et 
al. (1986). Preincubation of PDC with NADH and AcCoA leads to formation of a S6, S8 –
diacetyl-dihydrolipoamide intermediate that is not amenable to modification by NEM and 
the activity of the complex is retained. The presence of this activity in the recombinant 
complex lacking the E3BP subunit, demonstrates that E3BP is not uniquely involved in 
diacetylation. Similar results were obtained in the fourth reaction, where instead of NADH, 
NAD+ was added as a control. It was seen earlier that with the addition of NEM in the 
presence of NAD+, PDC activity was maintained as anticipated. These reactions 
demonstrate that the recombinant model of PDC can be used to determine potential 
physiological roles of individual components.  
The tight association of protein E3BP with E2 core prevents the detailed analysis of its 
functional involvement in the complex. Specific deletion of the region encoding subunit 
binding domain of E3BP in S. cervisiae PDC showed loss of high-affinity binding of E3 
and concomitant loss of overall activity (Lawson et al., 1991). Moreover, collagenase 
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treatment of native PDC complex provided information about the substitutional catalytical 
role of E3BP linked lipoamide groups for E2 lipoyl domains (Rahmatullah et al., 1990). 
Earlier 14C- acetylation studies in bovine heart PDC showed that lipoyl domains of E3BP 
are capable of E2 type reactions including diacetylation (Hodgson et al., 1986). Production 
of a versatile recombinant PDC model is another step towards understanding the structural 
and functional roles of E3BP under normal and disease conditions.    
In this study, a potential role of E3BP in promoting diacetylation of E2 enzyme was 
investigated. This phenomenon could be responsible for giving PDC a unique role as a 
metabolic ‘reservoir’ harbouring excess electrons and acetyl groups under abnormal 
physiological conditions. However, the diacetylation phenomenon was still found to occur 
in recombinant PDC devoid of E3BP. As this process appears to be exclusive to yeast and 
mammalian PDCs, it is presumably a characteristic property of the eukaryotic E2 enzyme. 
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Chapter 4 
 
Analysis of naturally occurring mutations 
in human PDC  
 
4.1 Introduction 
 
This chapter focuses on the investigation and analysis of three recently-discovered 
mutations in the 60-meric E2 enzyme of PDC that lead to clinical manifestation of PDC 
deficiency by unknown mechanisms. Clinical presentation and progression of this disorder 
is highly variable. An abnormal lactate build-up results in non-specific symptoms (e.g., 
severe lethargy, poor feeding, tachypnea), especially during times of illness, stress, or high 
carbohydrate intake. A number of acquired conditions including infections, severe 
catabolic states, tissue anoxia, dehydration and poisoning can give rise to hyperlactic 
acidaemia. All these causes should be ruled out before considering inborn errors of PDC 
metabolism. When the lactate / pyruvate ratio is normal or low, PDC deficiency is highly 
probable (Poggi-Travert et al., 1996).  
The definitive diagnosis of PDC deficiency is usually established by enzyme assay in 
patients’ cells or tissues commonly by measuring 14CO2 production from 14C-labelled 
pyruvate with subsequent confirmation of the basic defect by Western blotting with 
antibodies against subunits of the complex and /or by direct cDNA or genomic sequencing 
(Eschbach et al., 1987; Old and De Vivo, 1989; Otero et al., 1998). Detection of mutations 
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in the E1α gene using reverse transcription of total RNA, polymerase chain reaction 
amplification of the coding region of the gene and single-strand conformation 
polymorphism (SSCP) analyses have been found to be rapid and efficient approaches in 
the detection of gene defects (Matsuda et al., 1995). SSCP is the electrophoretic separation 
of single-stranded nucleic acids based on subtle differences in sequence (often a single 
base pair) which results in a different secondary structure and a measurable difference in 
mobility through a gel.  
 The mutations in this study were discovered for the first time at the Oxford Medical 
School by Dr. Garry Brown and his colleagues, where the patients are currently under 
clinical investigation. The mutations were detected by employing patients’ white blood 
cells to derive mRNA to prepare the relevant cDNA as a template for subsequent DNA 
sequencing. Two of these mutations are homozygous unusual ‘in-frame’ 3 base pair 
deletions in E2. One mutation is in the outer lipoyl domain of E2 leading to the deletion of 
glutamate 35 whereas the second mutation causes the loss of valine at position 455 that is 
located in the C-terminal domain. The third mutation leads to substitution of leucine for a 
phenylalanine at position 490 near the active site of E2. The main objective of this study 
was to evaluate the potential of our model recombinant PDC system for analysing newly- 
discovered genetic defects of this type. This evaluation should not only test the usefulness 
of this recombinant PDC model, but also lead to a detailed understanding of the precise 
basis of the molecular defects underlying the malfunctioning of the PDC complex in these 
patients. Another important aim was to correlate the findings with the severity of the 
clinical phenotype, methods of treatment and disease prognosis. These mutations could be 
producing a clinical phenotype by affecting a variety of properties of PDC including 
enzymatic function, enzyme-enzyme cooperativity, cofactor insertion, protein folding and 
complex assembly or stability. A description of the results achieved on detailed analysis of 
these three mutations is presented in this chapter. 
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4.2 Valine- 455 deletion in the E2 enzyme of PDC 
 
This case study was characterised by deletion of a highly conserved valine at position 455 
in the catalytic region of the E2 enzyme. A patient presented at Oxford Medical School 
with clinical symptoms corresponding to PDC deficiency. On clinical investigation, no 
detectable levels of E3BP were found. E2 levels were also found to be reduced, although 
this could represent partial loss of an epitope leading to loss of E2 recognition by the anti-
E2 monoclonal antibody. A detailed analysis of E3BP DNA was carried out for the 
presence of any mutation; however, genomic and cDNA for E3BP was found to be free of 
mutations. This led to further analysis of E2 genomic DNA with the discovery of the 
absence of a 3 base pair sequence encoding a highly conserved valine at position 455. 
Interestingly, the patient was found to be heterozygous for this mutation at the genomic 
level; however, at the cDNA level only the mutant transcript was detected and the genetic 
basis for the absence of mRNA corresponding to the normal allele is still under 
investigation (unpublished data). As this deletion is in the C-terminal region, it had the 
potential to disrupt E2 core assembly or its interaction with E3BP. In previous studies also, 
mutations in one enzyme subunit have been found to promote concomitant loss of its 
binding partner. Thus, in the E1 enzyme of PDC, amino acids at positions 88, 263 and 382-
387 were found to be essential for the linking of the alpha subunit with the beta subunit 
and for the activity of the holoenzyme (Marsac et al., 1997). In this study, these mutations 
in the gene for E1α caused depletion in the levels of not only E1α, but also of E1β.  
E3BP does not normally have an independent existence and it was postulated that the E2-
located valine deletion may affect integration of E3BP into the native core assembly. 
Therefore, examining whether or not the absence of E3BP protein was a secondary 
phenomenon induced by the E2-linked valine 455 deletion was the main focus of this 
study.  
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4.2.1 Creating the ∆V455 mutation in the E2 enzyme by site-
directed mutagenesis 
 
To mimic this mutation, standard site-directed mutagenesis was performed as discussed in 
Methods (section 2.2.11) using full length E2 cDNA housed in pET-14b as well as a non 
His-tagged version housed in pET-11b for co-expression with E3BP (housed in pET-28b). 
Mutagenic primers as described in Materials & Methods section 2.1.3 were used in both 
constructs. The insertion of the correct mutation was checked by DNA sequencing. 
 
4.2.2 Overexpression and purification of the ∆V455 E2 enzyme 
 
E2-pET-14b was transformed into E. coli BL21 (DE3) Star cells and overexpressed at 30 
ºC for 4-5 h. Overexpression was checked by SDS-PAGE analysis (Fig. 4.1). Mutant E2 
was purified in the same way as the wild-type using zinc metal chelate chromatography 
and gel filtration. Purified fractions were analysed by SDS-PAGE (Fig. 4.2). Purified 
mutant enzyme was subsequently used for comparing its acetyltransferase activity with 
wild-type E2 as described in section 4.2.4.  
 
4.2.3 Checking assembly of the ∆V455 E2:E3BP core by 
overexpression and purification 
 
The purification protocol for the co-expressed E2:E3BP ‘core’ relies on capturing E2 only 
when it is tightly bound to His-tagged E3BP so if E3BP failed to integrate correctly, the 
mutant E2 subunit will either be completely absent in purified E3BP preparations or 
present in reduced amounts. A failed association of mutant E2 and E3BP was predicted as 
a possible outcome resulting from this mutation. Clinical evaluation had also indicated the 
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absence of E3BP, possibly due to non integration, leading to its subsequent rapid 
degradation.  
To test this hypothesis, wild-type and ∆V455 E2 pET-11b constructs were co-transformed 
respectively, with the E3BP pET-28b construct. Both wild-type and mutant E2:E3BP cores 
were overexpressed and purified in the same way as previously described for the wild-type 
E2:E3BP core (Chapter 3, sections 3.3 & 3.4) The mutant core was also found to be 
associating properly and the subunit composition of wild-type and mutant cores appeared 
very similar as judged by SDS-PAGE analysis (Fig. 4.3). The same experiment was 
repeated by overexpressing wild-type and mutant cores at 37 ºC i.e. normal body 
temperature to determine whether the mutation was temperature sensitive. However, 
similar results were obtained compared to the experiment carried out at 30 ºC (data not 
shown).  
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Figure 4.1 Overexpression of wild-type, ∆V455 and F490L E2 enzymes 
 
SDS-PAGE analysis of overexpression of wild-type (lane 3), F490L (lane 5) and ∆V455 
(lane 7) recombinant E2 enzymes on a 4-12% Bis-Tris gel. The overexpressions were 
carried out in E. coli BL21 (DE3) Star cells at 30 ºC for 4-5 h and are shown at zero time 
(T0) and 5 h after induction (T5). Molecular weight markers (Mw) are in lane 1. See section 
4.3.2 for further analysis of the F490L mutation. 
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Figure 4.2: Purification of wild-type, ∆V455 and F490L E2 enzymes 
 
SDS-PAGE analysis of purified ∆V455 (lanes 1 & 2), F490L (lane 3) and wild-type (lane 
4) E2 enzymes on a 4-12% Bis-Tris gel. Wild-type and mutant enzymes were purified by 
zinc chelate chromatography. Molecular weight markers (Mw) are in lane 5.  
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Figure 4.3: Integration of E3BP with E2 in ∆V455 and wild-type E2:E3BP cores 
 
(A) Gel filtration profile of the ∆V455 E2:E3BP core showing a single peak eluting at the 
void volume. Prior to gel filtration on a HiPrep 16/60 Sephacryl S-300 High Resolution 
column attached to a BioCAD 700E workstation, the His-tagged E2:E3BP core was 
purified by zinc metal chelate chromatography.  
(B) SDS-PAGE analysis of  gel filtered wild-type and ∆V455 E2: E3BP cores on a 4-12% 
Bis-Tris gel shows that E3BP is integrated into the ∆V455 E2 core (lane 3) and was 
comparable to wild-type E2:E3BP core (lane 2). Molecular weight markers (Mw) are in 
lane 1. 
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4.2.4 Enzymatic activities of the ∆V455 E2 enzyme, E2:E3BP core 
and reconstituted PDC 
 
The acetyltransferase activities of the wild-type and ∆V455 E2 recombinant enzymes were 
determined according to the protocol described in Methods section 2.3.16. The enzymatic 
activity of the mutant E2 was approx. 50% of wild-type, taken as 100% control (Fig. 4.4 
A). Similarly, the acetyltransferase activities of recombinant wild-type and mutant 
E2:E3BP cores were determined to check whether the presence of E3BP led to retention of 
normal activity. However, the activity of the mutant core was again found to be low as 
compared to the wild-type E2:E3BP core (Fig. 4.4 B). In the next step, wild-type and 
recombinant PDCs were reconstituted from purified recombinant PDC components and 
enzymatic activities determined as described in Methods section 2.3.17. The overall 
activity of the mutant complex was also reduced to approx. 50% as compared to wild-type 
complex (Fig. 4.4 C). All enzymatic assays were performed in duplicate and equal amounts 
of enzymes used in each experiment.  
 
4.2.5 Western blot analysis of the wild-type and ∆V455 E2: E3BP 
cores 
 
Purified wild-type and ∆V455 E2:E3BP recombinant cores were subjected to Bradford 
assays and equal amounts were used to perform Western blotting with a monoclonal 
antibody (PD2) that recognises only lipoylated components of PDC. 
The ability of the ∆V455 E2:E3BP core to undergo lipoylation was not lost and was 
comparable to wild-type core as determined by Western blotting (Fig. 4.5).  
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Figure 4.4: Comparison of enzymatic activities of the wild-type and ∆V455 E2 
recombinant enzymes, E2:E3BP cores and PDCs 
 
Panels A & B show the reduced acetyltransferase activities of the mutant E2 and E2:E3BP 
cores a as compared to the wild-type E2 and the core. In panel C, wild-type and mutant 
PDCs were reconstituted from individual components and enzymatic activities compared. 
The activity of the mutant PDC is reduced as compared to the wild-type. All samples were 
assayed in duplicate and error bars shown where necessary.  
∆455-E2 ∆V455 E2:E3BP  Wild-typeE2:E3BP Wild type E2 
Wild-type PDC  ∆V455-PDC 
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Figure 4.5: Western blot analysis of wild-type and ∆V455 E2:E3BP cores 
  
(A) SDS-PAGE analysis of wild- type (lane 2) and ∆V455 E2:E3BP (lane 3) cores on  a 4-
12% Bis-Tris gel. Equal amounts of protein were loaded prior to Western blotting. 
Molecular weight markers (Mw) are in lane 1. 
(B) Western blot analysis of wild-type and ∆V455 E2:E3BP cores with PD2 antibody 
shows that mutant core (panel B, lane 2) was also lipoylated and lipoylation was 
comparable to wild-type E2:E3BP core (panel B, lane 1).  
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4.2.6 Far uv and fluorescence emission spectra of the wild-type 
and ∆V455 E2:E3BP cores  
 
Purified and gel filtered recombinant wild-type and ∆V455 E2:E3BP cores, dialysed in 50 
mM KH2PO4 buffer, were subjected to far uv spectrophotometry in the 190 to 260 nm 
range as described in Methods section 2.3.20. At these wavelengths the chromophore is the 
peptide bond. Alpha-helix, beta-sheet and random coil structures each give rise to a 
characteristic shape and magnitude of CD spectrum. The CD profile shown in Fig. 4.6 
suggested that there was no major change in the structure of the mutant core as its overall 
line-shape is the same as for wild-type. It was not possible to determine the alpha helix and 
beta sheet content as the data were not of good quality below 200 nm. 
A potential change in structure was also studied using intrinsic tryptophan fluorescence as 
described in Methods section 2.3.21. No shift in the wavelength of the fluorescence 
emission spectrum was observed in the mutant core and the result was comparable to wild-
type E2:E3BP (Fig. 4.7).  
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Figure 4.6: Far uv CD spectra of wild-type and ∆V455 E2:E3BP cores 
 
Wild-type and ∆V455 E2:E3BP cores were subjected to circular dichroism analysis and 
spectra recorded in the far uv region (190-260 nm). The CD signal was measured as molar 
ellipticity in degrees cm2 dmol-1 (Y-axis) as a function of wavelength (X-axis).   
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Figure 4.7: Fluorescence emission spectra of the wild-type and ∆V455 E2:E3BP cores 
 
Wild-type and ∆V455 E2:E3BP cores were excited with uv light of wavelength 295 nm. 
Fluorescence emission (in arbitrary units) was recorded over a range of 310-420 nm. 
Maximum emission of fluorescence occurred at 330 nm for wild-type as well as for the 
∆V455 E2:E3BP core.  
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4.2.7 Comparison of sedimentation coefficients of the wild-type 
and ∆V455 E2: E3BP cores 
 
Sedimentation velocity is an analytical ultracentrifugation method that measures the rate at 
which molecules move in response to centrifugal force. This sedimentation rate provides 
information about both the molecular mass and the shape of molecules. Sedimentation 
velocity experiments were performed as described in Methods section 2.3.19.2 to obtain 
more information on the assembly of the ∆V455 E2:E3BP core as compared to the wild-
type core. For sedimentation velocity experiments, wild-type and mutant E2:E3BP cores 
were co-expressed, purified (see sections 3.3 & 3.4), gel filtered (Methods section 2.3.12) 
and SDS-PAGE analysis performed to check the purity of the cores. No proteolysis or 
degradation was evident from SDS-PAGE analysis (Fig. 4.8 E). The sample concentrations 
were 3.33, 1.07 and 1.00 µM for the wild-type and 3.17, 3.45 and 0.88 µM for the mutant. 
Samples (380 µl) were loaded into 12 mm double sector centrepieces and data recorded  at 
4 ºC at a rotor speed of 20,000 rpm using interference optics. A series of 360 scans, 60 s 
apart was taken for each sample. Sedimentation coefficients were determined using 
SEDFIT (Schuck, 2000). The weight average s4,w  values were corrected to s20,w. The 
weight average sedimentation coefficient, s20,w for the wild-type core was determined as 
30.61+ 0.36 S (Fig. 4.8 A). The reported value of human E2:E3BP core is 32 S (Hiromasa 
et al., 2004). Behal et. al. (1994) reported sedimentation coefficients of 30 and 32 S for 
native E2:E3BP core at A280 = 0.25 and 0.5 respectively. They also observed sedimentation 
coefficient heterogeneity with increasing concentration. The weight average sedimentation 
coefficient, S20,w for the mutant cores was determined as 28.89 + 0.0 S (Fig. 4.8 C), slightly 
lower than for its wild-type equivalent. The mutant core also appeared to be more 
heterogenous than the wild-type indicating that there might be a degree of perturbation in 
its structure. However, this difference could also be caused by sample variability as only 
one sample preparation was analysed due to time constraints. More rigorous analysis of 
several mutant preparations would be necessary to confirm a significant difference.   
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Figure 4.8: Comparison of the sedimentation velocity analyses of the wild-type and 
∆V450 E2: E3BP cores 
 
c(s) distribution from SV interference data for 3.33 µM (____ ) , 1.07 µM (____) and 1.00 µM 
(___) wild-type E2:E3BP core (Fig. A) and distribution of the same after maximising c(s) to 
the peak observed at 30.40 S (Fig. B). c(s) distribution from SV interference data for 3.17 
µM(___), 3.45 µM (___) and 0.88 µM (___) ∆V450 E2:E3BP core (Fig. C) and c(s) 
distribution of the same after maximising c(s) to the peak observed at 28.89 S (Fig. D). 
SDS-PAGE analysis of the wild-type and mutant cores used in SV experiment (Fig. E).  
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4.2.8 Discussion of the effects of valine-455 deletion on the E2 
enzyme of PDC 
 
Our PDC model was employed here to study the influence of a specific valine deletion (val 
455) in the catalytic region of the E2 enzyme. This deletion was encountered in a patient 
with no detectable E3BP and reduced levels of E2. Therefore, it was anticipated that this 
deletion could be disrupting the formation of the E2:E3BP core with the subsequent 
degradation of E3BP. Such disruption has also been observed in patients with a defect in 
the E1α component leading to severe concomitant depletion of E1β (Saijo et al., 1996) 
presumably induced by an impaired ability to form heterotetrameric E1. However, no large 
scale disruption was detected in the recombinant mutant core and integration of E3BP 
appeared normal at both 30 ºC and 37 ºC (Fig. 4.3). Moreover, lipoylation of the E2:E3BP 
domains was not affected as predicted since this mutation is located in the C-terminal 
domain away from N-terminal lipoyl domains (Fig. 4.5). No major changes in secondary or 
tertiary structure were detected as determined by far uv spectrophotometry and 
fluorescence emission spectroscopy (Fig. 4.6 & Fig. 4.7) also suggesting that there was no 
gross perturbation of the E2:E3BP core assembly. A degree of heterogeneity of 
sedimentation coefficient was observed as compared to wild-type core (Fig. 4.8) although 
there was insufficient time to investigate the reproducibility of this phenomenon. 
However, this mutation did result in an overall reduction of PDC activity. The loss of 
activity was found in the mutant E2 enzyme, E2:E3BP core and at PDC level also (Figs. 
4.4 A, B & C). This could be due to partial disruption of the catalytic function of the E2 
enzyme. Indeed the deleted valine 455 is in the C-terminal region that houses the 
acetyltransferase active site. Resolution of the structure of the E2 of A. vinelandii showed 
two highly conserved residues-a histidine and an aspartic acid implicated in catalysis 
(Mattevi et al., 1993c). A third important residue His-610 in A. vinelandii  E2 PDC was 
also confirmed to play a catalytic role (Mattevi et al., 1993a). A conserved sequence motif, 
DHRXXDG, is thought to accommodate the histidine and aspartate necessary for catalysis 
(Radford et al., 1987). The valine residue deletion currently under investigation, is located 
76 amino acids before the conserved sequence motif in human E2. 
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Defects in the E2 enzyme of PDC were reported for the first time by (Robinson et al., 
1990) with clinical symptoms comprising reduced PDC activity and lactic acidaemia. Only 
two other mutations in E2 have been recently reported (Brown et al., 2004).   
In this analysis, it was seen that a stable E2:E3BP core was forming as assessed by AUC 
(Fig. 4.8). Possible structural alterations in the E2:E3BP core were evident from the 
heterogeneity of the peak of the mutant as compared to the wild-type core on 
sedimentation analysis. However, no major changes were detectable by far uv CD 
spectrophotometry and tryptophan fluorescence. In addition, there was significant loss of 
mutant PDC activity as compared to the wild-type PDC (Fig. 4.4 C). Substantial residual 
activity was retained in the mutant recombinant complex which was comparable to the 
patient’s PDC activity as measured by CO2 release assay (unpublished data, personal 
communication, G. Brown). As the E2 enzyme is the structural and functional centre of the 
PDC, its complete disruption is unlikely since it is required to sustain foetal development. 
Our data in this case could not readily be reconciled with the patient’s situation, because 
this mutation seemed to cause disruption of E2:E3BP core with reduced amounts of E2 and 
complete absence of E3BP in the patient. Interestingly, the genomic DNA analysis carried 
out by Dr. Garry Brown and colleagues detected no abnormality in E3BP genomic DNA. 
Moreover, the patient appears to produce mRNA exclusively from the mutant E2 allele. A 
complete re-evaluation of the patient’s enzymatic, immunological and genetic status with 
regard to PDC deficiency is currently in progress.  
Another similar type of case has been reported recently, where a patient displayed a 
clinical phenotype consistent with PDC deficiency (Dahl et al., 1992). Cultured skin 
fibroblasts from this patient demonstrated 55% reduction in PDC activity and markedly 
decreased immunoreactivity for the E1β. Surprisingly there were no pathological 
mutations in PDHA and PDHB genes coding for E1α and E1β subunits, respectively. 
However, PDC activity could be restored in cells from this patient and normal levels of 
E1β detected following treatment with MG132, a specific proteasomal inhibitor and with 
tryphostin 23, a specific inhibitor of epidermal growth factor receptor protein tyrosine 
kinase (EGFR-PTK). This study proposed that high basal levels of EGFR-PTK activity led 
to ubiquitination of cellular proteins. However, in this study it was unclear that why only 
E1β protein was prone to this process in the absence of any mutations and how 
mitochondrial proteins gained access to proteasomes located in the cytosolic and nuclear 
compartments.  
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In our study, the reduced levels of E2 and loss of E3BP in the patient could be due to 
enhanced degradation where E2 harbours a potentially pathological mutation and as a 
result E3BP may also remain unbound to E2 leading to their reduced levels. No such 
degradation could be observed employing our recombinant PDC model produced in E. coli 
where there is no equivalent proteasomal machinery and no translocation or processing of 
precursor polypeptides is required; hence, the defective mature protein may also assemble 
to form a core structure under these conditions.  
Indeed the data in this study suggest that although there may be some minor structural 
changes in the E2:E3BP core and there is an overall reduction in enzymatic activity the 
core has not failed to assemble in E. coli. However, this may not be the case in human cells 
where mutant or partially–misfolded proteins may be more readily recognised and 
degraded leading to a more obvious phenotype.   
 
4.3 Phenylalanine–490 to leucine mutation  
 
This case study was characterised by substitution of phenylalanine- 490 by leucine in the 
catalytic region of the E2 enzyme. A male patient born to first cousins presented at Oxford 
Medical School with clinical symptoms mainly of episodic dystonia, but also with 
significant developmental delay. Development was normal until 11 months of age but, 
after that there were episodes of arching of the body, stiffening of the limbs with flexion of 
wrists, eye-rolling and distress. Developmental progress slowed down, paroxysmal 
dystonia continued and at the age of eight years the patient was wheelchair bound. 
Dystonia, either as a main clinical feature or in combination with other neurological 
manifestations, is increasingly being recognized in patients with PDC deficiency (Brown et 
al., 2004; Lissens et al., 1996). The lactate concentration in both blood and cerebro-spinal 
fluid in the patient was normal. Neuropathology of PDC deficient patients has been found 
to be quite variable. In this patient, localised neuroradiological findings revealed 
circumscribed lesions restricted to the globus pallidus bilaterally. However, this finding 
and other clinical symptoms were also not distinctive and consistent with features of PDC 
deficiency. Therefore, diagnosis alone on clinical symptoms and biochemical tests was not 
enough and prompted more detailed investigations.  
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Various other conditions were ruled out before this mutation was diagnosed by using the 
patient’s mRNA to prepare the relevant cDNA as a template for subsequent DNA 
sequencing by Dr. Garry Brown and his colleagues. They further found an approx. 50% 
decline in PDC activity in crude fibroblast extracts by the radiolabelled CO2 release assay. 
This assay is not particularly accurate as the extent of inhibition is difficult to assess 
precisely since normal (wild-type) levels of PDC activity vary over a 2-fold range in 
individual patients. Moreover, from this assay alone, it was not clear whether the decline in 
activity was caused by loss of E2 activity per se or as an indirect effect caused by 
disruption in E2 interaction with E3BP or alterations in the core assembly. Therefore, the 
focus of this study was to determine if this represented a straightforward case of reduced 
enzymatic activity of E2 resulting from alterations in a residue that may be involved in the 
catalytic mechanism. Changes in structure and assembly of the E2:E3BP core were also 
assessed in the following experiments. 
 
4.3.1 Creating the F490L mutation in the E2 enzyme by site-
directed mutagenesis 
 
To mimic this mutation, site-directed mutagenesis was performed by preparing and using 
appropriate primers described in Materials & Methods section 2.1.3. Standard site-directed 
mutagenesis was performed as discussed in Methods section 2.2.11 using full length E2 
cDNA housed in pET-14b and also in pET-11b for co-expression with E3BP in pET- 28b. 
The presence of the correct mutation was checked by DNA sequencing.  
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4.3.2 Overexpression and purification of the F490L E2 enzyme 
 
E2 pET-14b was transformed into E. coli BL21 (DE3) Star cells and overexpressed at 30 
ºC for 4-5 h. Overexpressions were analysed by SDS-PAGE (Fig. 4.1). Mutant E2 enzyme 
was purified in the same way as wild-type using zinc chelate chromatography and gel 
filtration. To check the purity of the proteins, SDS-PAGE analysis of purified fractions 
was performed (Fig. 4.2). Purified mutant enzyme was subsequently used for comparing 
acetyltransferase activity with the wild-type E2 as described in section 4.3.4.  
 
4.3.3 Checking integration of the F490L E2:E3BP core by 
overexpression and purification  
 
F490L E2-pET-11b was co-expressed with the E3BP pET-28b construct at 15 ºC. Mutated 
and wild-type E2:E3BP cores were purified in the same way as wild-type core described in 
Chapter 3, section 3.4. The core was not found to be disrupted by the presence of the 
F490L mutation, as was evident from zinc chelate chromatography and gel filtration. In 
this case also, E2 was found to interact stably with E3BP and the integrated core could be 
purified owing to the presence of the N-terminal His-tag on E3BP (Fig. 4.9).   
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 Figure 4.9: Integration of E3BP with E2 in F490L mutation   
 
SDS-PAGE analysis of purified wild-type and F490L E2:E3BP cores on a 4-12% Bis-Tris 
gel. The presence of E2 in the F490L core shows that E3BP is integrated into E2 (lane 3) 
and was comparable to wild-type E2:E3BP core (lane 2). Molecular weight markers (Mw) 
are in lane 1. 
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4.3.4 Enzymatic activities of the F490L E2 enzyme, E2:E3BP core 
and PDC 
 
The acetyltransferase activities of the recombinant wild-type and F490L E2 enzymes were 
determined using the protocol described in Methods section 2.3.16. The activity of the 
mutant E2 was found to be approx. 50% of native E2 taken as 100% control (Fig. 4.10 A). 
Similarly, the acetyltransferase activity of the wild-type and F490L E2:E3BP cores were 
determined using the same protocol. The activity of the mutant core was also found to be 
low as compared to wild-type E2:E3BP core (Fig. 4.10 B). Wild-type and mutant PDCs 
were reconstituted as per the protocol described in Chapter 3 (see section 3.10). Enzymatic 
activity was determined as described in the Methods section (2.3.17). The overall activity 
of the F490L PDC was found to be reduced by approx. 30% as compared to wild-type 
complex (Fig. 4.10 C).   
 
 
 
 
 
 
 
 
 
Chapter 4  
 
122 
122 
0
20
40
60
80
100
120
E2wi ld P490L
0
20
40
60
80
100
120
E2w ild P4 90 L
Pe
rc
en
ta
ge
 
a
ct
iv
ity
 
 
                          
0
20
40
60
80
100
120
E2wild P490L
Pe
rc
e
n
ta
ge
 
a
c
tiv
ity
 
 
Figure 4.10: Comparison of the enzymatic activities of recombinant wild-type and 
F490L E2 enzyme, E2:E3BP core and PDC 
 
Panels A & B show the reduced acetyltransferase activities of the mutant E2 and E2:E3BP 
cores are as compared to the wild-type E2 and core. In Panel C, wild-type and mutant PDC 
were reconstituted from individual components and enzymatic activities compared. 
Activity of the mutant PDC is also reduced compared to wild-type. All samples were 
assayed in duplicate and error bars shown where necessary. 
Wild- type E2 
Wild type PDC 
F490L E2:E3BP 
  Wild-type E2:E3BP 
          F490L PDC 
           A 
 
  B 
C 
          F490L E2 
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4.3.5 Far uv and fluorescence emission spectra of the wild-type 
and F490L E2:E3BP cores  
 
The secondary structure of the mutant core was estimated using far uv spectrophotometry 
in the far uv spectral region (190-250 nm) as described in Methods section 2.3.20. The data 
were not of good quality in the 190-200 nm region (not shown) and therefore percentage of 
alpha helices and beta sheets could not be estimated. However, the line shapes of the 
spectra in the 200-280 nm region were similar overall for the mutant as well as wild–type 
core. This indicated that there were no major changes in the secondary structure of the 
mutant core as compared with the wild-type core (Fig. 4.11).  
Change in structure was also studied using tryptophan fluorescence as described in 
Methods section 2.3.21. However, no shift in the spectral emission peak (330 nm) was 
observed between the mutant and the wild-type E2:E3BP cores (Fig. 4.12). This suggested 
that there was no perturbation of the local environment in the region occupied by the six 
tryptophan residues located in the E2:E3BP core. 
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Figure 4.11: Far uv CD spectra of the wild-type and F490L E2:E3BP core 
 
Wild-type and F490L E2:E3BP cores were subjected to circular dichroism and spectra 
recorded in the far uv region (190-260 nm). The CD signal was measured as molar 
ellipticity in degrees cm2 dmol-1 (Y- axis) plotted as a function of wavelength (X -axis).   
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Figure 4.12: Fluorescence emission spectra of wild-type and F490L E2:E3BP cores  
 
Wild-type and F490L E2:E3BP cores were excited with uv light of wavelength 295 nm. 
Emission of fluorescence was recorded over a range of 310-420 nm. The figure shows that 
the maximum emission of fluorescence occurred at 330 nm wavelength for wild-type and 
F490L E2:E3BP cores.  
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4.3.6 Discussion of phenylalanine–490 to leucine mutation 
 
This mutation was found to cause reduced PDC activity and various clinical symptoms in a 
patient (Brown et al., 2004). Our data provided an explanation for the functional 
consequences of this deletion. The E2:E3BP core appeared to be integrating stably as 
evidenced from zinc chelate chromatography, gel filtration (Fig. 4.9), circular dichroism 
(Fig. 4.11) and tryptophan fluorescence studies (Fig. 4.12). However, there was loss of 
enzymatic activity in mutant E2, E2:E3BP core and recombinant PDC (Figs. 4.10 A, B & 
C). Earlier also, this mutation was shown to be responsible for reduced PDC activity by 
functional complementation in which activity was restored by transfecting normal E2 
cDNA into patient’s fibroblasts (Brown et al., 2004). However, in that study full activity 
could not be restored. Demonstration of loss of acetyltransferase activity using a 
recombinant model of PDC not only substantiated the functional complementation study 
but also provided more definitive diagnosis. The recombinant mutant PDC in this study 
lost about 50% enzymatic activity as compared to the normal or wild-type PDC. Thus, this 
mutation appears to be the reason for the loss of PDC activity in the patient also.  
This mutated phenylalanine residue is highly conserved across various eukaryotic and 
prokaryotic species and is reported to be responsible for substrate specificity in E2 
(Mattevi et al., 1993b) thus replacement of the phenylalanine by the smaller leucine 
residue could potentially affect acetyltransferase activity. In the corresponding position in 
the E2 enzyme of BCOADC, this position is occupied by serine, and it is proposed that the 
larger phenylalanine limits access to the active site to the smaller acetyl group substrate of 
E2-PDC (Mattevi et al., 1993c). Another plausible explanation could be that the catalytic 
activity is affected as this mutation is located 42 amino acids from the conserved motif, 
DHRXXXDG that is important for E2 catalytic activity and could potentially perturb the 
local environment in this active site region. Substantial residual enzymatic activity was 
retained, however, in agreement with PDC activity measurements on patient fibroblasts 
employing the CO2 release assay. Thus it is apparent that this mutation does not cause 
large-scale changes in the assembly of the ‘core’ that might have caused more severe loss 
of PDC function. In general all of these data are consistent with the F490L mutation having 
a direct affect on E2 activity and the underlying catalytic mechanism. 
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4.4 Glutamate 35 deletion in the E2 enzyme  
 
In this section the role of the glutamate 35 deletion in the outer lipoyl domain of the E2 
enzyme in a young patient was investigated. The patient was a male born at term to first 
cousins. He was in a good mental condition and the main clinical features were ataxia and 
dystonia, which developed at an early stage. He was introduced to a ketogenic diet that 
significantly resolved the symptoms. However, residual problems in fine-motor 
coordination still persisted at the age of 11 years. As ataxia and dystonia are increasingly 
being noted in PDC deficient patients, this led to a check for any abnormalities in genes 
encoding PDC subunits leading to discovery of this mutation.  
On sequencing cDNA derived from patient’s white blood cells, a highly conserved 3 base 
pair sequence encoding glutamate 35 in the outer lipoyl domain of the E2 enzyme was 
found to be missing. The involvement of this deletion in promoting reduced PDC activity 
was determined by functional complementation by expressing normal E2 in the patient’s 
fibroblasts. However, many questions remained unanswered as to how this mutation could 
lead to PDC deficiency since it affected only one lipoyl domain out of three in the 
E2:E3BP core. In previous studies, the presence of all E2-linked lipoyl domains were not 
found to be necessary for maximal E. coli PDC activity in vitro (Fussey et al., 1988). 
However, isogenic E. coli strains with three active lipoyl domains outgrew those with just 
one or two indicating that the loss of lipoyl domains does reduce PDC efficiency in vivo 
(Fussey et al., 1988). In this case study, however, there was about 70% reduction in PDC 
activity, as determined by CO2 release assay. This drastic loss of activity could not be 
readily accounted for solely by potential loss of lipoylation in the outer lipoyl domain 
since, there are an additional 72 inner and E3BP lipoyl domains in PDC, that should  be 
unaffected. Our own data in this thesis in Chapter 3 (see section 3.14, Fig. 3.12) also 
suggest that loss of lipoylation of the outer  domain in E2-PDC only causes 25-30% loss of 
enzymatic activity. Therefore, the main aim of this study was to determine how this 
mutation induced such a substantial decline in overall PDC activity.  
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4.4.1 Creating the E35D, E35Q and ∆E35 mutants of the outer 
lipoyl domain  
 
To study the role of this mutation, a 3 base pair ‘in frame’ deletion encoding glutamate 35 
in a GST outer lipoyl domain fusion construct (already available in laboratory) was created 
by site-directed mutagenesis using primers described in Materials & Methods section 2.1.3.  
Two other mutants of the lipoyl domain fused with GST were also created. In one 
construct, glutamate-35 was substituted by an aspartate (E35D) and in the other with a 
glutamine (E35Q) again by employing the relevant primers (Materials and Methods, 
section 2.1.3). These mutants were created to study the possible influence of charge and 
size of amino acid at this position when comparing with the ∆E35 mutant of the outer 
lipoyl domain. All mutations were checked by DNA sequencing as described in Methods 
section 2.2.7. 
 
4.4.2 Overexpression and purification of the wild-type, E35D, 
E35Q and ∆E35 lipoyl domains   
 
Wild-type, ∆E35, E35D, E35Q outer lipoyl domains and non-lipoylated K173Q inner 
lipoyl domain constructs in pGEX-2T were transformed into E. coli BL21 (DE3) cells, 
respectively. Transformed cells were grown and protein expression induced with IPTG at 
30 ºC for 4-5 h after cultures attained an A600 of 0.5. All the fusion proteins were found to 
be overexpressed in soluble form as analysed by SDS-PAGE. Recombinant lipoyl domain 
GST fusion proteins were purified by glutathione Sepharose 4B chromatography as 
described in Methods section 2.3.13 and analysed by SDS-PAGE (Fig. 4.13 A).  
 
Chapter 4  
 
129 
129 
4.4.3 Western blot analysis of wild-type, E35D, E35Q and ∆E35 
lipoyl domains 
 
Western blotting of wild-type, ∆E35, E35D, E35Q outer lipoyl domain and K173Q inner 
lipoyl domain fusion proteins was performed using a monoclonal antibody (PD2) that 
recognises lipoylated components of PDC using a protocol described in Methods section 
2.3.15. On Western blotting it was found that the ∆E35 lipoyl domain was not lipoylated 
when compared to the wild-type and the result was comparable to the non-lipoylatable 
mutant inner lipoyl domain (K173Q). The other two mutants of the outer lipoyl domain, 
E35D and E35Q, created to investigate the effect of change in charge and size on the 
folding and lipoylation status of this domain were found to be fully lipoylated (Fig. 4.13 
B). 
 
4.4.4 Non denaturing gel electrophoresis of the wild-type, E35D, 
E35Q and ∆E35 lipoyl domains 
 
The GST tags of wild-type, ∆E35, E35D and E35Q outer lipoyl domains were removed 
with thrombin by the protocol described in Methods section 2.3.14. Interestingly, it was 
noted that tags could be removed from the ∆E35 outer lipoyl domain in a short time 
interval (2 h), whereas for the wild-type and other two mutants it took about 8-10 h. After 
the removal of the GST tags, the proteins were first analysed by SDS-PAGE for checking 
of purity. Thereafter, they were analysed on a 6% native gel (Methods section 2.3.5). The 
∆E35 outer lipoyl domain was found to exhibit a markedly decreased mobility on the 
native gel as compared to the wild-type and the other mutants (Fig. 4.14) indicating either 
a major change in charge, conformation or aggregation state or a combination of these 
factors. 
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Figure 4.13: SDS-PAGE and Western blot analysis of the wild-type, E35D, E35Q, 
∆E35 outer lipoyl domains and K173Q inner lipoyl domain  
 
(A) SDS-PAGE analysis of purified wild-type (lane 2), E35D (lane 3), E35Q (lane 4), 
∆E35 (lane 5) outer lipoyl domain GST fusion proteins and K173Q inner lipoyl domain 
GST fusion protein (lane 6) resolved on a 4-12% Bis-Tris gel. Wild-type and mutant fusion 
proteins were purified by glutathione Sepharose 4B chromatography. Molecular weight 
markers (Mw) are in lane 1.  
(B) Western blot analysis of wild-type (lane 2), E35D (lane 3) E35Q (lane 4), ∆E35 (lane 
5) outer lipoyl domain GST fusion proteins and K173Q inner lipoyl domain GST fusion 
protein (lane 6) with PD2 antibody. The ∆E35 outer lipoyl domain is not detected (lane 5) 
and is comparable to the negative control, K173Q inner lipoyl domain (lane 6). 
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4.4.5 Structural prediction for the wild-type and ∆E35 outer lipoyl 
domains 
 
 A possible structural change in the ∆E35 lipoyl domain was suspected on the basis of ease 
of removal of its GST tag by thrombin, Western blotting and native gel electrophoresis. 
Therefore, it was decided to ascertain if any change in the structure of the mutant domain 
was predicted on the basis of Swiss modelling (see section 2.3.18). The structure of the 
outer human lipoyl domain has not been solved either by NMR or by X-ray 
crystallography; therefore both the structures were created based on sequence homology. 
The potential structure for the mutant lipoyl domain was found to be similar to the wild-
type lipoyl domain (Fig. 4.15 A & B). Overall its conformation appeared to be very similar 
to the lipoyl domain of B. stearothermophilus which consists of two 4-stranded antiparallel 
β sheets in the form of a flattened β-barrel with the lipoylatable lysine residue located on 
an exposed type-1 β turn in one of the β sheets (Dardel et al., 1993) (Fig. 4.15 C).  
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Figure 4.14: Non denaturing gel electrophoresis of the wild-type, E35D, E35Q and 
∆E35 lipoyl domains 
 
Native gel analysis on a 6% polyacrylamide gel shows that the ∆E35 outer lipoyl domain 
(lane 4) is either aggregated or has a major change in charge and/or shape as compared to 
wild-type (lane 1), E35D (lane 2) and E35Q (lane 3) outer lipoyl domains.   
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Figure 4.15: Structure prediction of the wild-type and ∆E35 lipoyl domain using 
Swiss modelling 
 
The structure of the wild-type (A) and ∆E35 (B) outer lipoyl domains as predicted by 
Swiss modelling (Schwede et al., 2003) was not found to be significantly altered and was 
similar to the structure of the lipoyl domain of B. stearothermophilus E2-PDC. (C) 
Adapted from Dardel et al. (1993). 
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4.4.6 Molecular weight determination of the wild-type, E35D, E35Q 
and ∆E35 lipoyl domains by size exclusion chromatography 
Size exclusion chromatography (SEC) separates proteins based on their size, shape or their 
hydrodynamic volume. SEC allows the separation of folded and unfolded forms, as the 
folded polypeptide elutes much later due to its more compact structure. The purified wild-
type, ∆E35 and E35D outer lipoyl domains were passed through a HiPrep 16/60 Sephacryl 
S-300 High Resolution column attached to a BioCAD 700E workstation as described in 
Methods section 2.3.12 and elution profiles compared. Similarly, the wild-type and ∆E35 
lipoyl domain GST fusion proteins were also subjected to gel filtration chromatography on 
the same column for comparative purposes.        
It was observed that the wild-type and E35D outer lipoyl domains eluted at the same 
elution volume whereas the ∆E35 outer lipoyl domain appeared at an earlier stage in the 
elution profile (Fig. 4.16 B). Ratio of elution volume to void volume Ve/Vo was calculated 
for each protein and was found to be 2.21 for the wild-type and for the E35D outer lipoyl 
domains, whereas for the ∆E35 lipoyl domain, this ratio was 1.98. Similarly, the main peak 
for the ∆E35 lipoyl domain GST fusion protein was also observed at an earlier stage and 
displayed a Ve/Vo of 1.52 whereas for the wild-type-GST construct, this value was 1.68 
(Fig. 4.16 C). 
The molecular masses of these proteins were calculated employing a calibration curve 
generated by plotting logarithm of molecular weights of known proteins on the Y-axis and 
Ve/Vo on the X-axis (Fig. 4.16 A). It was found that the molecular weight of the ∆E35 
outer lipoyl domain was twice that of wild-type lipoyl domain. Thus, the predicted 
molecular mass of this domain was 20.7 kDa; however, the observed molecular mass as 
determined from the standard curve (Fig. 4.16 A) was 45 kDa. A similar trend was 
observed when the molecular mass of the wild-type and mutant domains fused with GST 
were compared. The predicted molecular mass of the GST fusion mutant was 90 kDa; 
however, the observed molecular mass using the standard curve was 180 kDa. In both 
cases, the ∆E35 lipoyl domain was present as a dimeric species whilst also displaying an 
increased tendency to form aggregates of higher order and showing a substantial peak at 
the void volume in the case of the lipoyl domain GST fusion protein (Fig. 4.16 B & C).  
Chapter 4  
 
135 
135 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Molecular mass determination of the wild-type, E35D, E35Q and ∆E35 
lipoyl domains by size exclusion chromatography 
 
(A) Standard curve generated by plotting the logarithm of molecular weights of known 
proteins on the Y-axis and ratio of elution to void volume Ve/Vo on the X-axis. Ve/Vo of 
the test samples were determined by resolving on a HiPrep 16/60 Sephacryl S-300 High 
Resolution column attached to BioCAD 700E workstation. (B) Gel filtration elution 
profiles and Ve/Vo ratios of the wild-type, E35D, ∆E35 lipoyl domains (C) Gel filtration 
elution profiles and Ve/Vo ratios of the wild-type and ∆E35 lipoyl domain GST fusion 
proteins.  
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 4.4.7 Cross linking of the wild-type and ∆E35 lipoyl domains by 
glutaraldehyde treatment  
 
If two proteins physically interact with each other forming dimers or oligomers of higher 
order, then they can be covalently cross-linked chemically. Chemical cross linking offers a 
direct method of identifying both transient and stable interactions. This technique involves 
the formation of covalent bonds between two interacting proteins by using bifunctional 
reagents containing reactive end groups that link to functional groups such as primary 
amines and thiol groups of amino acid residues. Homo-bifunctional reagents, specifically 
reacting with primary amine groups (i.e. ε-amino groups of lysine residues) have been used 
extensively as they are soluble in aqueous solvents and can form stable inter- and intra-
subunit covalent bonds. Glutaraldehyde is a popular homo-bifunctional reagent, which is 
extensively used for cross linking. SDS polyacrylamide gels of oligomeric proteins, for 
instance dimeric proteins, after treatment with glutaraldehyde will show cross linked 
dimers where inter-subunit cross linking has occurred. In this experiment, purified wild-
type and ∆E35 outer lipoyl domains were treated with 2% (v/v) glutaraldehyde 
respectively for 30 min at room temperature. Thereafter, SDS-PAGE analysis of the treated 
samples was carried out employing the routine protocol outlined in Methods section 2.3.4. 
It was found that the wild-type lipoyl domain migrated at its normal molecular mass (20 
kDa) even after glutaraldehyde treatment whereas the ∆E35 outer lipoyl domain migrated 
more slowly corresponding to a molecular mass of approx. 45 kDa, consistent with its 
existence as a homodimer prior to cross linkage (Fig. 4.17).  
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Figure 4.17: SDS-PAGE analysis of the wild-type and ∆E35 lipoyl domains cross- 
linked with glutaraldehyde  
 
The Bis-Tris (4-12%) SDS gel was stained with Coomassie blue and shows that the ∆E35 
lipoyl domain present as a dimer after treatment with 2% glutaraldehyde (lane 3), whereas 
the wild-type outer lipoyl domain treated in same way is monomeric (lane 1). Wild-type 
and ∆E35 lipoyl domains without glutaraldehyde treatment are in lanes 2 and 4, 
respectively. Molecular weight markers (Mw) are in lane 5. 
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4.4.8 Analysis of the far uv spectra of the wild-type, E35D, E35Q 
and ∆E35 lipoyl domains by circular dichroism  
 
Secondary structure can be estimated by CD spectroscopy in the far-uv spectral region 
(190-250 nm). Samples of the wild-type, ∆E35, E35D and E35Q outer lipoyl domains, all 
free of their GST tags, were prepared as discussed in Methods section 2.3.20. Domains 
were examined for possible changes in secondary structure using CD spectroscopy in the 
far uv   region. The CD spectrum of the ∆E35 outer lipoyl domain was quite distinct when 
compared with the wild-type and other mutants (Fig. 4.18). Secondary structures were 
estimated using the CDSSTR algorithm which is available from the online DICHROWEB 
server hosted by the Birkbeck college (http://www.cryst.bbk.ac.uk). From the spectral data, 
the algorithm estimated that the wild-type and mutants E35D and E35E consisted of 
predominantly beta sheet structure (approx. 45%), whereas, the ∆E35 outer lipoyl domain 
consisted mainly of random coil.  
 
4.4.9 Near uv spectra of the wild-type E35D, E35Q and ∆E35 lipoyl 
domains by circular dichroism 
 
The CD spectrum of a polypeptide in the near-uv spectral region (250-350 nm) can be 
sensitive to certain aspects of tertiary structure. Over this wavelength range the major 
chromophores are the aromatic amino acids and disulphide bonds, that can give rise to 
individual spectral contributions and the CD signals produced can be a sensitive probe for 
detecting alterations in the overall tertiary structure of the protein. Signals in the region 
from 250-270 nm are attributable to phenylalanine residues, signals from 270-290 nm to 
tyrosine and those from 280-300 nm to tryptophan. Disulphide bonds give rise to broad 
weak signals throughout the near-uv spectrum. Samples of the wild-type, ∆E35, E35D and 
E35Q outer lipoyl domain were prepared as mentioned in Methods section 2.3.20. Near uv 
CD spectra in this region indicated that in the wild-type, E35D and E35Q outer lipoyl 
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domains, the aromatic amino acids such as tyrosine were in a rigid environment giving rise 
to well-defined troughs in this region. In contrast, in the ∆E35 outer lipoyl domain, this 
rigid environment was lost as indicated by the disappearance of the characteristic troughs 
centred around 278 nm, 286 nm and 292 nm (Fig. 4.19).  
 
4.4.10 Fluorescence emission spectra of the wild-type, E35D, 
E35Q and ∆E35 outer lipoyl domains  
 
Fluorescence emission spectra of the wild-type, E35D, E35Q and ∆E35 outer lipoyl 
domains were generated and analysed by exciting the individual samples at 295 nm as 
described in Methods section 2.3.21. The fluorescence emission spectra were recorded at 
320-350 nm. Maximum emission occurred at 330 nm for the wild-type, E35D and E35E 
outer lipoyl domains whereas maximum emission for the ∆E35 lipoyl domain shifted to 
345 nm (Fig. 4.20). This indicated that the single buried tryptophan residue in the ∆E35 
lipoyl domain was exposed to the external aqueous phase and this domain appeared to be 
largely unfolded as compared to the wild-type and other mutants. 
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Figure 4.18: Far uv CD spectra for the wild-type, E35D, E35Q and ∆E35 lipoyl 
domains 
 
The wild-type, E35Q, E35D and ∆E35 outer lipoyl domains were subjected to circular 
dichroism and spectra recorded in the far uv region (190-260 nm). The CD signal was 
measured as molar ellipticity in degrees cm2 dmol-1 (Y-axis) plotted as a function of 
wavelength (X-axis).   
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                                        Wavelength in nm  
 
 
--------  E35Q 
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Figure 4.19: Near uv CD spectra for the wild-type, E35D, E35Q and ∆E35 lipoyl 
domains 
  
The wild-type, E35Q, E35D and ∆E35 outer lipoyl domains were subjected to circular 
dichroism and spectra recorded in the near uv region (250-320 nm). The CD signal was 
measured as molar ellipticity in degrees cm2 dmol-1 (Y-axis) as a function of wavelength 
(X- axis).   
 
         250      260                      280                     300                        320  
                                         Wavelength in nm 
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Figure 4.20: Fluorescence emission spectra of the wild-type, ∆E35, E35D and E35Q 
outer lipoyl domains 
The wild-type, ∆E35, E35D and E35Q outer lipoyl domains were excited with uv light of 
wavelength 295 nm. Emission of fluorescence was recorded over the wavelength range 
310-420 nm. The data show that maximum emission of fluorescence occurs at 330 nm for 
the wild-type, E35D and E35Q lipoyl domains, whereas for the ∆E35 outer lipoyl domain, 
the peak of fluorescence emission shifts to 345 nm.  
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4.4.11 Creating the ∆E35, E35D and E35Q mutants of full length 
E2  
 
The glutamate-35 mutation was created in full length E2 cDNAs housed in pET-14b and 
pET-11b vectors respectively by site-directed mutagenesis using appropriate primers 
(Materials & Methods section 2.1.3). In the same way, E35D and E35Q mutants of E2 in 
pET-14b and pET-11b were also created for detailed analysis of these mutations. The 
primers specified in Materials & Methods (section 2.1.3) were used for creating E35D and 
E35Q E2 mutants. On DNA sequencing, the correct mutations were found to be 
incorporated into all the mutant constructs. Six mutant constructs of E2 namely: ∆E35 
pET-14b, ∆E35 pET-11b, E35D pET-14b, E35D pET-11b, E35Q pET-14b and E35Q pET-
11b were generated in this manner. The pET-14b constructs were required to study the 
effects of the glutamate 35 deletion on E2 activity whereas, the pET-11b constructs of E2 
facilitated co-expression with E3BP in pET-28b to obtain mutant E2:E3BP cores described 
in Section 4.4.14, enabling us to study the effects of this mutation on the E2:E3BP core 
and overall PDC activity. 
 
4.4.12 Overexpression and purification of the wild-type, ∆E35, 
E35D and E35Q E2 enzymes 
 
To overexpress wild-type, ∆E35, E35D and E35Q E2 enzymes, pET-14b constructs 
housing the relevant cDNAs were transformed into E. coli BL21 (DE3) cells. 
Overexpressions were carried out at 30 ºC for 5-6 h and visualised by SDS-PAGE (Fig. 
4.21). The N-terminally His-tagged proteins were purified by zinc chelate chromatography 
and viewed by SDS-PAGE (Fig.  4.22). 
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Figure 4.21: Overexpression of the wild-type, ∆E35, E35D and E35Q E2 enzymes 
 
SDS-PAGE analysis of overexpression of the wild-type (lane 3), ∆E35 (lane 5), E35D 
(lane 7) and E35Q (lane 9) recombinant E2 enzymes on a 4-12% Bis-Tris gel. The 
overexpressions were carried out in E. coli BL21 (DE3) cells at 30 ºC for 4-5 h and are 
shown at zero time (T0) and 5 h after induction (T5). Molecular weight markers (Mw) are 
in lane 1. 
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Figure 4.22: SDS-PAGE analysis of purified wild-type, ∆E35, E35D and E35Q E2 
enzymes 
 
SDS-PAGE analysis of the purified wild-type (lane 4), ∆E35 (lane 3), E35D (lane 2) and 
E35Q (lane1) recombinant E2 enzymes on a 4-12% Bis-Tris gel. Wild-type and mutant 
enzymes were purified by zinc chelate chromatography. Molecular weight markers (Mw) 
are in lane 5.  
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4.4.13 Enzymatic activity of wild-type and ∆E35, E35D and E35Q 
mutants of E2  
The acetyltransferase activities of the purified wild-type, ∆E35, E35D and E35Q E2 
enzymes were compared spectrophotometrically following the protocol described in 
Methods section 2.3.16. Equal amounts of wild-type and mutant E2 enzymes were used to 
determine acetyltransferase activity by initially performing Bradford assays (see section 
2.3.11). Further SDS-PAGE analysis of these enzymes was carried out to ensure that equal 
amounts were assayed for acetyltransferase activity. All activity assays were performed in 
duplicate with wild-type control and the E35D mutant displaying 100% activity. In 
comparison, the E35Q E2 mutant displayed approx. 80%, whereas ∆E35 E2 displayed only 
approx. 20% activity (Fig. 4.23). These results were found to be reproducible with 3 
different preparations of recombinant wild-type and mutant E2s. 
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Figure 4.23: Comparison of acetyltransferase activity of the wild-type, ∆E35, E35D 
and E35Q E2 enzymes   
 
Percentage enzymatic activities of wild-type and mutant E2 enzymes are shown. Error bars 
indicate extent of variation between duplicates.  
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4.4.14 Co-transformation and overexpression of the wild-type, 
∆E35, E35D and E35Q E2:E3BP cores 
Wild-type E2 cDNA in pET-11b and E3BP cDNA in pET-28b were co-transformed into E. 
coli BL21 (DE3) Star cells and single colonies employed for overexpression studies. 
Overexpression yielded the most soluble E2:E3BP core at 15 ºC (Chapter 3, Fig. 3.5). The 
∆E35, E35D and E35Q E2:E3BP cores were successfully overexpressed in the same 
manner. Lipoic acid (0.1 mM) was added to each before induction with 1 mM IPTG. The 
solubility of the ∆E35 E2:E3BP core was also checked at 37 ºC, 30 ºC, 22 ºC and 15 ºC, 
and was found to be maximal at 15 ºC (Fig. 4.24). Therefore, in subsequent experiments, 
wild-type and mutant E2:E3BP cores were all overexpressed at 15 ºC overnight.   
 
4.4.15 Purification of the wild-type and ∆E35, E35D and E35Q 
E2:E3BP cores 
The E2:E3BP cores contained only N-terminally His-tagged E3BP and consequently their 
purification relied on the formation of a stable E2:E3BP core assembly in which E3BP co-
integrated with its E2 partner. Mutant cores could be purified successfully by metal chelate 
chromatography in a similar manner as described for the wild-type core in Chapter 3 (see 
section 3.4). The purified wild-type and mutant cores were also subjected to gel filtration 
on a HiPrep 16/60 Sephacryl S-300 High Resolution column attached to a BioCAD 700E 
workstation before viewing by SDS-PAGE (Fig. 4.25). On SDS-PAGE analysis, the ∆E35 
core was found to contain reduced levels of E2 and a high proportion of E3BP as compared 
to the wild-type core. Several preparations of this mutant core analysed by routine SDS-
PAGE consistently displayed this feature, which was the first indication of abnormal 
assembly.   
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Figure 4.24: Solubility check of ∆E35 E2:E3BP core overexpressed at various 
temperatures 
 
The ∆E35 E2:E3BP core was overexpressed at 15 ºC, 22 ºC, 30 ºC and 37 ºC in E. coli 
BL21 (DE3) Star cells. SDS-PAGE analysis on a 4-12% Bis-Tris gel shows that at 37 ºC, 
30 ºC and 22 ºC, mutant E2:E3BP was largely insoluble and present in the pellet fraction 
(PS)( lanes 3, 6 and 10 respectively). When overexpressed at 15 ºC overnight, this protein 
was present in the soluble supernatant (SS) (lane 12). Whole cell extracts (WE) in lanes 1, 
4, 8 and 11, respectively. Molecular weight markers (Mw) are in lane 7.   
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 Figure 4.25: SDS-PAGE of the purified wild-type, ∆E35, E35D and E35Q E2:E3BP 
cores 
 
SDS-PAGE analysis of the purified wild-type (lane 2), ∆E35 (lane 3), E35D (lane 6) and 
E35Q (lane 7) recombinant E2:E3BP cores on a 4-12% Bis-Tris gel. Wild-type and mutant 
enzymes were purified by zinc chelate chromatography and gel filtration. Gel also shows 
∆V455 and F490L E2:E3BP cores in lanes 4 and 5, respectively. Molecular weight 
markers (Mw) are in lane 1.  
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4.4.16 Enzymatic activity of the wild-type, ∆E35, E35D and E35Q 
E2:E3BP cores 
Purified wild-type, ∆E35, E35D and E35Q E2:E3BP cores (see section 4.4.13) were 
checked for protein levels by performing Bradford assays as described in Methods section 
2.3.11. SDS-PAGE analysis was also carried out to ensure that equal amounts of wild and 
mutant cores were assayed for acetyltransferase activity. Assays were conducted to 
compare wild-type (taken as a 100% control) with the mutant cores, in the same manner as 
for the wild-type and mutant E2 enzymes (see section 4.4.13). In the previous E2 assay, it 
was seen that ∆E35 E2 showed very low activity (80% reduction). The purpose of 
employing E2 cores containing E3BP was to establish if the presence of E3BP had any 
influence on ∆E35 E2 activity. As previously however, the E35D core displayed 100% 
activity, the E35Q core displayed approx. 80% whereas  the ∆E35 core assembly displayed 
only 20% of the control activity levels, in agreement with the values obtained employing 
the wild-type and mutant E2 enzymes. Thus the pattern of results on assembled native and 
mutant E2:E3BP cores was similar to those obtained for the equivalent set of purified E2 
samples.  
 
4.4.17 Comparison of overall PDC activity in recombinant 
preparations of reconstituted wild-type, ∆E35, E35D and E35Q 
core assemblies 
 
Wild-type, ∆E35, E35D and E35Q E2:E3BP cores were reconstituted into wild-type and 
mutant PDCs by adding stoichiometric amounts of E1 and E3 respectively (see Chapter 3, 
section 3.11). Enzymatic assays were performed in duplicate with freshly prepared wild-
type and mutant PDCs as per the protocol described in Methods section 2.3.17. Wild-type 
PDC was taken as control with 100% activity. In comparison, the E35D PDC displayed 
80%, E35Q PDC 75%, whereas the ∆E35 PDC displayed consistently low activity of about 
10 -12 % (Fig. 4.27). 
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Fig 4.26: Comparison of enzymatic activity of wild-type, ∆E35, E35D and E35Q 
E2:E3BP cores   
 
Percentage enzymatic activities of mutant E2:E3BP cores relative to the wild-type as 100% 
control are shown. Samples were assayed in duplicate and error bars are shown where 
necessary and indicate extent of variation between duplicates.  
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Figure 4.27: Comparison of recombinant PDC activities reconstituted with the wild-
type, ∆E35, E35D and E35Q E2:E3BP cores 
 
 Enzymatic activities of the wild-type and mutant PDCs reconstituted from individual 
components are shown with respect to wild-type complex as control. Samples were 
assayed in duplicate and error bars shown where necessary indicating the extent of 
variation between duplicates.   
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4.4.18 Far UV spectra of the wild-type, ∆E35, E35D and E35Q E2: 
E3BP cores by circular dichroism  
 
The wild-type and mutant cores were subjected to CD in the region of 190-250 nm and 
spectra recorded as described in Methods section 2.3.20.  
The data were not of high quality in the 190-200 nm region and therefore, quantitative 
estimation of  α helix and β sheet content was not attempted. However, differences were 
observed in the spectra of the ∆E35 mutant core as compared to the wild type and other 
mutant cores, where a well defined peak at 206 nm is absent in the ∆E35 core (Fig. 4.28). 
 
4.4.19 Fluorescence emission spectra of the wild-type, ∆E35, 
E35D and E35Q E2:E3BP cores 
 
Fluorescence emission spectra of the wild-type, ∆E35, E35D and E35Q; E2:E3BP cores 
were also compared as described in the Methods section 2.3.21. It was found that 
maximum fluorescence emission spectrum of ∆E35 E2:E3BP core shifted from 330 nm to 
343 nm, as compared to the spectra of the wild-type and other mutant cores, which emitted 
maximally at 330 nm (Fig. 4.29). Since the single E2 polypeptide contains 4 tryptophans 
and E3BP polypeptide contains 2, this suggests large scale perturbation of the core 
assembly in which several tryptophans are exposed to the aqueous environment.  
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Figure 4.28: Far uv CD spectra of the wild-type, E35Q, E35D and ∆E35 E2:E3BP 
cores 
 
Wild-type, E35Q, E35D, and ∆E35 E2:E3BP cores were subjected to circular dichroism 
and spectra recorded in the far uv region (190-260 nm). The CD signal was measured as 
ellipticity in degrees cm2 dmol-1 (Y-axis) plotted as a function of wavelength (X-axis).   
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Figure 4.29: Fluorescence emission spectra of wild type, E35Q, E35D, ∆E35 E2:E3BP 
cores  
 
Wild-type, E35D, E35Q, ∆E35 E2:E3BP cores were excited with uv light of wavelength 
295 nm. Emission of fluorescence was recorded over a range of 310-420 nm. Figure shows 
that the maximal emission of fluorescence occurred at 326 nm for the wild-type, E35D and 
E35Q cores, whereas for the ∆E35 core, maximal fluorescence emission shifted to 343 nm.  
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4.4.20 Comparison of sedimentation behaviour of the wild-type 
and ∆E35 E2:E3BP cores 
Major disruption of the ∆E35 E2:E3BP core was anticipated as observed from circular 
dichroism and intrinsic tryptophan fluorescence studies. Therefore, sedimentation velocity 
experiments were conducted in order to provide further insights into the nature of the 
mutant core assembly. These experiments were performed as described in the Methods 
section 2.3.19.2 and the sedimentation behaviour of the ∆E35 E2:E3BP core was compared 
to the wild-type core. Wild-type and mutant cores were co-expressed, purified (see sections 
3.3 & 3.4), gel filtered (see the Methods section 2.3.12) and SDS-PAGE analysis 
conducted for checking the purity of the cores. No proteolysis or degradation was evident 
from SDS-PAGE analysis (Fig. 2.30 E).  
The sample concentrations analysed were 3.33, 1.07 and 1.00 µM for the wild-type and 
2.06, 1.72, 1.07, 2.60, 2.26 and 0.50 µM for the mutant. Samples (380 µl) were loaded into 
12 mm double sector centrepieces and data recorded at 4 ºC at a rotor speed of 20000 rpm 
using interference optics. A series of 360 scans, 60 s apart was taken for each sample. 
Sedimentation coefficients were determined using SEDFIT (Schuck, 2000). The weight 
average s4,w  values were corrected to s20,w. The weight average sedimentation coefficient, 
s20,w for the wild-type cores was determined as 30.61+0.36 S, whereas sedimentation 
coefficient for the mutant core displayed a great degree of heterogeneity (8-40 S). A small 
amount of the mutant core showed a sedimentation coefficient comparable to wild-type 
core, but the vast majority was present as sedimenting species of lower Mr value. This 
result was anticipated, in view of previous CD spectroscopy, fluorescence tryptophan and 
enzymatic assays that indicated the probability of major disruption in its assembly. A range 
of sedimentation coefficients (30-32 S) for normal E2:E3BP core and 8 S for unassembled 
trimers of E2 produced upon treatment of the core by chaotrophic agents have been 
reported  (Behal et al., 1994). These 8 S species associated non-cooperatively to give 
additional assembly intermediates exhibiting sedimentation coefficients of 10-32 S. In this 
case also, the lower sedimenting species (Fig. 2.30 C) could be trimers of E2, which have 
failed to assemble into a proper core as a result of this mutation.   
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S20,w  
 
                                                                      
Fig. 2.30: Comparison of the sedimentation velocity analyses of wild-type and ∆E35 
E2:E3BP cores 
 
c(s) distribution from SV interference data collected for 3.33 µM (____), 1.07 µM (____) and  
1.00 µM (___) wild-type E2:E3BP core (Fig. A) and maximising c(s) to the peak observed 
at 30.40 S (Fig. B). c(s) distribution from SV interference data collected for 2.06 µM (__   ), 
1.72 µM (___), 1.07 µM (___), 2.60 µM (___), 2.26 µM (___) and 0.50 µM (___) ∆E35 E2:E3BP 
core (Fig. C) and maximising c(s) to the peak observed at 34 S (Fig. D). SDS-PAGE 
analysis of the wild-type and mutant cores used in this SV experiment (Fig. E). 
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4.4.21 Discussion of Glutamate 35 deletion 
 
In this chapter the glutamate 35 deletion in the lipoyl domain of the E2 enzyme of PDC, 
encountered in a clinical case has been analysed in detail employing our model 
recombinant PDC. None of the mutations (∆E35, ∆V455 and P490L), discussed in this 
Chapter have been identified in 50 dihydrolipoamide acetyltransferase (DLAT) alleles 
analysed to date, nor were they found in any DLAT cDNA or genomic sequences in the 
human EST (expressed sequence tag) and genomic DNA databases (Brown et al., 2004). In 
fact, no other mutations have been reported so far in the lipoyl domains of E2 of PDC. This 
may be due to the fact that such mutations might be prevalent, but do not produce a 
significant phenotype leading to failure of detection in the absence of a real necessity to 
diagnose them at genetic level. The non severity of the phenotype could also be 
attributable to functional redundancy owing to the presence of multiple lipoyl domains on 
E2 and E3BP that is also genetically advantageous. As a result the affected person may be 
carrying the mutation leading to slightly decreased PDC activity, but without producing 
any major health problems. In contrast, mutations in the E1α and E3 components produce 
mild to severe, but more detectable phenotypes.  
The glutamate deletion was an interesting mutation in the sense that loss of lipoylation per 
se would not be expected to cause such severe clinical symptoms in the patient. 
Nevertheless it was important to demonstrate that the mutation was indeed the cause of the 
PDC deficiency and also to investigate the molecular basis of disruption of normal 
complex function in this case.  
The precise role of the mutation was studied at three levels- at the lipoyl domain, at the E2 
enzyme and at the PDC level. In all cases, two more mutants were investigated in parallel, 
namely E35D and E35Q, in order to better understand the role of the deleted glutamate 35. 
These mutants enabled us to establish whether a change in charge or size of amino acid 
was the over-riding factor for structural perturbation or the actual presence of the 
glutamate residue was more important. At the lipoyl domain level, it was seen that the 
∆E35 lipoyl domain was non-lipoylated as compared to the wild-type and the other two 
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mutant domains. A monoclonal antibody (PD2) was employed for Western blotting, that 
recognises only the lipoylated components of PDC (Thomson et al., 1998). Lipoylation or 
insertion of lipoic acid on a particular lysine is a very specific phenomenon, occurring only 
if a precise structural cue is present (Wallis and Perham, 1994) and is indicative of the 
presence of correctly folded lipoyl domain. In the the case of glutamate 35 deletion, this 
structural cue appears to have been lost. This result was the first indication that this 
deletion caused a change in the structure of the lipoyl domain. The other two mutant 
domains, however, were still found to be lipoylated (Fig. 4.13) showing that glutamate-35 
is an important and specific residue in this region required for the correct folding of the 
lipoyl domain or the maintenance of its structural stability. This result also confirmed that 
not only the DKA motif at the site of lipoylation is important, but that residues located 
some distance away from the site (12 residues to the N-terminal side in this case) are also 
essential for recognition.  
The relative ease with which GST tags could be cleaved from the ∆E35 lipoyl domain as 
compared to the wild-type and other mutant domains also indicated that the ∆E35 mutant  
provided less steric hindrance to proteolytic attack by thrombin, suggesting that it was not 
properly folded. Major alterations were again observed when this domain was run on a 
non-denaturing gel indicating either a gross change in charge or oligomerisation state (Fig. 
4.14). Striking differences were also observed in intrinsic tryptophan fluorescence 
indicating that ∆E35 lipoyl domain was not folded properly and that its single tryptophan 
was exposed to solvent.  
The aromatic amino acids tryptophan, tyrosine and phenylalanine are all capable of 
contributing to the intrinsic fluorescence of proteins. When all three residues are present in 
a protein, pure emission from tryptophan can be obtained by photoselective excitation at 
wavelengths above 295 nm (Eftink, 1991). Although tyrosine and phenylalanine are 
natural fluorophores, tryptophan is the most extensively used amino acid for fluorescence 
analysis of proteins. In a protein containing all three fluorescent amino acids, observation 
of tyrosine and phenylalanine fluorescence is often complicated by interference from 
tryptophan caused by resonance energy transfer (Eftink, 1991). The application of tyrosine 
and phenylalanine fluorescence is therefore mostly limited to tryptophan-free proteins; 
however, a recent study reports an exception to this (Ruan et al., 2002). More importantly, 
tyrosine fluorescence is insensitive to environmental factors such as polarity (Ross, 1992). 
Fluorescence of phenylalanine is weak and seldom used in protein studies. Hence, the term 
‘natural protein fluorescence’ is almost always associated with tryptophan fluorescence. 
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Tryptophan residues serve as intrinsic, site-specific fluorescent probes for protein structure 
and dynamics. The well documented sensitivity of tryptophan fluorescence to 
environmental factors such as polarity makes it a valuable tool in studies of this type by 
providing specific and sensitive information on protein structure and its interactions 
(Eftink, 1991). As a result of the exposure of a buried tryptophan, the maximum emission 
spectrum shifts 10 to 20 nm to longer wavelengths as compared to the spectra of the same 
protein in which tryptophan is still buried. This phenomenon was seen in the glutamate 
deleted lipoyl domain as well as the mutant E2:E3BP core (Fig. 4.20 & Fig. 4.29). 
However, in the lipoyl domain only a single tryptophan residue accounts for total 
fluorescence emission. In contrast, in the E2:E3BP core, there are 4 tryptophan residues in 
the single polypeptide chains of E2, one in the outer lipoyl domain, one in the extreme N-
terminal region and two in the catalytic domain. Moreover, there are two tryptophans in the 
E3BP polypeptide, one each in the lipoyl domain and C-terminal catalytic domain. All 
these tryptophans contribute to the net fluorescence emission spectrum for the E2:E3BP 
core. Interestingly, in the mutant core the spectral shift to longer wavelength as compared 
to the wild type core, is contributed by a number of tryptophan residues indicating that 
there are major structural changes. The lipoyl domains of A. vinelandii OGDC and B. 
stearothermophilus PDC also have a single tryptophan residue occupying the centre of the 
hydrophobic core consisting of a number of residues (Berg et al., 1996; Dardel et al., 1993) 
and is key to stability of this domain by holding the beta sheets together. 
 Loss of secondary and tertiary structure in the ∆E35 lipoyl domain was visible by far uv 
spectrophotometry, where it appeared as a random coil compared to more structured beta 
sheets in the wild-type and other two mutants. In near uv spectrophotometry, signals 
arising from aromatic amino acids in a rigid environment were also lost in this particular 
mutant as compared to the wild type and other mutants. From all these observations, it was 
evident that ∆E35 lipoyl domain had undergone a major structural change because of this 
single deletion. This change in structure could not be revealed through structural modelling 
based on known lipoy domain structures (Fig. 4.15) indicating the limitations of such 
computer generated structures to mimic structural changes resulting from point mutations.  
It was further observed that the ∆E35 lipoyl domain had a pronounced tendency to form 
dimers and also aggregates of higher order as viewed by gel filtration (Fig. 4.16). Folding 
of newly-synthesized proteins in vivo is believed to be facilitated by the cooperative 
interaction of a defined group of proteins known as molecular chaperones. Proteins in a 
non-native state are normally protected from aggregation by these chaperones. The first 
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events in the formation of proteins are the most critical. Starting at the ribosome, nascent 
polypeptides undergo complex folding processes that can be endangered by aggregation 
reactions. Proteins with organellar destinations such as mitochondria require correct 
targeting to the translocation machineries located in the organellar membranes and 
prevention from premature folding. In the case of mitochondrial precursors, maintenance 
of an ‘unfolded’ state is a prerequisite for permitting efficient translocation. The high 
precision and speed of these processes is ensured by a cystosolic system consisting of 
molecular chaperones, folding catalysts and targeting factors (Bukau et al., 1996). Folding 
and assembly of mitochondrial protein complexes takes place only as they emerge into the 
mitochondrial matrix.  
Misfolded, denatured or damaged proteins present in a non-native state may expose 
‘sticky’ hydrophobic regions or patches that are highly prone to aggregation (Bukau et al., 
1996). Many neurodegenerative diseases are caused by genetic mutations that can lead to 
accumulation of aggregated toxic proteins in neuronal inclusions and plaques (Taylor et al., 
2002). Our data indicate that the ∆E35 domain is misfolded exposing ‘sticky’ hydrophobic 
surfaces leading to formation of aggregates, mostly dimers but also higher order aggregates 
on occasions. Initially in this study, it was thought that the ‘stickiness’ of the lipoyl domain 
led to immobility of the lipoyl ‘swinging arms’ and hence reduction of PDC activity. 
However, subsequent data revealed an 80% reduction in E2 activity.  This E2 assay is not 
dependent on the lipoyl domain or subunit binding domain regions of E2 so this marked 
reduction in E2 activity suggested that this N-terminal mutation was affecting assembly of 
the C-terminal domain, perhaps because of premature and inappropriate interactions of the 
N-termini. This prompted analysis of the core assembly using AUC, revealing that the 
correct core assembly was not forming in the presence of the glutamate mutation. Based on 
these observations a schematic model is proposed (see Chapter 6, Fig. 6.1) indicating how 
this mutation might affect normal trimer formation and/or subsequent steps in E2:E3BP 
core formation.   
 The effect of this mutation on acetyltransferase activity was studied in the E2 enzyme and 
E2:E3BP core. Intrinsic acetyltransferase activities of the ∆E35 enzyme and E2:E3BP core 
were found to be reduced by around 80% or more. The overall activity of reconstituted 
PDC complex with the glutamate mutation was also determined and compared to wild-type 
recombinant PDC using the standard spectrophotometric assay that monitors formation of 
NADH at 340 nm. The activity of mutant PDC was again found to be very low (approx. 
10-15%) as compared to the wild-type.  
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This loss of activity could not be attributed solely due to loss of lipoylation in the outer 
lipoyl domains of the enzyme and in the core. Although lipoylation of PDC is crucial for 
catalysis, the inner lipoyl domains in the E2 enzyme and E3BP lipoyl domains in the core 
were still lipoylated (data not shown). In studies employing E. coli PDC, where only one 
lipoyl domain was functional out of three lipoyl domains in tandem repeat, the activity of 
the complex was comparable to wild-type complex (Allen et al., 1989). Our own data 
(Chapter 3, section 3.14) also showed that the loss of one lipoylatable lysine in the 
complex caused only a 25-35% decline in complex activity. However, the overall complex 
activity due to the ∆E35 mutation was found to extremely low, in the range 10-15% of the 
wild-type control. This drastic decline in enzymatic activity can be explained in terms of 
improper E2:E3BP core formation. The loss of core structure in the event of glutamate 
mutation is evident from tryptophan fluorescence and far uv spectrophotometry. However, 
more rigorous evidence comes from analytical ultracentrifugation, where the sedimentation 
coefficient of the ∆E35 E2:E3BP core is not only lower than the wild-type core, but also 
indicates the presence of several molecular species (Fig. 4.30). The premature aggregation 
of ‘sticky’ lipoyl domains may lead to the formation of mostly abnormal, less compact or 
low molecular weight core with abnormal subunit composition rather than the normal high 
molecular weight 60:12 meric E2:E3BP core. However, in the sedimentation velocity 
experiment, it was also found that a small amount of normal sized core was present that 
could account for the 10-20% residual activity and was in agreement with the patient’s 
PDC activity as determined by CO2 release assay.   
The low activity in the patient’s PDC could also be explained partly by E1 and E3 enzyme 
binding to a large population of inactive cores and therefore be catalytically ineffective. E1 
catalysed reductive acetylation of a lipoyl group depends on the 3D structure of lipoyl 
domain (Dardel et al., 1993). Some isoforms of PDC kinase, particularly isoform 4, appear 
to bind more strongly to the outer lipoyl domain of the mammalian enzyme (Tuganova et 
al., 2002; Yeaman et al., 1978). In this study the structure of outer lipoyl domain has also 
found to be lost (Fig. 4.19 & Fig. 4.20) which might impair the attachment of this kinase in 
vivo leading to further dysregulation of the complex.  
These experimental data showed that glutamate 35 mutation is crucial for the structural 
integrity of the complex and has different consequences from the earlier mutation 
investigated in Chapter 3 in which the single lipoylatable lysine is replaced by glutamine.  
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The two mutants (E35D & E35Q), studied simultaneously were not found to be equivalent 
to the deletion mutant. The aspartate substitution was similar in all respects to the wild-
type in terms of structure and function, whereas very slight structural and functional 
changes were shown by the glutamine mutant. Thus, alterations in the size and charge of 
amino acids at this position have only minor effects on core assembly and function 
whereas the omission of the glutamate-35 indicates its importance for the folding, 
assembly and integrity of the entire E2:E3BP core. These data provide a detailed 
explanation for the unexpected severity of the effect of the glutamate 35 deletion in the 
outer lipoyl domain of E2, accounting for the unusual nature of the PDC deficiency in this 
patient. 
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Chapter 5 
 
  
A preliminary investigation of the subunit 
organisation of the recombinant 2-
oxoglutarate dehydrogenase (OGDC) 
  
5.1 Introduction  
 
The 2-oxoglutarate dehydrogenase (OGDC), along with the pyruvate dehydrogenase 
(PDC) and branched chain 2-oxoacid dehydrogenase complex (BCOADC), collectively 
constitute the family of 2-oxoacid dehydrogenase multi-enzyme complexes. They are 
important in controlling carbon flux from carbohydrate precursors and a select group of 
amino acids into and around the tricarboxylic acid cycle. Located in the mitochondrial 
matrix, the mammalian complexes catalyze the irreversible oxidative decarboxylation of 
their respective 2-oxoacid substrates yielding the appropriate acyl CoA derivatives, NADH 
and CO2. Central to this catalysis is the consecutive action of their three catalytic 
components, each present in multiple copies : a substrate-specific 2-oxoacid dehydrogenase 
Chapter 5  
 
166 
166 
(E1), a distinct dihydrolipoamide acyltransferase (E2) and a common dihydrolipoamide 
dehydrogenase (E3) (Behal et al., 1993; Patel and Harris, 1995).  
The OGDC appears to be much more conserved in evolution than the PDC; both E. coli 
and pig heart complexes exhibit similar quaternary structures (Koike and Koike, 1982; 
Tanaka et al., 1972; Yeaman et al., 1978), and unlike eukaryotic PDC or BCOADC, 
mammalian OGDC is not regulated by phosphorylation and dephosphorylation (Koike and 
Koike, 1982).  
OGDC is an important mitochondrial multienzyme complex that has been increasingly 
associated with a number of neurological disorders. It catalyzes a critical step in the Krebs 
cycle that is also important in the metabolism of the excitotoxic neurotransmitter, 
glutamate. In human brain, the activity of OGDC is lower than that of any other enzyme of 
energy metabolism, including phosphofructokinase, aconitase and the electron transport 
complexes (Sheu and Blass, 1999). Thus deficiencies of OGDC are likely to impair brain 
energy metabolism and therefore brain function, leading to the manifestation of 
neurological symptoms. The severity of the neurological symptoms varies according to the 
nature of the deficiency. Several disorders implicating OGDC defects have been 
recognized including infantile lactic acidosis, psychomotor retardation in childhood, 
intermittent neuropsychiatric disease with ataxia and other motor manifestations, 
Friedreich's and other spinocerebellar ataxias, Parkinson's disease and Alzheimer's disease 
(AD) (Butterworth and Besnard, 1990; Gibson et al., 1988; Mastrogiacomo et al., 1996; 
Terwel et al., 1998).  
The persistence of abnormalities in the OGDC and particularly in its E2o component in 
familial AD fibroblasts indicates that abnormalities of this complex are an intrinsic part of 
the AD process (Sheu and Blass, 1999). OGDC is not uniformly distributed in human 
brain, and the neurons that appear selectively vulnerable in human temporal cortex in AD 
are enriched in OGDC. A statistically significant negative correlation was observed 
between OGDC activity and neurofibrillary tangle count in AD parietal cortex 
(Mastrogiacomo et al., 1993). However, reduced levels of OGDC are a feature of some, 
but not all patients with AD (Kish, 1997). Reproducible reductions occur in the PDC, 
OGDC and cytochrome oxidase activities in AD brain and evidence suggests that OGDC 
deficiencies may be genetic in some cases whereas evidence that the other two enzyme 
systems have a genetic component is lacking (Gibson et al., 1998). 
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 In recent studies, OGDC has been found to be a primary site of ROS production in 
normally functioning mitochondria (Starkov et al., 2004). This complex is also one of 
several major autoantigens in primary biliary cirrhosis. Loss of OGDC activity is observed 
in thiamine deficiency and it was recently demonstrated that the response of brain OGDC 
activity, mRNA levels and immunoreactivity of its E1o, E2o and E3 components to 
thiamine deficiency is region and time dependent. Loss of OGDC activity in brain cortex is 
probably related to post-translational modification rather than a loss of protein whereas, in 
the sub-medial thalamic nucleus, transcriptional and post-translational modifications may 
account for diminished activity (Shi et al., 2007).  
Less information is available on the subunit organization and the mode of interaction of 
constituent enzymes of OGDC as compared to PDC and BCOADC. The constituent 
enzymes of OGDC are assembled in a tight but non-covalent fashion around a 24-meric 
E2o core, exhibiting octahedral symmetry. In prokaryotes, in combination with its catalytic 
role, the oligomeric E2o core is responsible for tethering and orientating both the E1o and 
E3 enzymes within the complexes via compact, peripheral subunit-binding domains 
(Mande et al., 1996; Mattevi et al., 1992; Yeaman et al., 1978). However, analysis of rat 
and human E2-OGDC genes revealed the absence of any E1- or E3-binding motifs, 
although such sequences were readily located in the E2-OGDC genes from other 
organisms, notably E. coli (Spencer et al., 1984) and Azotobacter vinelandii (Westphal and 
de Kok, 1990). 
Studies on mammalian OGDC, employing subunit-specific proteolysis and N-terminal 
sequence analysis, have identified a proteolytically-sensitive region at the extreme N-
terminus of the E1o component with significant sequence similarity to the E3BP and E2 
components of mammalian PDC (Rice et al., 1992). These similarities suggested that E1o 
might perform some functions normally devolved to E2 or E3BP in PDC and E2-
BCOADC.  
Selective limited tryptic or arg C degradation of OGDC resulted in a single cleavage in 
E1o, producing an N-terminal fragment (approx. Mr 10,000), abolition of E3 binding and 
dissociation of an active E1'o species (Mr 100,000). Complete disassembly of OGDC 
following this proteolytic event indicated that this region of E1o was critical for the 
maintenance of complex stability and integrity. A putative peripheral subunit-binding 
domain has been identified at the site of tryptic attack (Rice et al., 1992). To further 
characterise the N-terminal E1o fragment and to map the precise residues involved in 
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maintaining critical contact with E2o and E3, N-terminal fragments of human E1o have 
been cloned, overexpressed and purified and their binding potential tested in this Chapter 
in order to obtain a better understanding the subunit organisation of this complex. These 
studies should provide a more comprehensive insight into OGDC subunit interactions 
contributing to overall complex integrity and enable preliminary mapping of regions of 
E1o/E3 involved in generation of a stable association with the E2o core. A clear 
understanding of its overall structural organisation is essential in view of mounting 
evidence for a role for OGDC in a range of neurodegenerative disorders and its 
involvement in oxidative stress responses. Moreover, this study should provide initial data 
on the feasibility of producing a recombinant OGDC model (equivalent to our PDC model) 
that can be employed for studying its role(s) in disease in future.  
 
5.2 Cloning of full length E1o 
Two putative cDNA clones for human E1o were obtained from GeneService, Cambridge. 
Primers (Materials & Methods section 2.1.4) were designed to amplify the cDNA and to 
introduce Nde 1 and Xho 1 sites at the 5’ and 3’ termini of the amplicon. For PCR, after 
initial denaturation at 94 °C for 5 min, reactions were cycled 30 times through 94 °C (30 
s), 62 °C (30 s) and 72 °C (40 s) with a final incubation at 72 °C for 5 min. PCR products 
were resolved on a 1% (w/v) agarose gel and were found to be amplified in 6 individual 
PCRs from one clone, each yielding a major band of 3 kbp consistent with the predicted 
size for E1o cDNA (Fig. 5.1 A). Successful amplification confirmed that this plasmid 
contained a full length copy of the gene. Amplified PCR product was extracted as 
described in Methods section 2.2.3 and a sample of pET-14b vector was prepared by 
digestion with Nde1 and Xho1 restriction enzymes. Digested vector was also run on an 
agarose gel and gel extracted. Then, 100 ng of vector was mixed with a 3-fold molar 
excess of insert. For ligation, a Quick Ligation Kit from New England Biolabs was used. 
Ligation mix (5 ng) was transformed into competent E. coli TOP 10 cells and the bacteria 
plated onto LB-amp agarose plates. After overnight incubation at 37 °C, clones were 
screened by colony PCR for the presence of insert. In colony PCR, around 5-6 colonies 
were picked, individually suspended in 7 µl of sterilized distilled water and streaked onto a 
master plate for future use. Individual bacterial suspensions were heated at 95 °C for 5 
min, chilled on ice and centrifuged to collect 4 µl of supernatant as a crude DNA template 
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for PCR. Diagnostic colony PCR was carried out with primers as described earlier. Only 
two clones were found to be positive. Positive clones were further screened by restriction 
digestion analysis (Fig. 5.1 B) and the correct reading frame and E1o sequence again 
confirmed by DNA sequencing.  
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Figure 5.1: Cloning of the E1o cDNA 
 
(A) PCR amplification of the E1o cDNA (lanes 2-7) with Nde1 and Xho1. 10 kb ladder in 
lane 1. (B) Restriction digestion of the two putative E1o clones using Nde1 and Xho1 
releasing pET-14b vector and E1o cDNA insert of the predicted size (lanes 1 & 2). 10 kb 
ladder in lane 3. 
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5.3 Overexpression of E1o 
E1o plasmids were transformed into competent E. coli BL21 (DE3) cells to enable E1o 
expression as His-tagged protein. Overexpression was attempted at 18 °C as well as 30 °C 
with 1 mM IPTG. No expression was detected on SDS-PAGE analysis as well on Western 
blotting with anti-His tag antibody (data not shown). 
Microbial proteins are relatively easy to express in the E. coli host system. Many 
mammalian proteins have also been overexpressed successfully although these can be 
more difficult to obtain in active, folded form. E. coli is the quickest and most economical 
expression host of choice, being easy to scale to large volumes and suitable for generation 
of labelled proteins. However, not all large proteins can be successfully overexpressed in 
E. coli. Moreover, it is often not feasible to perform post-translational modifications that 
are required for function. E1o is a homodimer of two 100 kDa subunits and, in this case, it 
proved impossible to achieve detectable expression of this enzyme in the time available. 
To date, there are no reports in the literature on successful expression of recombinant 
mammalian E1o. In fact, the native enzyme is also extremely labile and difficult to study 
because of its tight association with E2o.  
 
5.4 Subcloning of E2o 
 
An E2o construct in pET-14b was already available in the laboratory. As the vector is 
ampicillin resistant, it is not suitable for carrying out co-expression with other ampicillin 
resistant vectors. Therefore, E2o cDNA was subcloned from pET-14b into pET-28b, 
thereby conferring kanamycin resistance as well as incorporating a N-terminal His-tag. 
Minipreps of E2o pET-14b were prepared and digested with Xho1 (Fig. 5.2 A). The 
digested E2o DNA was gel extracted by the standard protocol (Methods section 2.2.3). 
Minipreps of pET-28b vector were also made and cut with Xho1 in a suitable buffer. The 
linearised DNA was treated with 2.5U of calf alkaline phosphatase for 60 min. Alkaline 
phosphatase removes 5´ phosphates from the DNA and prevents re-circularization of cloning 
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vectors. The treated DNA was run on a 1% (w/v) agarose gel and was gel extracted using 
the Promega kit as per manufacturer’s instructions. The gel extracted E2o and pET-28b 
DNAs were ligated as described in Methods section 2.2.5. The ligation mixture was 
transformed into E. coli DH5α cells. A control transformation was also carried out in the 
absence of ligation mixture. Colonies appeared on the test plate and none in the control. 
Single colonies were picked, grown overnight in LB medium and minipreps were prepared. 
The plasmids, thus prepared, were cut with Xho1 and the digested DNA mixture was run 
on a 1% (w/v) agarose gel. The expected size of DNA insert was released indicating 
successful subcloning (Fig. 5.2 B). The correct orientation of the DNA, subcloned in pET- 
28b vector was checked by overexpression of E2o and subsequent SDS-PAGE analysis 
(Fig. 5.2 C).   
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Figure 5.2: Subcloning of the E2o 
 
(A) E2o was released from the pET-14b vector by digestion with Xho1 (lanes 1, 2 & 3). 
pET-28b vector was linearised by digesting with Xho1 (lanes 5 & 6). 10 kb ladder in lane 
4. (B) Restriction digestion of six E2o clones of pET-28b with Xho1 (lanes 1-6). 10 kb 
ladder in lane 7. (C) Orientation of the  E2o cDNA was checked by overexpressing in E. 
coli BL21 (DE3) cells at 30 ºC for 4-5 h. SDS-PAGE analysis shows overexpression at 
zero time (T0) and 5 h after induction (T5). T0 for the last overexpression is not shown here. 
Four clones out of five tested were found to be overexpressing (lanes 5, 7, 9 & 10). 
Molecular weight markers (Mw) are in lane 1. 
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5.5 To investigate a possible interaction between the E2o 
and E3 enzymes of OGDC 
 
To check for any potential interaction between the E2o and E3 enzymes of OGDC, both 
enzymes were overexpressed individually at 30 ºC for 4-5 h. As both enzymes were His-
tagged, each was purified using zinc chelate chromatography. Purified enzymes were 
dialysed against 150 mM NaCl, 50 mM potassium phosphate, pH 7.5. The two enzymes 
were mixed and passed through a HiPrep 16/60 Sephacryl S-300 High Resolution column 
attached to a BioCAD 700E workstation equilibrated with 50mM potassium phosphate, 
150 mM NaCl, pH 7.5. Two separate peaks of eluted protein were observed. On SDS-
PAGE analysis of the individual peaks, it was found that the first peak eluting at the void 
volume contained only E2o whereas the second peak consisted solely of homodimeric E3 
that eluted at the expected position for a 100,000 Mr species (Fig. 5.3). Thus no stable 
association between E2o and E3 could be detected under these conditions. 
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Figure 5.3: Post–translational mixing of E2o and E3 followed by gel filtration  
 
(A) E3 and E2o were overexpressed individually and purified by zinc chelate 
chromatography as described in Methods section 2.3.6. Purified fractions of each were 
mixed post–translationally and gel filtered through a Sephacryl HiPrep S-300 High 
Resolution column attached to a BioCAD 700E workstation. Two eluted peaks were 
observed, one at the void volume and another where the E3 homodimer elutes routinely. 
(B) SDS-PAGE analysis of the two peaks showed E2o (lane 1) eluting at the void volume 
and E3 (lane 2) in the later peak. Molecular weight markers (Mw) are in lane 3.   
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5.6 Overexpression and solubility check of His-tagged N 
and C-terminal truncates of E1o 
 
Constructs of the N-terminal (first 579 bases) and C-terminal (next 2313 bases) region of 
E1o in pET-14b vector were available in the laboratory. The fidelity of the constructs was 
re-checked by DNA sequencing prior to transforming individually into E. coli BL21 (DE3) 
cells. Overexpression was induced at 18 °C overnight with 1 mM IPTG when cultures 
attained an A600 of 0.5. On SDS-PAGE analysis, it was found that the N-terminal fragment 
was overexpressed whereas the C-terminal fragment failed to overexpress (Fig. 5.4 A & B) 
and could not be detected on Western blotting with an anti-His tag antibody (data not 
shown). Again, possibly owing to its large size, the E. coli expression system did not prove 
suitable for overexpression as was the case for full length E1o. A solubility check of the 
overexpressed N-terminal fragment was performed as described in the Methods section 
2.3.3. and the fragment was found to be insoluble (Fig. 5.4 A).  
 
5.7 Co-expression and interaction study on the His-
tagged N-terminal fragment of E1o and E2o 
 
His-tagged N-terminal E1o (comprising the first 193 amino acids) and His-tagged E2o 
were co-transformed into E. coli BL21 (DE3) cells and overexpressed at 22 °C. Co-
transformation was possible because the E2o construct was housed in pET-28b, a 
kanamycin resistant vector whereas the other construct was located in the ampicillin 
resistant plasmid pET-14b. The identities of co-expressed and His-tagged E2o and N-
terminal E1o present in cell extracts were confirmed by Western blotting using anti-His tag 
antibody (Fig. 5.5 B). This blot also showed that N-terminal E1o overexpression was low 
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when co-expressed with E2o compared to the levels achieved when overexpressed on its 
own. 
The solubility of the co-expressed proteins was analysed by the standard protocol 
(Methods section 2.3.3) and resolved by SDS-PAGE. Notably, it was seen that N-terminal 
E1o fragment that was completely insoluble when expressed alone (Fig. 5.4), now became 
partially soluble when co-expressed with E2o as shown by SDS-PAGE (Fig. 5.5 A).  
This indicated the possibility that the N-terminal E1o truncate may be co-integrated with 
E2o in a similar fashion to the way in which E3BP is integrated with E2 in PDC. Both the 
N-termini of E1o as well as E2o were His-tagged and therefore, could be purified on zinc 
chelate chromatography. However, its stable integration could be observed on gel filtration 
when the putative purified complex appeared as a single peak at the void volume on a 
HiPrep 16/60 Sephacryl S-300 High Resolution column and both the proteins could 
apparently be visualised by SDS-PAGE (Figs. 5.6, A & B). Owing to lack of availability of 
a suitable E1o antibody for confirming the identity of the putative E1o fragment co-eluting 
with E2o at the void volume, the binding between the two could not be determined 
unequivocally as the possibility remained that this band could represent a truncated, His-
tagged N-terminal product of E2o. Therefore, this apparent direct interaction was further 
examined by preparing two glutathione-S-transferase (GST) constructs of N-terminal E1o 
followed by their co-expression with E2o and purification (see sections 5.10 and 5.13) 
using ‘pull down’ assays. 
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Figure 5.4: Overexpression of the His-tagged N-terminal fragment and C-terminal 
region of E1o 
 
(A) The N-terminal fragment of E1o was overexpressed at 18 ºC overnight in E. coli BL21 
(DE3) cells. SDS-PAGE analysis shows expression at zero time (T0) (lane 2) and 15 h after 
induction (T15) (lane 3). Solubility checking showed that it was mostly insoluble and 
present in the pellet sample (PS) (lane 5). Supernatant sample (SS) is in lane 4. Molecular 
weight markers (Mw) are in lane 1. (B) The C-terminal region of E1o was overexpressed at 
18 ºC overnight. SDS-PAGE analysis shows no detectable overexpression of protein 
corresponding to an anticipated 86 kDa species, 15 h after induction (T15) (lane 3). 
Molecular weight markers (Mw) are in lane 1. 
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Figure 5.5: Detection of co-expression of N-terminal E1o fragment and E2o 
 
(A) E2o and the N-terminal E1o fragment were co-expressed at 22 ºC overnight. SDS-
PAGE analysis on a 4-12% Bis-Tris shows expression at zero time (T0) and 15 h after 
induction (T15). Solubility checking showed that both E2o as well as a band corresponding 
to the expected size of the E1o fragment were soluble and present in the supernatant 
sample (SS) (lane 2). Pellet sample (PS) in lane 1. Molecular markers are in lane 5. (B) 
Since the levels of expression were poor, the identities of His-tagged E2o & N-terminal 
E1o fragment were confirmed by Western blotting with anti-His tag antibody. Blotting 
analysis shows overexpressed N-terminal E1o (lane 1) as a positive control and co-
expressed E2o and N-terminal E1o (lane 2).   
E2O 
 
 
E1O (N-terminal 
fragment)   
PS  SS    T15 T0    Mw          
  1     2   3     4     5           
 kDa 
 
 
97.0 
 
66.0 
 
45.0 
33.0 
 
20.1 
 
14.4 
E2o 
N-terminal 
E1o 
N-terminal 
E1o 
 
                     1                       2 
 B 
A 
kDa 
 
97.0 
 
66.0 
 
45.0 
 
 
33.0 
 
20.1 
 
14.4 
Chapter 5  
 
180 
180 
.  
 
 
 
 
 
                                                
 Figure 5.6: Gel filtration of co-expressed and purified E2o and N-terminal E1o  
 
(A) E2o and N-terminal E1o were co-expressed and purified by zinc chelate 
chromatography. Purified fractions were pooled and gel filtered through a Sephacryl 
HiPrep S-300 High Resolution column attached to a BioCAD 700E workstation. (B) On 
SDS-PAGE analysis of the single peak eluting at the void volume, E2o as well as a 
putative E1o fragment were visualised indicating the possible formation of a high Mr 
complex between the two species (lane 2). Molecular weight markers (Mw) are in lane 1. 
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5.8 Subcloning cDNA encoding an N-terminal E1o 
fragment (166 amino acids) into pGEX-2T  
 
The E1o cDNA sequence encoding the first 166 amino acids of mature E1o was subcloned 
into pGEX-2T using the previous N-terminal construct housed in pET-14b as a template. 
This step was carried out in order to facilitate protein-protein interaction studies using ‘pull 
down’ assays with a GST-fused E1o fragment and His-tagged E2o. It was also considered 
that expression of the E1o fragment as a GST fusion may aid solubility when expressed in 
the absence of E2o, thereby enabling investigations on whether any potential binding to 
E2o occurred in a co- or post-translational fashion.   
For cloning, the first 498 nucleotides were amplified by PCR and BamH1 and EcoR1 sites 
were created at the 5’ and 3’ termini of the amplicon by designing and employing suitable 
primers (Materials & Methods section 2.1.4). For PCR, after initial denaturation at 94 °C 
for 5 min, reactions were cycled 30 times through 94 °C (30 s), 56 °C (30 s) and 72 °C (40 
s) with a final incubation at 72 °C for 5 min. PCR products were resolved on a 1% (w/v) 
agarose gel and were found to be amplified as expected. Amplified PCR product was 
extracted using a gel extraction kit as described in Methods section 2.2.3. A sample of 
pGEX-2T vector was prepared by digestion with BamH1 and EcoR1 then run on a 1% 
(w/v) agarose gel and extracted. Digested vector (100 ng) was mixed with a 3-fold molar 
excess of insert for ligation using the Quick Ligation Kit from New England Biolabs. 
Ligation mix (5 ng) was transformed into competent E. coli TOP 10 cells and the bacteria 
plated onto LB-amp agarose plates containing ampicillin. After overnight incubation at 37 
°C, colonies appearing on the plate were picked and plasmids prepared. Plasmids were 
screened by restriction digestion with BamH1 and EcoR1 (Fig. 5.7). Positive clones were 
further checked by sequencing.  
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5.9 Overexpression and purification of the N-terminal E1o 
GST fusion protein (first 166 amino acids) 
 
The pGEX-2T construct containing N-terminal E1o cDNA (corresponding to the first 166 
amino acids) was transformed into E. coli BL21 (DE3) cells. Overexpression was carried 
out at 30 °C for 4-5 h after induction with 1 mM IPTG. Expression was analysed by SDS-
PAGE (Fig. 5.8).  
Frozen pellet from an overexpressed culture (500 ml) was disrupted by French press 
treatment as described in Methods section 2.3.2 and the soluble supernatant fraction 
containing GST-fusion protein purified by glutathione Sepharose 4B chromatography 
(Methods section 2.3.13). Two protease inhibitor tablets (EDTA free) were added before 
French press treatment. 
SDS-PAGE analysis of the purified fractions showed extensive degradation of the GST- 
tagged E1o fragment. However, some intact fusion protein (predicted size 45 kDa; 18 kDa 
E1o fragment coupled to the 27 kDa subunit of GST) could be isolated. Lower Mr 
degradation products of this fusion protein and a band corresponding to the GST protein 
(27 kDa) were also observed (Fig. 5.8). Neither addition of 1 mM EDTA and DTT nor 
expressing at lower temperatures in subsequent experiments helped to limit this 
degradation.  
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Figure 5.7: Cloning of the N-terminal E1o fragment (corresponding to first 166 amino 
acids) into pGEX-2T  
 
PCR product corresponding to the N-terminal E1o region (first 166 amino acids) was 
cloned into pGEX-2T. Diagnostic restriction digestion of putative clones was performed 
with BamH1 and EcoR1. One clone was positive out of four tested (lane 3) releasing 
correct-sized insert and vector. Clones in lanes 2 and 4 were discarded as the vector size 
was incorrect although they appeared to contain appropriate inserts. 10 kb ladder in lane 5.   
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Figure 5.8: Overexpression and purification of the E1o fragment (first 166 amino 
acids) fused with GST 
 
(A) N-terminal E1o fragment (166 amino acid) fused with GST was overexpressed at 30 
ºC for 4-5 h. SDS-PAGE analysis on a 4-12% Bis-Tris shows expression at zero time (T0) 
and after 5 h induction (T5). The protein was purified using a glutathione Sepharose 4B 
column (lane 1) and shows extensive degradation. Molecular weight markers (Mw) are in 
lane 4.  
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5.10 Interaction between E2o and the GST fused E1o N-
terminal fragment (first 166 amino acids) 
 
The pGEX-2T construct containing the 5’ region of the open reading frame of mature E1o- 
cDNA (166 amino acids) and E2o cDNA in pET-28b were co-transformed into E. coli 
BL21 (DE3) cells. Overexpression was attempted at 30 °C for 4-5 h after induction with 1 
mM IPTG. Protein expression was analysed by SDS-PAGE (Fig. 5.9). Pellet (500 ml 
culture) was disrupted using French press treatment as described in Methods section 2.3.2 
and the soluble supernatant fraction containing GST fusion protein purified by glutathione 
Sepharose 4B affinity chromatography as described in the Methods section 2.3.13. Two 
tablets of protease inhibitors (EDTA free) were added before French press treatment. 
SDS-PAGE analysis of the purified fractions showed the presence of a band of the 
predicted size for E2o and therefore a possible integration of E2o with the E1o fragment 
(Fig. 5.9). In the previous experiment also (section 5.7), the N-terminal E1o fragment was 
found to be integrating with E2o. No Western blotting was attempted at this point in order 
to verify the identities of the constituent polypeptides because of extensive degradation of 
the purified proteins.  
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 Figure 5.9: Co-expression and purification of the E2o and N terminal E1o GST 
fusion protein (first 166 amino acids) 
 
SDS-PAGE analysis shows co-expression of E2o and N terminal E1o GST fusion protein 
at zero time (T0) and 5 h (T5) after induction. Soluble fraction obtained from an 
overexpressed culture (500 ml) after French Press treatment was purified using a 
glutathione Sepharose 4B column (lane 4) indicating possible E2o co-association with the 
E1o fragment. Molecular weight markers (Mw) are in lane 1.  
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5.11 Subcloning cDNA encoding an N-terminal E1o 
fragment (83 amino acids) into pGEX-2T   
The previous experiment (see section 5.10), again suggested a possible integration of E2o 
with the N-terminal E1o GST fusion protein. However, substantial degradation of the E1o 
fragment was also observed in several attempts to repeat this study, making it difficult to 
draw any definitive conclusions. To determine more precisely the putative E2o binding site 
on E1o and to possibly limit degradation, the first 83 amino acids of mature E1o 
corresponding to the first 249 nucleotides of mature E1o were subcloned into pGEX-2T.  
For this investigation, the first 249 nucleotides were amplified and BamH1 and EcoR1 sites 
created at the 5’ and 3’ termini of the amplicon by designing and employing the primers as 
described in Materials & Methods section 2.1.4. For PCR, after initial denaturation at 94 
°C for 5 min, reactions were cycled 30 times through 94 °C (30 s), 58 °C (30 s) and 72 °C 
(40 s) with a final incubation at 72 °C for 5 min. PCR products were resolved on a 1% 
(w/v) agarose gel and were found to be amplified. Amplified PCR products were extracted 
using a gel extraction kit as described in Methods section 2.2.3. pGEX-2T vector was 
prepared by digestion with BamH1 and EcoR1 restriction enzymes and digested vector  
also run on an agarose gel and gel extracted. Then, 100 ng vector was mixed with 3-fold 
molar excess of insert for ligation employing a Quick Ligation Kit from New England 
Biolabs. Ligation mix (5 ng) was transformed into competent E. coli TOP 10 cells and the 
bacteria were plated onto LB agarose containing ampicillin. After overnight incubation at 
37 °C, clones were prepared and screened by restriction digestion with BamH1 and EcoR1 
for the presence of the correct-sized insert (Fig. 5.10). Positive clones were further checked 
by DNA sequencing.    
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Figure 5.10: Cloning of the E1o cDNA fragment encoding its N-terminal sequence (83 
amino acids) into pGEX-2T  
 
PCR product encoding the N-terminal E1o fragment was cloned into pGEX-2T. Restriction 
digestion of putative recombinant clones treated with BamH1 and EcoR1 is shown. One 
clone was positive, out of three tested (lanes 2-4), containing an insert of the right size 
(lane 3).                                   
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5.12 Overexpression and purification of the N-terminal 
E1o GST fusion protein (first 83 amino acids) 
 
The N-terminal E1o GST fusion protein (containing the first 83 amino acids) was 
overexpressed and purified in the same manner as the 166 amino acid E1o-GST fusion 
protein described in section 5.9. On SDS-PAGE analysis, this fragment was also found to 
be sensitive to degradation although this was less problematic than for the larger N-
terminal truncate (Fig. 5.11). However, significant amounts of intact fusion protein of the 
predicted size (36 kDa) were present (9 kDa E1o fragment fused with the 27 kDa GST). 
Free GST (27 kDa) was also observed (Fig. 5.11). The proteolytical degradation did not 
appear to occur during overexpression in vivo, but was apparent after French press 
treatment or at the end of the purification process. Addition of 1% (v/v) rat serum reduced 
but did not completely eliminate this degradation. Further addition of more protease 
inhibitors (2 mM PMSF, 0.15 µM leupeptin, 15 µM aprotinin, 1.5 µM pepstatin) and also 
ensuring that the purification process was conducted rapidly and efficiently at 4 °C still did 
not prevent significant degradation.  
 
5.13 Interaction between E2o and N-terminal E1o GST 
fusion protein (first 83 amino acids) 
 
N-terminal E1o cDNA (corresponding to first 83 amino acids) in pGEX-2T and E2o 
cDNA in pET-28b were co-transformed into E. coli BL21 (DE3) cells. Overexpression was 
carried out at 30 °C for 4-5 h after induction with 1 mM IPTG. The expression was 
analysed by SDS-PAGE. Pellet from overexpressed culture (500 ml) was disrupted by 
French press treatment as described in Methods section 2.3.2 and the soluble supernatant 
fraction purified by glutathione Sepharose 4B chromatography (Methods section 2.3.13). 
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Two tablets of protease inhibitors (EDTA free) and 1% (v/v) rat serum were added before 
French press treatment.  
SDS-PAGE analysis of the purified fractions showed the presence of E2o along with E1o 
GST fusion protein (Fig 5.11). The presence of E2o was further confirmed using an anti-
His tag antibody to detect His-tagged E2o (Fig. 5.12 A). 
To ensure that E2o was interacting specifically with the E1o fragment and not with free 
GST, E2o was also co-expressed with free GST in BL21 (DE3) cells at 30 °C for 4-5 h 
after induction with 1 mM IPTG. The supernatant fraction from a disrupted pellet (500ml  
culture) was purified by glutathione Sepharose 4B chromatography. On Western blotting 
of the purified fraction with anti-His tag antibody, His-tagged E2o could not be detected 
(Fig. 5.12 B) indicating that E2o was not binding adventitiously to the GST tag. These 
results demonstrated conclusively for the first time that the first 83 amino acids of N-
terminal E1o were crucial for integrating with E2o. 
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Figure 5.11: Purification of N-terminal E1o GST fusion protein (first 83 amino acids) 
alone and when co-expressed with E2o  
 
E1o fragment (first 83 amino acids) fused with GST was overexpressed alone and with 
His-tagged E2o at 30 ºC for 4-5 h in two individual experiments. Soluble fractions 
obtained from both overexpressed cultures (500 ml) after French Press treatment were 
purified separately using glutathione Sepharose 4B chromatography. SDS-PAGE analysis 
of purified fractions on a 4-12% Bis-Tris SDS gel shows the N-terminal E1o GST fusion 
protein (83 amino acids) (lane 2) and E2o integrated with N-terminal E1o GST fusion 
protein (lane 3). Molecular weight markers (Mw) are in lane 1. 
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Figure 5.12: Confirming the interaction of E2o with its N-terminal E1o partner  
 
(A1) N-terminal E1o GST fusion protein (83 amino acids) and His-tagged E2o were co-
expressed. SDS-PAGE analysis of the fractions purified using glutathione Sepharose 4B 
chromatography (lane 3) and E2o purified by zinc chelate chromatography as a positive 
control (lane 2). (A2) Western blotting of the above with anti-His tag antibody shows that 
E2o was integrated with E1o GST-fusion protein (lane 3). E2o as positive control is in lane 
2. (B1) SDS-PAGE analysis of co-expressed E2o and GST purified on glutathione 
Sepharose 4B (lane 3), E2o as positive control in lane 4 and GST as negative control is in 
lane 2. Molecular weight markers are in lane 1. (B2) Western blotting of the above with 
anti-His tag antibody shows that E2o was absent (lane 3) and therefore does not bind non-
specifically with the GST tag.  
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5.14 Discussion of subunit organisation in the OGDC 
 
The structure and subunit organization of mammalian OGDC has not been analysed in 
depth as compared to other organisms although its E2o core is similarly organised as a 24-
meric cube with octahedral (432) symmetry (Reed and Hackert, 1990). In contrast, the 
structure and catalytic mechanism of the bacterial E2o core, to which the E1o and E3 
components are tethered non-covalently, has been elucidated in some detail (Hackert et al., 
1983). In mammalian OGDC, an early report also suggested that E1o appears to bind more 
tightly to E2o than does E3 (Yeaman et al., 1978).  
Studies on mammalian OGDC, employing subunit-specific proteolysis and N-terminal 
sequence analysis, have identified a proteolytically sensitive site in the N-terminal region 
of E1o that, on cleavage, leads to rapid inactivation of the complex and dissociation of 
both a large, enzymatically-active, C-terminal E1’o fragment and E3. This region also 
displays significant sequence similarity to the E3BP and E2 components of mammalian 
PDC (Rice et al., 1992). These similarities suggested that E1-OGDC may perform some 
functions normally devolved to E2:E3BP in PDC and E2 in BCOADC. Further indirect 
evidence, in support of additional roles for E1o, came when the genes for rat and human 
E2o were cloned (Nakano et al., 1991; Nakano et al., 1994). Analysis of their predicted 
primary structures failed to locate any E1o or E3-binding motifs, although such sequences 
were readily located in E2-OGDC genes from other organisms, notably Escherichia coli 
(Spencer et al., 1984) and Azotobacter vinelandii (Westphal and de Kok, 1990). Another 
report suggested that single copies of full length bovine E1o and E3 form a stable 1:1 
complex that binds to the E2o core with high affinity via the N-terminal region of E1o 
(McCartney et al., 1998).  
In mammalian OGDC, the E1o enzyme also has high affinity for the E2o core assembly, a 
property it shares with the E3BP of PDC (Sanderson et al., 1996a). This affinity is so great 
that attempts to use low (non-denaturing) levels of GdmCl to dissociate E1o from the intact 
core also proved futile. The successful dissociation of mammalian OGDC into active E2o 
and E1o/E3 fractions was achieved by employing high levels of MgCl2 and slightly 
alkaline pH to achieve optimal dissociation with minimal denaturation of the individual 
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enzymes, yielding functionally active E2o and E1o/E3 fractions (McCartney et al., 1998). 
These studies provided the first direct biochemical evidence that uniquely, in mammalian 
OGDC, its constituent E1o enzyme is responsible for binding the E3 component to the core 
of this multienzyme complex.  
As indicated previously, selective proteolysis of bovine OGDC with protease arg C has 
shown that, with a single cleavage, a 100 kDa E1’o C-terminal fragment and E3 are 
released from E2o (Rice et al., 1992). The cleavage site of E1’o in bovine OGDC is shown 
in Fig. 5.13 and this amino acid sequence shows great similarity with the human E1o. 
However, as the precise arg C cleavage site in bovine E1o is not conserved in human E1o, 
it is not known whether human E1o can be selectively cleaved in a similar fashion. 
Interestingly, there is no direct evidence to show that E3 interacts with E1’o with high 
affinity (Rice et al., 1992). In previous studies, on gel permeation of an isolated, full-length 
E1o/E3 fraction under associative conditions, the presence of a higher Mr assembly 
(303,000 kDa) corresponding to an E1:E3 sub-complex exhibiting 1:1 stoichiometry was 
detected. Moreover, it was observed that limited proteolysis of OGDC promotes release of 
both a large C-terminal E1’o fragment and E3, implying that sequences critical for their 
tight interaction with the E2o core reside in the N-terminal region (McCartney et al., 1998). 
It was not clear, however, from these two previous publications whether E3 was released 
directly as a consequence of its binding to E1o or whether E3 association with the core is 
also dependent on the integrity of the extreme N-terminal region of E1o. A potential 
interaction between E1’o and E3 could not be evaluated in this study owing to the non-
availability of recombinant E1’o.  
In this chapter, the main aim was to map the region of E1o that was involved in 
maintaining high affinity contact with E2o. For this, full length E1o was cloned in pET-
14b. Nucleotide sequence corresponding to the first 193, 166 and 83 amino acids of mature 
E1o were also cloned in pET-14b and pGEX-2T respectively. For studying the co-
expression of E1o with E2o, E2o cDNA was subcloned into a kanamycin resistant vector, 
namely pET-28b. All the cloning strategies employed were successful; however, no 
detectable expression of full length E1o was achieved in E. coli. Difficulties in 
overexpressing and producing soluble E1-PDC were also observed in the past, but finally 
solved by cloning into pQE-9, and overexpressing in E. coli M15 cells although only 
limited amounts of active E1 were produced. The available His-tagged, N-terminal E1o 
fragment (193 amino acids) failed to produce soluble protein (Fig. 5.5). However, when 
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this N-terminal fragment was co-expressed with E2o, a putative soluble N-terminal E1o: 
E2o complex was obtained and the two proteins co-eluted on gel filtration (Fig. 5.6 A, B). 
This was the first indication that indeed the N-terminal region of E1o was capable of 
forming a stable complex with E2o. However, this was an ambiguous result because the N-
terminal fragment was identified only on the basis of SDS-PAGE analysis and Coomassie 
blue staining. The same result was obtained subsequently by employing two different 
pGEX-2T constructs harbouring different lengths of N-terminal E1o. 
To examine whether the first 80-85 amino acids or a longer N-terminal E1o sequence was 
required to promote this high affinity interaction, two pGEX-2T constructs of E1o N-
terminal truncates were employed. Both E1o GST fusion proteins (83 and 166 amino acids 
respectively) were relatively soluble as compared to the His-tagged E1o fragment and 
appeared to bind tightly with E2o in GST ‘pull down’ assays using glutathione Sepharose 
4B chromatography (Figs. 5.9 & 5.11). In addition, interaction of E2o with wild-type GST 
was excluded in control ‘pull down’ assays and Western blotting (Fig. 5.12 B). The 
interaction between E2o and the short (83 amino acid) N-terminal E1o fragment was also 
confirmed by Western blotting (Fig. 5.12 A) showing that the presence of this extreme N-
terminal region was crucial for binding to E2o. These data were consistent with earlier 
selective proteolysis data in bovine OGDC where a 61 amino acid N-terminal E1o 
fragment remains attached to E2o upon treatment of OGDC with arg C (McCartney et al., 
1998).  
In a parallel study, the affinity of E3 for E2o was examined by purifying the two enzymes 
individually followed by mixing and gel filtration (Fig. 5.3 A, B). The two enzymes did 
not display any affinity for each other, eluting as individual peaks at their respective 
elution volumes on gel filtration. Thus E3 is unable to enter into a stable association 
directly with E2o as anticipated. Therefore, E1o involvement appears crucial for mediating 
formation of a stable multienzyme assembly that promotes E3 integration with the E2o 
core.  
Although it is possible that the N-terminal residues of E1o may be involved in interacting 
with E3 directly, nevertheless no co- or post-translational binding studies between N-
terminal E1o and E3 were performed as a result of time constraints. However, it was 
shown that the extreme N-terminal region (first 83 amino acids) of E1o co-integrated with 
E2o to form a stable complex and moreover, it was conclusively demonstrated that E2o 
alone does not bind E3 to OGDC.        
Chapter 5  
 
196 
196 
 
Most of the earlier research investigating the morphology and subunit organisation of 
OGDC have employed native complex purified from various organisms. The isolation of 
individual enzyme components has proved difficult owing to the tight association of the 
E1o and E2o components. Stringent conditions using chaotrophic agents such as 3 M 
MgCl2 are required to achieve separation. In this project, recombinant enzymes were 
employed in an attempt to overcome these difficulties. Recently recombinant homodimeric 
E1o from E. coli has been crystallised and its structure elucidated in detail (Frank et al., 
2007). Interestingly, this crystal structure could only be obtained when the first 84 amino 
acid residues were removed by tryptic digestion. It was suggested by the authors that this 
distinctive N-terminal region may extend outwards from the core ‘fold’ and is required to 
mediate interactions with the other components of OGDC. These observations also show 
that the N-terminal E1o region is likely to be structurally dynamic, consistent with its 
presence preventing the crystallisation process. This N-terminal segment displays a high 
degree of immunogenicity as compared to the large C-terminal E1’o region in mammalian 
OGDC (McCartney et al., 1998), also indicative of the presence of a flexible and/or 
extended region of polypeptide.  
In our current research, the first 83 and 166 amino acids of human E1o have been cloned, 
overexpressed and purified as GST fusion proteins. These fragments were very prone to 
degradation and therefore any possible interactions of E3 with these N-terminal E1o 
truncates alone or with an equivalent E1o:E2o subcomplex could not be assessed in the 
time available. Degradation was controlled to some extent by addition of 1% (v/v) rat 
serum containing serine protease inhibitors that are effective against trypsin, chymotrypsin 
and elastase (Kuehn et al., 1984). Another reason for rapid degradation could be the 
intrinsic susceptibility of the N-terminal E1o region to proteolysis, a property that has been 
noted also with bovine E1o. This again indicates its probable presence as an extended, 
flexible segment of polypeptide as suggested by Frank et al. (2007).  
In this series of experiments, E1o protein production was problematic, in terms of good 
yields of soluble protein and degradation of GST-tagged protein; however, degradation 
was reduced to some extent when E1o fragments were co-expressed with E2o when a 
stable E1o:E2o complex could be purified. It was not possible, however, to determine if a 
stable interaction between E2o and this N-terminal E1o region could also occur post-
translationally owing to the rapid degradation of the various E1o truncates.  Assessing if 
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either these short N-terminal E1o fragments or the large E1’o C-terminal polypeptide can 
enter into a stable association with E3 is clearly a priority for future work.  
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E1 OGDC bovine TAPVA- EPFLSGTSSNYVEEMYYAWLENPKSVHKSWDIFFRNTNAGAPPGT 
E1 OGDC human SAPVAAEPFLSGTSSNYVEEMYYAWLENPKSVHKSWDIFFRNTNAGAPPGT 
 
E1 OGDC bovine AYQSPLPLSPG- LSAVAR    AGPLVEAQPNVDKLV 
E1 OGDC human  AYQSPLPLSRGSLAAVAH  A QSLVEAQPNVDKLV 
                               
Figure 5.13: Alignment of first 83 amino acids of mature N-terminal E1o of bovine 
and human OGDC 
 
The arrow shows the site where E1’o forms as a result of arg C cleavage of bovine heart 
OGDC. The amino acids in magenta match completely showing high degree of homology 
between human and bovine E1o. The E1’o sequence in bovine starts from residue G, 
probably due to loss of A residue due to the presence non-specific amino peptidases.    
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Chapter 6 
 
Conclusions 
 
In the last 20 years, the 2-oxoacid dehydrogenase complexes have continued to be the 
subject of intensive investigation. Thus the constituent enzymes have now been cloned, 
overexpressed and purified from a variety of different organisms. Most of the research on 
these complexes has so far been based on the analysis of structure, function and interaction 
of the constituent enzymes, regulated by their associated kinases and phosphatases in the 
case of mammalian PDC and BCOADC. 
In this study, for the first time all the constituent catalytic subunits/enzymes of human PDC 
were overexpressed, purified to homogeneity and reconstituted to form a fully functional 
recombinant PDC model. This recombinant multienzyme complex with an overall Mr 9-10 
MDa was found to be fully active in enzymatic assays and displayed a similar specific 
activity (3.5-4 µmol NADH min –1 mg protein–1) to PDC extracted from human heart tissue 
(Palmer et al., 1993). The recombinant model was prepared with a view to studying 
recently identified novel mutations in the E2 enzyme encountered in three patients 
diagnosed with PDC deficiency symptoms at Oxford Medical School. Before using this 
recombinant model to analyse the effect of these mutations on structure, function and 
assembly, the model was first tested to assess its ability to mimic the effects of combining 
active and inactive lipoyl domains in the E2:E3BP core. For this, eight mutant recombinant 
E2:E3BP cores were constructed, overexpressed, purified and reconstituted to form 
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functional complex by the addition of E1 and E3, in which the lipoyl domains of E2 and 
the single lipoyl domain of E3BP were mutated in various combinations to prevent 
lipoylation and thereby render the domains completely inactive (see section 3.14).  
In this study, as has been previously observed with E. coli PDC, there appears to be a 
considerable degree of functional redundancy in terms of the presence of multiple lipoyl 
domains. Thus loss of lipoylation of either outer or inner lipoyl domains of E2 resulted in 
only a 25-35% decline in overall activity. In addition, the presence of lipoylated or non-
lipoylated E3BP had little apparent effect on PDC activity. Interestingly, mutant PDCs in 
which E2 lipoyl domains were totally inactive still retained approx. 10-15% activity 
mediated by the 12 remaining lipoyl groups of E3BP. This latter observation is in 
agreement with a previous study (Sanderson et al., 1996a), in which E2 lipoyl domains 
were removed by collagenase treatment generating a modified complex that still retained 
15% residual activity.  
In previous studies assessing a role for the presence of multiple lipoyl domains, the local 
environment of the remaining lipoyl domain(s) in mutant PDCs was highly perturbed, 
potentially reducing steric hindrance effects and allowing the remaining domain(s) greater 
flexibility to visit the active sites of all 3 enzymes during the catalytic cycle. This could 
have led to overestimation of the activity of the modified complex and the versatility of 
individual lipoyl domains in serving as effective substrates for all 3 active sites. In this 
study for the first time, a full complement of correctly folded lipoyl domains was retained, 
either in active or inactive form in the recombinant PDC, without affecting the native 
structure of the complex and their redundancy status re-evaluated. However, results were 
consistent with earlier studies demonstrating the existence of a high degree of functional 
redundancy and showing that all lipoyl domains on E2 and E3BP appeared to interact 
effectively with all three partner enzymes.    
The validity of the recombinant PDC model for analysing natural mutations was also 
assessed in another study where the function of the normal recombinant PDC was 
compared to recombinant PDC without E3BP. PDC devoid of E3BP displayed residual 
activity of 3-8% in the presence of stoichiometric amounts of E3. About 10-20% activity 
has been reported in patients lacking the E3BP subunit (Marsac et al., 1993) where E3 is 
considered to bind weakly to a secondary site on E2. However, the activity of recombinant 
complex lacking E3BP could be significantly raised by adding a 100-200 fold excess of 
E3. This result substantiated an important previous finding by Dr. Susan Richards in this 
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laboratory using surface plasmon resonance (unpublished data) that the E1 binding site on 
E2 retains a residual affinity for E3. When excess amounts of E3 were added to wild-type 
recombinant PDC, its activity declined gradually due to partial displacement of E1 from its 
E2-binding site, again confirming its retention of a residual affinity for E3.   
Further analysis of recombinant PDC lacking E3BP was used to study whether E3BP was 
uniquely involved in the diacetylation reaction i.e. the production of a S6, S8 diacetyl-
dihydrolipoamide intermediate that is known to be exclusive to mammalian and yeast 
PDC. The role of diacetylation is unknown but could be of physiological importance, 
enabling PDC to act as a reservoir of acetyl groups and electrons under conditions of 
excess acetyl CoA and NADH production e.g. in diabetes, high fat diet or in starvation, 
providing a buffer against ketone body production. Diacetylated forms of PDC (produced 
by treatment with AcCoA and NADH or pyruvate in the absence of AcCoA) are protected 
from inactivation by the specific thiol group inhibitor, NEM (Sanderson et al., 1996b). 
Recombinant PDC lacking E3BP, but with a 200-fold excess of E3, was similarly treated 
with AcCoA and NADH. Recombinant PDC in which E3BP was absent, in addition to 
wild-type control was found to be protected from the inhibitory effect of NEM, indicating 
that the E3BP component was not responsible for diacetylation. The recombinant model of 
PDC was found to be an ideal tool to study this phenomenon because it is difficult to 
obtain native PDC complex lacking E3BP which is tightly integrated into the E2 core and 
cannot be readily removed without E2 disassembly. To date no enzymatic function has 
been identified for E3BP and our current analysis also rules out its potential involvement in 
the diacetylation process that is presumably mediated by E2. 
After checking the functional properties of our recombinant PDC model, it was 
successfully employed to study three natural mutations observed in patients. Two of these 
mutations were unusual homozygous ‘in-frame’ 3 base pair deletions in E2. One mutation 
was in the outer lipoyl domain of E2 leading to the deletion of glutamate 35 whereas the 
second mutation caused the loss of valine at position 455 that is located in the C-terminal 
domain. The third mutation was the substitution of a leucine for a phenylalanine at position 
490 near the active site of E2. The main objective of this study was to analyse these 
mutations in order to gain detailed information on the molecular basis of these PDC defects 
and also ascertain the validity of this model recombinant PDC system for analysing newly- 
discovered genetic mutations of this type. 
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All these mutations caused symptoms of PDC deficiency in the relevant patients; however, 
the exact mechanism of production of clinical symptoms was unclear. Moreover, in the 
case of the glutamate-35 deletion where the deletion was near to a lipoylatable lysine in the 
outer lipoyl domain, the clinical symptoms were difficult to explain simply in terms of 
possible loss of lipoylation of a single lipoyl domain. Inactivation of a single E2 lipoyl 
domain leads to only about 25-30% reduction in the PDC activity and was not expected to 
elicit any obvious phenotype. Moreover the patient showed about 70% loss of activity as 
measured by CO2 release assay. All mutations were successfully introduced into E2:E3BP 
cores and a series of experiments conducted to determine changes in structure, enzymatic 
function and assembly of the mutant complexes. It was demonstrated that the glutamate 
deletion not only affected lipoylation per se, but led to misfolding of the outer domain or 
domain instability rendering it ‘sticky’ and prone to aggregation. In addition, it was 
observed that the proper folding of this N-terminal region is crucial for the correct folding 
and assembly of the C-terminal domain of E2 and its integration with E3BP. It is proposed 
that inappropriate interactions of the N-termini of E2 polypeptide chains disrupt native 
trimer assembly involving the C-terminal regions of E2 and/or E3BP (Fig. 6.1). Indeed the 
AUC data suggested that a proper core was not forming in this case, which could be caused 
by premature and inappropriate aggregation of outer lipoyl domains leading to aberrant 
core assembly/function. However, in these experimental conditions some core of the 
correct size was present and indeed the extent of native core formation correlates well with 
the residual activity in the patient.    
The reduced PDC function in the case of F490L mutation appeared to be a relatively 
straightforward case where no major structural changes were detected, but partial loss of 
acetyltransferase activity was confirmed due to the presence of this mutation in the vicinity 
of the catalytic site. Moreover, this phenylalanine has also been reported to be important 
for the determination of substrate specificity (Mattevi et al., 1993b). It would be of great 
interest to assess the ability of this mutant E2 to use with other substrates to determine if it 
had acquired a broader substrate specificity as a result of this mutation.  
Analysis of the valine-455 deletion proved to be problematic. This mutation was 
responsible for the deletion of a highly conserved valine-455 that has the potential to 
disrupt the catalytic activity or E2 core assembly. A partial loss of catalytic activity (about 
50%) was demonstrated in the mutant PDC as well as the E2 enzyme and E2:E3BP core 
although in all other respects core formation and E3BP integration appeared normal. 
However, in this case the patient appeared to retain no immunologically detectable levels 
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of E3BP. Our initial working hypothesis was that the valine-455 deletion on E2 may be 
responsible for prevention of E3BP integration and that free E3BP was rapidly degraded 
but no evidence was obtained to support this prediction. A full clinical, genetic and 
biochemical re-evaluation of this patient is currently in progress.  
In this project, a reconstituted model of PDC comprising all three constituent enzymes and 
the accessory structural protein, E3BP has been used for the first time to uniquely evaluate 
these rare mutations. From a clinical viewpoint, the in vitro approaches employed here can 
form a basis for providing more comprehensive diagnosis and possibly developing 
improved treatment regimes in future. Often diagnosis of such mutations leading to PDC 
deficiency is made from clinical symptoms and CO2 release assays of cultured fibroblasts 
which are cumbersome, time-consuming, expensive and require considerable expertise. 
This type of study employing recombinantly-produced complex should provide important 
new information on subunit interactions/organisation and mode of assembly. Moreover, the 
the data obtained will enable clinicians and patients to gain a much clearer picture of the 
precise biochemical lesions associated with a particular genetic defect. Although PDC has 
been studied extensively for its structural and functional roles, nevertheless, the 
development of this novel model system can further provide new insights into the 
functioning of PDC at a molecular level under normal and disease conditions 
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Figure 6.1: Schematic representation depicting formation of normal and abnormal 
cores of E2:E3BP carrying the ∆E35 E2 mutation   
The upper part of the diagram (A) shows formation of normal trimers of E2 and E3BP 
polypeptides interacting via their C-terminal domains leading to native core assembly. In 
the case of the ∆E35 mutation in the outer lipoyl domain (B), abnormal oligomers of E2 
and E3BP have an increased tendency to aggregate due to inappropriate association of the 
N-termini of E2 polypeptide disrupting native trimer assembly that involves the C-terminal 
regions of E2 and/or E3BP. The dotted line indicates that a small amount of native core is 
also being assembled under these conditions.    
Native 48:12 meric 
E2:E3BP    core
Abnormal 
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Native E2
∆ E35 E2
E3BP
E3BP
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The last chapter describes our preliminary attempts to generate a recombinant OGDC 
model. Human OGDC is less widely studied as compared to PDC. Its constituent enzymes 
are equivalent to those in PDC i.e. E1, E2 and E3, but without any homologue of E3BP. 
However, a recombinant model of OGDC on similar lines to PDC is not yet available 
owing to difficulties in producing soluble full length, high Mr, homodimeric E1o. 
However, in this study N-terminal fragments of E1o (first 83, 166 and 193 amino acids) 
have been cloned, overexpressed and purified. Analysis of nucleotide sequence and 
deduced amino acid sequence of E2o has failed to detect any obvious well defined E3/E1o 
binding domains although biochemical evidence suggests that N-terminal of E1o seems to 
carry out some roles assigned to E3BP in PDC.  
E2o and E3 were successfully overexpressed and interaction studies showed that E3 did 
not bind directly to E2o in the OGDC. However, the extreme N-terminal region of E1o 
(first 83 amino acids) did co-integrate with E2o although it was not demonstrated if this 
could occur post-translationally as well as co-translationally. Previous studies have also 
implicated this region of E1o in E3 binding although this was not tested in the current 
study. 
In summary, it has proved feasible to produce a recombinant human PDC that maintained 
its structural and functional capabilities. It was then successfully utilised to evaluate 
several natural mutations in considerable detail. For OGDC, which like PDC is also 
implicated in a number of genetic, metabolic, autoimmune and neurodegenerative diseases, 
a recombinant model on similar lines should be fully developed and used in future studies 
to facilitate investigation on its involvement in a number of neurological and degenerative 
disorders linked to oxidative stress.   
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